0001493152-20-021209.txt : 20201113 0001493152-20-021209.hdr.sgml : 20201113 20201113061234 ACCESSION NUMBER: 0001493152-20-021209 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201113 DATE AS OF CHANGE: 20201113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VYCOR MEDICAL INC CENTRAL INDEX KEY: 0001424768 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 203369218 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34932 FILM NUMBER: 201309071 BUSINESS ADDRESS: STREET 1: 951 BROKEN SOUND PARKWAY STREET 2: SUITE 320 CITY: BOCA RATON, STATE: FL ZIP: 33487 BUSINESS PHONE: 562.558.2000 MAIL ADDRESS: STREET 1: 951 BROKEN SOUND PARKWAY STREET 2: SUITE 320 CITY: BOCA RATON, STATE: FL ZIP: 33487 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the fiscal quarter ended September 30, 2020

[ ]	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

	For the transition period from to

VYCOR MEDICAL, INC.

(Exact name of small business issuer as specified in its charter)

Delaware	001-34932	20-3369218
(State of	(Commission	(IRS Employer
Incorporation)	File Number)	Identification No.)

951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487

(Address of principal executive offices) (Zip code)

Issuer’s telephone number: (561) 558-2020

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock		VYCO		OTCQB

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [ ]		Accelerated Filer [ ]
Non-accelerated Filer [ ] (Do not check if a smaller reporting company)		Smaller Reporting Company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

There were 26,895,692 shares outstanding of registrant’s common stock, par value $0.0001 per share, as of November 13, 2020.

Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]

TABLE OF CONTENTS

		Page
	PART I

Item 1.	Financial Statements	3

	Unaudited Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019	3

	Unaudited Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2020 and 2019.	4

	Unaudited Consolidated Statement of Stockholders’ Deficiency for the three and nine months ended September 30, 2020 and 2019.	5

	Unaudited Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019.	6

	Notes to Unaudited Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4.	Controls and Procedures	24

	PART II

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3.	Defaults Upon Senior Securities	25

Item 4.	Mine Safety Disclosures	25

Item 5.	Other Information	25

Item 6.	Exhibits	25

SIGNATURES		26

PART 1

ITEM 1. FINANCIAL STATEMENTS

VYCOR MEDICAL, INC.

Consolidated Balance Sheets

(Unaudited)

	September 30, 2020			December 31, 2019
ASSETS
Current Assets
Cash	$	74,935		$	60,717
Trade accounts receivable		137,397			274,551
Inventory		179,714			208,353
Prepaid expenses and other current assets		90,854			92,694
Current assets of discontinued operations		2,004			20,117
Total Current Assets		484,904			656,432

Fixed assets, net		389,146			364,953

Intangible and Other assets:
Patents, net of accumulated amortization		14,343			23,326
Security deposits		6,000			6,000
Operating lease - right of use assets		135,003			31,658
Long term assets of discontinued operations		-			9,574
Total Intangible and Other assets		155,346			70,558
TOTAL ASSETS	$	1,029,396		$	1,091,943

LIABILITIES AND STOCKHOLDERS’ DEFICIENCY
Current Liabilities
Accounts payable	$	131,117		$	245,412
Accrued interest: Other		316,798			280,765
Accrued interest: Related party		66,767			44,921
Accrued liabilities - Other		116,085			233,067
Accrued liabilities - Related Party		1,297,480			973,110
Notes payable: Other		555,666			328,032
Notes payable: Related Party		310,873			230,873
Current operating lease liabilities		44,079			28,010
Current liabilities of discontinued operations		9,884			82,216
Total Current Liabilities		2,848,749			2,446,406

Operating lease liability - Long term		88,097			-

STOCKHOLDERS’ DEFICIENCY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 270,307 and 270,307 issued and outstanding as at September 30, 2020 and December 31, 2019 respectively		27			27
Common Stock, $0.0001 par value, 55,000,000 shares authorized at September 30, 2020 and December 31, 2019, 26,999,026 and 25,391,884 shares issued and 26,895,692 and 25,288,550 outstanding at September. 30, 2020 and December 31, 2019 respectively		2,700			2,539
Additional Paid-in Capital		28,699,931			28,306,592
Treasury Stock (103,334 shares of Common Stock as at September 30, 2020 and December 31, 2019 respectively, at cost)		(1,033	)		(1,033	)
Accumulated Deficit		(30,736,750	)		(29,790,258	)
Accumulated Other Comprehensive Income		127,675			127,670
Total Stockholders’ Deficiency		(1,907,450	)		(1,354,463	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	$	1,029,396		$	1,091,943

See accompanying notes to consolidated financial statements

VYCOR MEDICAL, INC.

Consolidated Statements of Comprehensive Loss

(Unaudited)

	For the three months ended September 30,						For the nine months ended September 30,
	2020			2019			2020			2019

Revenue	$	275,925		$	322,884		$	850,430		$	1,061,393
Cost of Goods Sold		40,551			28,962			98,338			97,446
Gross Profit		235,374			293,922			752,092			963,947

Operating expenses:
Depreciation and Amortization		14,495			15,218			43,780			44,855
General and administrative		427,250			444,371			1,260,742			1,344,853
Total Operating expenses		441,745			459,589			1,304,522			1,389,708
Operating loss		(206,371	)		(165,667	)		(552,430	)		(425,761	)

Other income (expense)
Interest expense: Related Party		(7,836	)		(5,315	)		(21,846	)		(15,331	)
Interest expense: Other		(12,099	)		(12,109	)		(36,033	)		(36,074	)
Loss on foreign currency exchange		(484	)		(3	)		(829	)		(207	)
Gain on other income		6,000			-			6,000			-
Total Other Income (expense)		(14,419	)		(17,427	)		(52,708	)		(51,612	)

Loss Before Credit for Income Taxes		(220,790	)		(183,094	)		(605,138	)		(477,373	)
Credit for income taxes		-			-			-			-
Net Loss from continuing operations		(220,790	)		(183,094	)		(605,138	)		(477,373	)
Income (Loss) from discontinued operations, net of tax		22,503			(26,515	)		(16,984	)		(97,838	)
Net loss		(198,287	)		(209,609	)		(622,122	)		(575,211	)

Preferred stock dividends		(162,185	)		(162,185	)		(324,370	)		(324,370	)
Net Loss available to common stockholders	$	(360,472	)	$	(371,794	)	$	(946,492	)	$	(899,581	)
Other Comprehensive Loss
Foreign Currency Translation Adjustment		3			7			5			2
Comprehensive Loss		(198,284	)		(209,602	)		(622,117	)		(575,209	)

Net Loss Per Share – basic and diluted
Loss from continuing operations	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.02	)
Income (Loss) from discontinued operations	$	0.00		$	(0.00	)	$	(0.00	)	$	(0.00	)
Net loss available to common stockholders	$	(0.01	)	$	(0.02	)	$	(0.04	)	$	(0.04	)

Weighted Average Number of Shares Outstanding – Basic and Diluted		26,365,801			24,222,946			25,832,084			23,689,516

See accompanying notes to consolidated financial statements

VYCOR MEDICAL, INC.

Consolidated Statement of Stockholders’ Deficiency

(Unaudited)

																			Additional					Accum
	Common Stock				Preferred C				Preferred D				Treasury Stock						Paid-in		Accumulated			OCI
	Number		Amount		Number		Amount		Number		Amount		Number			Amount			Capital		Deficit			(Loss)		Total

Balance at June 30, 2020		26,463,312	$	2,646		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	28,573,484	$	(30,376,278	)	$	127,672	$	(1,673,482	)
Issuance of stock for board and consulting fees		535,714		54																112,447							112,501
Directors deferred compensation granted		-																		14,000							14,000
Issuance of shares pursuant to exercise of warrants																											-
Accumulated Comprehensive Loss																									3		3
Net loss for period ended September 30, 2020																						(360,472	)				(360,472	)
Balance at September 30, 2020		26,999,026	$	2,700		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	28,699,931	$	(30,736,750	)	$	127,675	$	(1,907,450	)

																			Additional					Accum
	Common Stock				Preferred C				Preferred D				Treasury Stock						Paid-in		Accumulated			OCI
	Number		Amount		Number		Amount		Number		Amount		Number			Amount			Capital		Deficit			(Loss)		Total

Balance at December 31, 2019		25,391,884	$	2,539		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	28,306,592	$	(29,790,258	)	$	127,670	$	(1,354,463	)
Issuance of stock for board and consulting fees		1,607,142		161																337,339							337,500
Directors deferred compensation granted		-																		56,000							56,000
Issuance of shares pursuant to exercise of warrants																											-
Accumulated Comprehensive Loss																									5		5
Net loss for period ended September 30, 2020																						(946,492	)				(946,492	)
Balance at September 30, 2020		26,999,026	$	2,700		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	28,699,931	$	(30,736,750	)	$	127,675	$	(1,907,450	)

																			Additional					Accum
	Common Stock				Preferred C				Preferred D				Treasury Stock						Paid-in		Accumulated			OCI
	Number		Amount		Number		Amount		Number		Amount		Number			Amount			Capital		Deficit			(Loss)		Total

Balance at June 30, 2019		24,320,456	$	2,432		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	28,039,699	$	(29,197,473	)	$	127,668	$	(1,028,680	)
Issuance of stock for board and consulting fees		535,714		54																112,447							112,501
Directors deferred compensation granted		-																		21,000							21,000
Issuance of shares pursuant to exercise of warrants																											-
Accumulated Comprehensive Loss																									7		7
Net loss for period ended September 30, 2019																						(371,794	)				(371,794	)
Balance at Setember 30, 2019		24,856,170	$	2,486		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	28,173,146	$	(29,569,267	)	$	127,675	$	(1,266,966	)

																			Additional					Accum
	Common Stock				Preferred C				Preferred D				Treasury Stock						Paid-in		Accumulated			OCI
	Number		Amount		Number		Amount		Number		Amount		Number			Amount			Capital		Deficit			(Loss)		Total

Balance at December 31, 2018		23,244,028	$	2,324		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	27,771,868	$	(28,669,686	)	$	127,673	$	(768,827	)
Issuance of stock for board and consulting fees		1,612,142		162																338,278							338,440
Directors deferred compensation granted		-																		63,000							63,000
Issuance of shares pursuant to exercise of warrants																											-
Accumulated Comprehensive Loss																									2		2
Net loss for period ended September 30, 2019																						(899,581	)				(899,581	)
Balance at September 30, 2019		24,856,170	$	2,486		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	28,173,146	$	(29,569,267	)	$	127,675	$	(1,266,966	)

See accompanying notes to consolidated financial statements

VYCOR MEDICAL, INC.

Consolidated Statement of Cash Flows

(Unaudited)

	For the nine months ended
	September 30,
	2020			2019
Cash flows from operating activities:
Net loss	$	(622,121	)	$	(575,211	)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization of intangible assets		8,983			9,170
Depreciation of fixed assets		35,939			37,201
Inventory provision		9,418			9,418
Stock based compensation		393,500			401,440

Changes in assets and liabilities:
Accounts receivable		137,154			44,521
Inventory		19,221			(34,455	)
Prepaid expenses		2,661			(33,309	)
Accrued interest - Related Party		21,846			15,332
Accrued interest - Other		36,033			35,901
Accounts payable		(114,295	)		104,518
Accrued liabilities - Other		(116,982	)		(25,818	)
Changes in discontinued operations, net		(54,218	)		497
Cash used in operating activities		(242,862	)		(10,795	)
Cash flows from investing activities:
Purchase of fixed assets		(60,132	)		(21,560	)
Changes in investing activities of discontinued operations, net		9,574			2,496
Cash used in investing activities		(50,558	)		(19,064	)
Cash flows from financing activities:
Proceeds from Notes Payable - Related Party		80,000			17,873
Proceeds from Paycheck Protection Program and EIDL		208,600			-
Proceeds net of repayments Notes Payable - Other		19,034			25,244
Cash provided by financing activities		307,634			43,117
Effect of exchange rate changes on cash		4			(1,093	)
Net increase (decrease) in cash		14,218			12,165
Cash at beginning of period		60,717			78,011
Cash at end of period	$	74,935		$	90,176

Non-Cash Transactions:
Common stock issued to related party for payment of accrued liabilities	$	0		$	0

See accompanying notes to consolidated financial statements

VYCOR MEDICAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

(Unaudited)

1. BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Vycor Medical, Inc. (the “Company” or “Vycor”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in consolidated financial statements have been omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2019 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

The unaudited consolidated financial statements as of and for the nine months ended September 30, 2020 and 2019, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition, results of operations and cash flows. The results of operations for the nine months ended September 30, 2020 and 2019 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts on the unaudited consolidated financial statements have been reclassified to conform to the current period presentation.

Ability to continue as a Going Concern

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $946,492 for the nine months ended September 30, 2020 and has not generated sufficient positive cash flows from operations. As of September 30, 2020 the Company had a working capital deficiency of $688,725, excluding related party liabilities of $1,675,120. These conditions, among others, raise substantial doubt regarding our ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

The Company is executing on a plan to achieve a reduction in cash operating losses. Included within the working capital deficiency above is a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”), together with accrued interest of $316,798, which has a maturity date of December 31, 2020, having been extended on a number of occasions from its initial due date of June 11, 2011. At this time, it is not known whether any further extension of the note beyond December 31, 2020 will be available. However, the Company believes it may not have sufficient cash to meet its various cash needs through November 30, 2021 unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Fountainhead, the Company’s largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case. The Company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all. If adequate funds are not available, the Company may have to delay or curtail development or commercialization of products, or cease some of its operations.

2. SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision GmbH have been accounted for as discontinued operations.

Recent Accounting Pronouncements

From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that, other than as disclosed above, such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

Discontinued Operations

In accordance with ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meets the criteria in paragraph 205-20-45-1E to be classified as held for sale. When all of the criteria to be classified as held for sale are met, including management, having the authority to approve the action, commits to a plan to sell the entity, the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations (which we presented as operations to be disposed and operations disposed), less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations in accordance with ASC 205-20-45.

Leases

The Company has one leased building in Boca Raton, Florida that is classified as operating lease right-of use (“ROU”) assets and operating lease liabilities in the Company’s unaudited consolidated balance sheet as per ASC 842. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement. Operating lease expense is recognized on a straight-line basis over the lease term and is included in cost of Selling, General and Administrative expenses.

The standard was effective for us beginning January 1, 2019. The Company elected the available practical expedients on adoption. The adoption had a material impact on our unaudited consolidated balance sheets, but did not have a material impact on our unaudited consolidated statements of comprehensive loss. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

	September 30, 2020		September 30, 2019
Stock options outstanding		680,000		700,000
Warrants to purchase common stock		-		3,717,826
Debentures convertible into common stock		2,937,133		2,707,933
Preferred shares convertible into common stock		1,272,052		1,272,052
Directors Deferred Compensation Plan		1,442,571		1,075,908
Total		6,331,756		9,473,719

Covid-19

In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China, and has since spread to a number of other countries, including the United States. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition, as of the time of the filing of this Form 10-Q, several states in the United States remain in states of emergency, and travel restrictions continue to be applied in several countries around the world, including the United States. Vycor Medical experienced a reduction in demand during the nine months ended September 30, 2020 in the US and Internationally. Although neurosurgery is not considered an elective procedure, general hospital dislocation and diversion of resources away from non-emergency surgeries, or surgeries that can be postponed for a short period without harm, has impacted our revenues during the nine months ended September 30, 2020 and could continue to do so. In addition, sales and marketing efforts by Vycor’s representatives have been disrupted or curtailed due to lockdown and social distancing, and this has and may continue to hinder the recovery of revenues. While our operations are principally located in the United States, and our sub-contract manufacturers are located in the United States, we participate in a global supply chain, and the existence of a worldwide pandemic, the fear associated with COVID-19, or any, pandemic, and the reactions of governments around the world in response to COVID-19, or any, pandemic, to regulate the flow of labor and products and impede the travel of personnel, may impact our ability to conduct normal business operations, which could adversely affect our results of operations and liquidity. Disruptions to our supply chain and business operations, or to our suppliers’ or customers’ supply chains and business operations, could include disruptions from the closure of supplier and manufacturer facilities, interruptions in the supply of raw materials and components, personnel absences, or restrictions on the shipment of our or our suppliers’ or customers’ products, any of which could have adverse ripple effects on our manufacturing output and delivery schedule. Although we have implemented business continuity plans for our offices and personnel to enable continuity of service remotely, if a critical number of our employees become too ill to work, or we are not able to access a sufficient quantity of our inventory for shipment due to enforced office closures, our production ability could be materially adversely affected in a rapid manner. Similarly, if our customers experience adverse business consequences due to COVID-19, or any other, pandemic, demand for our products could also be materially adversely affected in a rapid manner. Global health concerns, such as COVID-19, could also result in social, economic, and labor instability in the countries and localities in which we or our suppliers and customers operate. Any of these uncertainties could have a material adverse effect on our business, financial condition or results of operations.

3. DISCONTINUED OPERATIONS

In April 2020, the board of Vycor took the decision to close the German operations of NovaVision, including the German office and NovaVision GmbH, and instead migrate to a licensed business model; in June 2020 Vycor announced that it would be entering into a license agreement and transition agreement (the “Agreements”) with HelferApp GmbH, a cognitive therapy specialist. Under the Agreements, HelferApp is licensed to provide NovaVision’s products and therapies in Germany, Austria and Switzerland to patients and professionals; and has assumed responsibility for the current patients of NovaVision in the territory. The NovaVision German office was closed effective June 30, 2020. The Company will continue to fund the remaining expenses of the German operations, which are non-material, until such a time as NovaVision GmbH will be formally wound up.

Reconciliation of the Major Line Items constituting Loss from discontinued operations, net of tax, that are presented in the Consolidated Statements of Comprehensive Loss

	For the three months ended September 30,						For the nine months ended September 30,
	2020			2019			2020			2019
Major line items constituting loss from discontinued operations
Revenue	$	2,851		$	23,424		$	41,527		$	65,471
Cost of Goods Sold		616			2,565			4,835			9,188
Gross Profit		2,235			20,859			36,692			56,283

Operating expenses:
Depreciation and Amortization		-			(103	)		-			156
Selling, general and administrative		15,304			47,045			87,986			152,240
Total Operating expenses		15,304			46,942			87,986			152,396
Operating loss		(13,069	)		(26,083	)		(51,294	)		(96,113	)

Other income (expense)
Loss on foreign currency exchange		(879	)		(432	)		(2,141	)		(1,725	)
Other income (loss)		36,451						36,451
Total Other Income (expense)		35,572			(432	)		34,310			(1,725	)

Income (loss) Before Credit for Income Taxes		22,503			(26,515	)		(16,984	)		(97,838	)
Credit for income taxes		-			-			-			-
Loss from discontinued operations, net of tax	$	22,503		$	(26,515	)	$	(16,984	)	$	(97,838	)

Other income comprises the net of non-cash adjustments made in connection with the Agreements with HeflerApp and the closure of the German operation: adjustments for assets and liabilities transferred to HelferApp or NovaVision Inc. or otherwise written off - $12,308; elimination of historic balance for NovaVision GmbH legal expenses funded by NovaVision Inc. - $34,727; and certain accruals for employee costs – ($10,584).

4. NOTES PAYABLE

Related Parties Notes Payable

Related Party Notes Payable consists of:

	September 30, 2020		December 31, 2019

On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $30,000. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2021 or on demand by the Payee.	$	30,000	$	30,000
Between March 26, 2018 and April 24, 2020 the Company issued various promissory notes to Fountainhead Capital Management Limited for $280,873. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. Six notes were extended on their due dates for another twelve months. The Notes will be due between December 2020 and July 2021 or on demand by the Payee.		280,873		200,873
Total Related Party Notes Payable	$	310,873	$	230,873

Other Notes Payable

Other Notes Payable consists of:

	September 30, 2020		December 31, 2019
On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011, and has been extended on a number of occasions. On the note’s most recent due date, the note was extended to December 31, 2020. The note is personally guaranteed by certain officers and directors of the Company. See further note below	$	300,000	$	300,000
On May 16, 2020, the Company was granted a loan from Citizens Bank N.A. in the aggregate amount of $58,600, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The Loan, which was in the form of a Note dated May 16, 2020 issued by the Borrower, matures on May 16, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 16, 2020. The Note may be prepaid by the Borrower at any time prior to maturity with no prepayment penalties. Under the terms of the PPP, the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. The Company’s use of the Loan qualifies and intends to apply once the forgiveness program commences.		58,600		-
On July 7, 2020, the Company was advised that the Small Business Administration (SBA) had approved a $150,000 loan under the Economic Injury Disaster Loan Program pursuant to the Coronavirus Aid, Relief and Economic Security (CARES) Act (“Loan”). The Loan, evidenced by a promissory note dated July 7, 2020, has a term of thirty (30) years, bears interest at a fixed rate of three and three-quarters percent (3.75%) per annum, with monthly payments in the amount of $731.00 per month commencing twelve (12) months from the date of the note and is secured by essentially all of the assets of the Company. The proceeds of the Loan will be used for general working capital purposes to alleviate economic injury caused by disaster occurring in the month of January 2020 and continuing thereafter.		150,000		-
Insurance policy finance agreements and other.		47,066		28,032
Total Other Notes Payable:	$	555,666	$	328,032

In January 2018 the Company entered into an amendment agreement (the “Amendment”) with EuroAmerican Investments (“EuroAmerican”) regarding its $300,000 loan note (the “Note”). Under the Amendment, the Note was extended and the conversion terms of the Note were reduced to $0.21, the same as the offering price of the 2018 Offering. Conversion of the Note and accrued interest would result in the issuance of 2,937,133 shares of Common Stock as of September 30, 2020. Notwithstanding, EuroAmerican agreed that the Note could not be converted without first offering the Company the right to redeem the Note at principal and accrued interest, and secondly Fountainhead the right to purchase the Note, which cannot be converted prior to such offer and the failure of the Company and Fountainhead to exercise such option in accordance with the amendment terms. In addition, the Company agreed to issue warrants to purchase 2,308,405 shares of Common Stock at $0.27, the same terms as the 2018 Offering, exercisable for three years from January 1, 2018, if and when the conversion option is exercised. The amendment was recognized as a modification, based on the guidance in ASC 470-50.

The Company routinely finances all their insurance policies through a third party finance company which requires a down payment and subsequent monthly payments, the time periods vary from 10 months to 12 equal monthly payments.

5. LEASE

The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $5,700 plus sales tax per month that will expire on September 30, 2020. Based on the original lease agreement, the Company had the one-time option to renew the lease for another three years with minimum annual rent at market price, not less than the original lease payment amount. In January 2020, the Company exercised the option to extend the original lease for another three years with the expiration date of August 31, 2023. In accordance with ASC 842-10-35, the Company considered this lease extension as the modification of the original lease and re-measured the lease liability and the right-of-use assets on the commencement date of the lease extension.

The Company recognized the following in its unaudited consolidated balance sheet at September 30, 2020 and December 31, 2019:

	September 30, 2020		December 31, 2019

Operating Lease ROU Assets	$	135,003	$	31,658
	$	135,003	$	31,658

Operating Lease Liabilities
Current portion		44,079		28,010
Long-term portion	$	88,097	$	-
	$	132,176	$	28,010

6. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION

(a) Business segments

The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Revenue:
Vycor Medical	$	250,648	$	301,053	$	776,932	$	988,786
NovaVision	$	25,277	$	21,831	$	73,498	$	72,607
	$	275,925	$	322,884	$	850,430	$	1,061,393
Gross Profit
Vycor Medical	$	211,089	$	273,146	$	683,125	$	895,484
NovaVision	$	24,285	$	20,776	$	68,967	$	68,463
	$	235,374	$	293,922	$	752,092	$	963,947

	September 30, 2020		December 31, 2019
Total Assets:
Vycor Medical	$	990,852	$	1,036,857
NovaVision		36,540		25,395
Discontinued operations		2,004		29,691
Total Assets	$	1,029,396	$	1,091,943

(b) Geographic information

The Company operates in two geographic segments, the United States and Europe. Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Revenue:
United States	$	270,851	$	320,476	$	839,992	$	1,051,237
Europe	$	5,074	$	2,408	$	10,438	$	10,156
	$	275,925	$	322,884	$	850,430	$	1,061,393
Gross Profit
United States	$	230,321	$	291,536	$	741,675	$	953,861
Europe	$	5,053	$	2,386	$	10,417	$	10,086
	$	235,374	$	293,922	$	752,092	$	963,947

	September 30, 2020		December 31, 2019
Total Assets:
United States	$	1,014,817	$	1,055,312
Europe		12,575		6,940
Discontinued operations		2,004		29,691
Total Assets	$	1,029,396	$	1,091,943

7. EQUITY

Common Stock and Stock Grants

During January to September 2020 and 2019, the Company granted 266,664 shares of Common Stock (valued at $56,000) to non-employee Directors. Under the terms of the Directors Deferred Compensation Plan, the receipt of these shares is deferred until the January 15^thfollowing the termination of their services as a director. As of September 30, 2020 these shares have yet to be issued.

During January to September 2020 and 2019, under the terms of the Consulting Agreement referred to in note 10, the Company issued 1,607,142 of Common Stock to Fountainhead for fees of $337,500 in each period respectively.

Warrants and Options

The details of the outstanding warrants and options are as follows:

STOCK WARRANTS:

				Weighted average
	Number of shares			exercise price per share
Outstanding at December 31, 2019		3,717,826		$	0.27
Granted		-			-
Exercised		-			-
Cancelled or expired		(3,717,826	)	$	0.27
Outstanding at September 30, 2020		-		$	0.00

STOCK OPTIONS:

				Weighted average
	Number of shares			exercise price per share
Outstanding at December 31, 2019		700,000		$	0.28
Granted		-			-
Exercised		-			-
Cancelled or expired		(20,000	)		(0.27	)
Outstanding at September 30, 2020		680,000		$	0.28

As of September 30, 2020, the weighted-average remaining contractual life of outstanding warrants and options is 0 and 0.74 years, respectively.

8. SHARE-BASED COMPENSATION

Stock Option Plan

Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option-vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis.

For each of the nine months ended September 30, 2020 and 2019, the Company recognized share-based compensation of $0 for employee stock options.

Stock appreciation rights may be granted either on a stand-alone basis or in conjunction with all or part of any other stock options granted under the plan. As of September 30, 2020 there were no awards of any stock appreciation rights.

Non-Employee Stock Compensation

The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date”. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.

Aggregate stock-based compensation for stock granted to non-employees for each of the nine months ended September 30, 2020 and 2019 was $266,664 and $299,997. The expense related to stock not issued during each of the periods ended September 30, 2020 and 2019 comprises $56,000 and $63,000, related to stock granted but not issued to directors under the Directors Deferred Compensation Plan. As of September 30, 2020, there was $0 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.

Stock-based Compensation Valuation Methodology

Stock-based compensation resulting from the issuance of Common Stock is calculated by reference to the valuation of the Stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. Expected volatility is based on the historical volatility of a peer group of publicly traded companies. The expected term of options and warrants was based upon the expected life of the option or warrant, and the risk-free rate is based on the U.S. Treasury Constant Maturity rate.

There were no options or warrants issued during either of the periods ending September 30, 2020 and 2019.

9. COMMITMENTS AND CONTINGENCIES

Lease

The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $5,700 plus sales tax per month. The lease terminates September 30, 2020 and has been extended for a further three years to August 31, 2023. The Company’s subsidiary in Germany occupied premises on a rolling 12 month lease agreement with a 3 month notice period of EUR1,650 per month (approximately $1,815), which was terminated effective June 30, 2020. Rent expense for the nine months ended September 30, 2020 and 2019 for the continuing operations was $59,008 and $57,202 respectively. See Note 5.

Potential German tax liability

In June 2012 the Company’s NovaVision German subsidiary received a preliminary assessment for Magdeburg City trade tax of €75,000 (approximately $82,000), with an additional interest charge of €12,000 (approximately $13,200). This assessment is for the 2010 fiscal year and relates to the Company’s acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period was preliminarily reduced to zero. The Company did not accept this trade tax assessment and appealed against it to the relevant tax authorities with a view to its reduction. The relevant tax authorities agreed to suspend the assessment pending the outcome of certain court hearings and proposed tax legislation, and the Company agreed to make monthly payments on account totaling €75,000 (approximately $82,000) which were completed in October 2016 and fully expensed. At that time the Company appealed against the interest charge of €12,000 (approximately $13,200) which the tax authorities did not accept but also agreed to suspend pending the outcome of the hearings and proposed legislation outlined above. Accordingly, the Company has made no provision for this liability in the nine months ended September 30, 2020 and the year ended December 31, 2019 respectively.

10. CONSULTING AND OTHER AGREEMENTS

The following agreements were entered into or remained in force during the period ended September 30, 2020:

Consulting Agreement with Fountainhead

In March 2017 and effective April 1, 2017, the Company amended the Fountainhead Consulting Agreement (“the Amended Agreement”). Under the Amended Agreement, fees of $450,000 are payable to Fountainhead, with an option to receive $5,000 per month in cash and the remainder payable in Company Common Stock issued at the higher of $0.21 and the average price for the 30 days prior to issuance, and deliverable at the end of each fiscal quarter. The Consulting Agreement also contains provisions for Fountainhead to receive a higher proportion of its fees in cash subject to certain future liquidity events and Board approval. Under the terms of the Amended Agreement, Fountainhead provides the executive management team of the Company, including the positions of CEO, President and CFO, whose employment agreements with the Company stipulate they receive no remuneration from the Company.

During the nine months ended September 30, 2020 and September 30, 2019, under the terms of the Amended Agreement, Fountainhead received total fees of $337,500, which were paid through the issuance of 1,607,142 shares of Company Common Stock.

11. RELATED PARTY TRANSACTIONS

Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at September 30, 2020, 59.7% of the Company’s Common Stock and 70% of the Company’s Preferred D Stock. Peter Zachariou owns 26% of the Company’s Preferred D Stock. Adrian Liddell, Chairman, is a consultant for Fountainhead.

During each of the nine months ended September 30, 2020 and September 30, 2019, under the terms of the Consulting Agreement referred to in note 10, the Company issued 1,607,142 shares of Common Stock to Fountainhead for fees of $337,500.

During each of the nine months ended September 30, 2020 and 2019, the Company accrued an aggregate of $324,370 of Preferred D Stock dividends, of which $226,037 was in respect of Fountainhead and $83,386 was in respect of Peter Zachariou.

During the nine months ended September 30, 2020 and 2019 the Company issued unsecured loan notes to Fountainhead for a total of $80,000 and $17,873, respectively. The loan notes bear interest at a rate of 10% and are due on demand or by their one-year anniversary.

There were no other related party transactions during the nine months ended September 30, 2020 and 2019.

12. CONCENTRATION

Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals.

Sales Concentration:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Number of customers over 10%		0			1			1			1
Percentage of sales		0	%		12	%		14	%		10	%

Accounts Receivable Concentration

	At September 30,			At December 31,
	2020			2019

Number of customers over 10%		2			1
Percentage of accounts receivable		11% and 15	%		37	%

The Company has three sub-contract manufacturers from which it purchases, respectively, VBAS injection molded parts, completed and sterilized VBAS units, and VBAS extension arms. Purchases from these manufacturers vary from quarter to quarter, with no purchases in some quarters, however on an annual basis purchases from each manufacturer represent over 10% of total annual purchases.

13. SUBSEQUENT EVENTS

The Company has evaluated the existence of events and transactions subsequent to the balance sheet date through the date the unaudited consolidated financial statements were issued and has determined that there were no significant subsequent events or transactions which would require recognition or disclosure in the financial statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward Looking Statements

This Interim Report on Form 10-Q contains, in addition to historical information, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PLSRA”), Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding Vycor Medical, Inc. (the “Company” or “Vycor,” also referred to as “us”, “we” or “our”). Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Forward-looking statements involve risks and uncertainties. Forward-looking statements include statements regarding, among other things, (a) our projected sales, profitability, and cash flows, (b) our growth strategies, (c) anticipated trends in our industries, (d) our future financing plans and (e) our anticipated needs for working capital. They are generally identifiable by use of the words “may,” “will,” “should,” “anticipate,” “estimate,” “plans,” “potential,” “projects,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” or the negative of these words or other variations on these words or comparable terminology. These statements may be found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Description of Business,” as well as in this Form 10-Q generally. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

Any or all of our forward-looking statements in this report may turn out to be inaccurate. They can be affected by inaccurate assumptions we might make or by known or unknown risks or uncertainties. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially as a result of various factors, including, without limitation, the risks outlined under “Risk Factors” and matters described in this Form 10-Q generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. You should not place undue reliance on these forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities laws, we undertake no obligation to publicly update any forward-looking statements, whether as the result of new information, future events, or otherwise. We intend that all forward-looking statements be subject to the safe harbor provisions of the PSLRA.

1. Organizational History

The Company was formed as a limited liability company under the laws of the State of New York on June 17, 2005 as “Vycor Medical LLC”. On August 14, 2007, we converted into a Delaware corporation and changed our name to “Vycor Medical, Inc.”. The Company’s listing went effective on February 2009 and on November 29, 2010 Vycor completed the acquisition of substantially all of the assets of NovaVision, Inc. (“NovaVision”) and on January 4, 2012 Vycor, through its wholly-owned NovaVision subsidiary, completed the acquisition of all the shares of Sight Science Limited (“Sight Science”).

2. Overview of Business

Vycor is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and operates two distinct business units within the medical device industry. Vycor Medical designs, develops and markets medical devices for use in neurosurgery. NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Both businesses adopt a minimally or non-invasive approach. Both technologies have strong sales growth potential, address large potential markets and have the requisite regulatory approvals. The Company has 65 issued or allowed patents and a further 9 pending. The Company leverages joint resources across the divisions to operate in a cost-efficient manner.

The Company periodically engages in discussions with potential strategic partners for or purchasers of each or both of our operating divisions. In April 2020, the board of Vycor took the decision to close the German operations of NovaVision, including the German office and NovaVision GmbH, and instead migrate to a licensed business model; in June 2020 Vycor announced that it would be entering into a license agreement and transition agreement (the “Agreements”) with HelferApp GmbH, a cognitive therapy specialist. Under the Agreements, HelferApp is licensed to provide NovaVision’s products and therapies in Germany, Austria and Switzerland to patients and professionals; and has assumed responsibility for the current patients of NovaVision in the territory. The NovaVision German office was closed effective June 30, 2020.

Vycor Medical

Vycor Medical designs, develops and markets medical devices for use in neurosurgery. Vycor Medical’s ViewSite Brain Access System (“VBAS”) is a next generation retraction and access system that was fully commercialized in early 2010 and is the first significant technological change to brain tissue retraction in over 50 years in contrast to significant development in most other neuro-surgical technologies. Vycor Medical is ISO 13485:2016 and MDSAP (Medical Device Single Audit Program) certified, and VBAS has U.S. FDA 510(k) clearance and CE Marking for Europe (Class III) for brain and spine surgeries, and regulatory approvals in a number of other international markets. Vycor Medical has 27 granted and 9 pending patents.

NovaVision

NovaVision provides non-invasive, computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other brain injury, and has 38 granted patents.

Strategy

The Company is continuing to execute on a plan to achieve revenue growth and a reduction in cash operating losses¹. For Vycor Medical this plan includes in particular: increasing market penetration in the US through broadening of the distribution network and programs to increase penetration in existing hospitals; increasing international growth in territories where we are not represented or under represented; and continued new product development. The first phase of the modification of the existing VBAS product range to make it more compatible with the most common IGS systems was completed in September 2017 and has been well received by surgeons, resulting in increased hospital penetration and revenues particularly in the US. The second phase of the development of further IGS integration is complete, subject to regulatory clearances and approvals. Upon regulatory clearances and product release of this new VBAS AC model range the Company intends to conduct a multi-center study to provide additional clinical data on the product. We will also be exploring with surgeons and focus groups additional selected development work targeted at increasing the ease and applicability of our products to additional common procedures. For NovaVision, given the company’s resources, and the large size and diversity of its end markets, we believe that the most efficient way to tackle the distribution of its broad range of patient and professional products is by partnering with entities that have either direct access to the end users or a desire and financial wherewithal to leverage the NovaVision therapy platform. As a result, the Company has now closed the NovaVision German office and is entering into a license agreement with HelferApp, a cognitive therapy specialist, for Germany, Austria and Switzerland, and is seeking similar partnerships in other territories with regional companies able to leverage NovaVision’s clinically supported vision therapies. Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.

The NovaVision German operation accounted for a very substantial proportion of Vycor’s operating cash loss¹during the year ended December 31, 2019. This proportion has been reduced during the nine months ended September 30, 2020 for two reasons: firstly, the selling, general and administrative expenses of NovaVision Germany have been reduced as the operation has been wound down; and secondly due to the impact on Vycor revenues from Covid-19 discussed below.

¹Operating Loss before Depreciation, Amortization and non-cash Stock Compensation

COVID-19

In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China, and has since spread to a number of other countries, including the United States. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition, as of the time of the filing of this Form 10-Q, several states in the United States remain in states of emergency, and travel restrictions continue to be applied in several countries around the world, including the United States. Vycor Medical experienced a reduction in demand during the three months ended September 30, 2020 in the US and Europe. Although neurosurgery is not considered an elective procedure, general hospital dislocation and diversion of resources away from non-emergency surgeries, or surgeries that can be postponed for a short period without harm, has impacted our revenues during the nine months ended September 30, 2020 and could continue to do so. In addition, sales and marketing efforts by Vycor’s representatives have been disrupted or curtailed due to lockdown and social distancing, and this has and may continue to hinder the recovery of revenues. While our operations are principally located in the United States, and our sub-contract manufacturers are located in the United States, we participate in a global supply chain, and the existence of a worldwide pandemic, the fear associated with COVID-19, or any, pandemic, and the reactions of governments around the world in response to COVID-19, or any, pandemic, to regulate the flow of labor and products and impede the travel of personnel, may impact our ability to conduct normal business operations, which could adversely affect our results of operations and liquidity. Disruptions to our supply chain and business operations, or to our suppliers’ or customers’ supply chains and business operations, could include disruptions from the closure of supplier and manufacturer facilities, interruptions in the supply of raw materials and components, personnel absences, or restrictions on the shipment of our or our suppliers’ or customers’ products, any of which could have adverse ripple effects on our manufacturing output and delivery schedule. Although we have implemented business continuity plans for our offices and personnel to enable continuity of service remotely, if a critical number of our employees become too ill to work, or we are not able to access a sufficient quantity of our inventory for shipment due to enforced office closures, our production ability could be materially adversely affected in a rapid manner. Similarly, if our customers experience adverse business consequences due to COVID-19, or any other, pandemic, demand for our products could also be materially adversely affected in a rapid manner. Global health concerns, such as COVID-19, could also result in social, economic, and labor instability in the countries and localities in which we or our suppliers and customers operate. Any of these uncertainties could have a material adverse effect on our business, financial condition or results of operations.

Comparison of the Three Months Ended September 30, 2020 to the Three Months Ended September 30, 2019

Revenue and Gross Margin:

	Three months ended
	September 30,
	2020		2019		% Change
Revenue:
Vycor Medical	$	250,648	$	301,053		-17	%
NovaVision	$	25,277	$	21,831		16	%
	$	275,925	$	322,884		-15	%
Gross Profit
Vycor Medical	$	211,089	$	273,146		-23	%
NovaVision	$	24,285	$	20,776		17	%
	$	235,374	$	293,922		-20	%

Vycor Medical recorded revenue of $250,648 from the sale of its products for the three months ended September 30, 2020, a decrease of $50,405 over the same period in 2019. Sales of VBAS devices have been significantly disrupted during the 2020 period in the US and internationally by COVID-19. Although neurosurgery is not considered an elective procedure, general hospital dislocation and diversion of resources away from non-emergency surgeries, or surgeries that can be postponed for a short period without harm, has impacted our revenues during the three months ended September 30, 2020. In addition, sales and marketing efforts by Vycor’s representatives have been disrupted or curtailed due to lockdown and social distancing, and this has hindered the recovery of revenues. Sales in the three months ended September 30, 2020 showed some recovery over the three month period ended June 30, 2020, increasing by $31,651 or 14%, primarily in the US. Gross margin of 84% and 91% was recorded for the three months ended September 30, 2020 and 2019, respectively.

NovaVision recorded revenues of $25,277 for the three months ended September 30, 2020, an increase of $3,446 over the same period in 2019. Gross margin was 96%, compared to 95% for the same period in 2019.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses decreased by $17,121 to $427,250 for the three months ended September 30, 2020 from $444,371 for the same period in 2019. Included within Selling, General and Administrative Expenses are non-cash charges for stock based compensation as the result of amortizing employee and non-employee shares, warrants and options which have been issued by the Company over various periods. The charge for the three months ended September 30, 2020 was $126,500, a $7,000 decrease from the charge in 2019 of $133,500, following the departure from the Board of Oscar Bronsther from July 1, 2020. Also included within Selling, General and Administrative Expenses are Sales Commissions, which decreased by $3,955 from $56,761 to $52,806 in 2020, reflecting the reduced level of sales in the US due to COVID-19.

The remaining Selling, General and Administrative expenses decreased by $6,166 from $254,110 to $247,944 in 2020.

An analysis of the change in cash and non-cash G&A is shown in the table below:

	Cash G&A			Non-Cash G&A
Legal, patent, audit/accounting, regulatory		(11,872	)		-
Board, financial and scientific advisory		(6,075	)		(7,000	)
Payroll		(2,380	)		-
Other (sales/travel/regulatory/premises)		14,161			-
Commissions		(3,955	)		-
Total change		(10,121	)		(7,000	)

Interest Expense:

Interest comprises expense on the Company’s debt and insurance policy financing. Related Party Interest expense for the three months ended September 30, 2020 was $7,836 compared to $5,315 for 2019. Other Interest expense for the three months ended September 30, 2020 was $12,099 compared to $12,109 for 2019.

Comparison of the Nine Months Ended September 30, 2020 to the Nine Months Ended September 30, 2019

Revenue and Gross Margin:

	September 30,
	2020		2019		% Change
Revenue:
Vycor Medical	$	776,932	$	988,786		-21	%
NovaVision	$	73,498	$	72,607		1	%
	$	850,430	$	1,061,393		-20	%
Gross Profit
Vycor Medical	$	683,125	$	895,484		-24	%
NovaVision	$	68,967	$	68,463		1	%
	$	752,092	$	963,947		-22	%

Vycor Medical recorded revenue of $776,932 from the sale of its products for the nine months ended September 30, 2020, a decrease of $211,854. Sales of VBAS devices have been significantly disrupted, particularly from March to June, in the US and internationally by COVID-19 Although neurosurgery is not considered an elective procedure, general hospital dislocation and diversion of resources away from non-emergency surgeries, or surgeries that can be postponed for a short period without harm, has impacted our revenues during the six months ended September 30, 2020. In addition, sales and marketing efforts by Vycor’s representatives have been disrupted or curtailed due to lockdown and social distancing, and this has hindered the recovery of revenues. Gross margin of 88% was recorded for the nine months ended September 30, 2020 versus 91% for the same period in 2019.

NovaVision recorded revenues of $73,498 for the nine months ended September 30, 2020, an increase of $891 over the same period in 2019 and gross margin of 94%, compared to 94% for the same period in 2019.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses decreased by $84,111 to $1,260,742 for the nine months ended September 30, 2020 from $1,344,853 for the same period in 2019. Included within Selling, General and Administrative Expenses are non-cash charges for share based compensation as the result of amortizing employee and non-employee shares, warrants and options which have been issued by the Company over various periods. The charge for the nine months ended September 30, 2020 was $393,500, a decrease of $7,940 over $401,440 in 2019, following the departure from the Board of Oscar Bronsther from July 1, 2020. Also included within Selling, General and Administrative Expenses are Sales Commissions, which decreased by $38,259 from $187,622 to $149,363, reflecting the reduced level of sales in the US due to COVID-19.

The remaining Selling, General and Administrative expenses decreased by $37,912 from $755,791 to $717,879. Regulatory fees reduced by $49,367 reflecting the completion of the transition to a new EU Notified Body for Vycor; patent fees reduced by $20,296 reflecting the level of patent filing and prosecution activity in the 2019 period; the professional fees related to the closure of NovaVision Germany and the license agreement resulted accounting and legal fees increasing by $17,303.

An analysis of the change in cash and non-cash G&A is shown in the table below:

	Cash G&A			Non-Cash G&A
Legal, patent, audit/accounting, regulatory		(47,495	)		-
Board, financial and scientific advisory		(18,915	)		(7,000	)
Sales, marketing and travel		(7,215	)		-
Payroll		12,234			(939	)
Other (travel/regulatory/premises)		23,478			-
Commissions		(38,259	)		-
Total change		(76,172	)		(7,939	)

Interest Expense:

Interest comprises expense on the Company’s debt and insurance policy financing. Related Party Interest expense for the nine months ended September 30, 2020 was $21,846 compared to $15,331 for 2019. Other Interest expense for the nine months ended September 30, 2020 was $36,033 compared to $36,074 for 2019.

Income (loss) from Discontinued Operations:

The reduction in operating loss for the three and nine months ended September 30, 2020 compared to the same periods in 2019, from $26,083 to $13,069 and from $96,113 to $51,294, respectively, is primarily due to a reduction in Selling, general and administrative expenses as a result of the wind-down of operations in Germany.

Liquidity

The following table shows cash flow and liquidity data for the periods ended September 30, 2020 and December 31, 2019:

	September 30, 2020			December 31, 2019			$ Change
Cash	$	74,935		$	60,717		$	14,218
Accounts receivable, inventory and other current assets	$	409,969		$	595,715		$	(185,746	)
Total current liabilities	$	(2,848,749	)	$	(2,446,406	)	$	(402,343	)
Working capital	$	(2,363,845	)	$	(1,789,974	)	$	(573,871	)
Cash provided by financing activities	$	307,634		$	43,117		$	264,517

Operating Activities. Cash used in operating activities comprises net loss adjusted for non-cash items and the effect of changes in working capital and other activities. The net repayment of normal insurance financing should also be taken into account when considering cash used in operating activities.

The following table shows the principle components of cash used in operating activities during the nine months ended September 30, 2020 and 2019, with a commentary of changes during the periods and known or anticipated future changes:

	September 30, 2020			September 30, 2019			$ Change
Net loss	$	(622,122	)	$	(575,211	)	$	(46,911	)

Adjustments to reconcile net loss to cash used in operating activities:
Amortization and depreciation of assets	$	44,922		$	46,371		$	(1,449	)
Share based compensation	$	393,500		$	401,440		$	(7,940	)
Other	$	9,418		$	9,418		$	0
	$	447,840		$	457,229		$	(9,389	)

Net loss adjusted for non-cash items	$	(174,282	)	$	(117,982	)	$	(56,300	)
Changes in working capital
Accounts receivable	$	137,154		$	44,521		$	92,633
Accounts payable and accrued liabilities	$	(231,277	)	$	78,700		$	(309,977	)
Inventory	$	19,221		$	(34,455	)	$	53,676
Prepaid expenses and net insurance financing repayments	$	21,695		$	(8,065	)	$	29,760
Accrued interest (not paid in cash)	$	57,879		$	51,233		$	6,646
Changes in discontinued operations, net	$	(54,218	)	$	497		$	(54,715	)
	$	(49,546	)	$	132,431		$	(181,977	)

Cash provided by (used in) operating activities, adjusted for net insurance repayments	$	(223,828	)	$	14,449		$	(238,277	)

The adjustments to reconcile net loss to cash of $174,282 in the period have no impact on liquidity. The change in Net loss adjusted for non-cash items of ($56,300) was primarily due to the impact of COVID-19 on the Vycor division sales, which also accounts for the reduction in accounts receivable of $137,154. At December 31, 2019 there was an increase in accounts payable and accrued liabilities mainly due to expenditure on regulatory for the transition to a new EU Notified Body, and regulatory and testing for the VBAS development occurring during the fourth quarter. The change in accounts payable and accrued liabilities of $231,277 was mainly due to the settlement of these accounts. The net change of $54,218 in discontinued operations comprised a reduction of $72,331 in liabilities being transferred to the license partner, NovaVision, Inc. or eliminated; offset by a $18,113 reduction in assets being to the license partner, NovaVision, Inc. or written off.

Additional inventory of $40,559 was purchased during the nine months ended September 30, 2020 as part of normal production, and the Company anticipates purchasing additional new inventory of approximately $80,000 during the next twelve months.

Investing Activities. Cash used in investing activities of continuing operations for the nine months ended September 30, 2020 was $60,132, which reflected expenditure on the second phase of modifying the VBAS product suite to make it easier to integrate with IGS. The Company anticipates additional expenditures for this second phase, including work to obtain regulatory clearances and approvals, of approximately $40,000. The $9,574 change in investing activities of discontinued operations was due the writing off of long term assets.

Financing Activities. During the nine months ended September 30, 2020 the Company received funds of $80,000 in respect of loans from Fountainhead. The Company also received a loan of $58,600 during the period, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, and a $150,000 loan from the Small Business Administration (“SBA”) EIDL program.

Liquidity and Plan of Operations, Ability to Continue as a Going Concern

As described earlier in this ITEM 2 “Strategy”, the Company is continuing to execute on a plan to achieve revenue growth and a reduction in cash operating losses². For Vycor Medical this plan includes in particular: increasing market penetration in the US through broadening of the distribution network and programs to increase penetration in existing hospitals; increasing international growth in territories where we are not represented or under represented; and continued new product development. The first phase of the modification of the existing VBAS product range to make it more compatible with the most common IGS systems was completed in September 2017 and has been well received by surgeons, resulting in increased hospital penetration and revenues particularly in the US. The second phase of the development of further IGS integration is complete subject to regulatory clearances and approvals. Upon regulatory clearances and product release of this new VBAS AC model range the Company intends to conduct a multi-center study to provide additional clinical data on the product. We will also be exploring with surgeons and focus groups additional selected development work targeted at increasing the ease and applicability of our products to additional common procedures. For NovaVision, given the company’s resources, and the large size and diversity of its end markets, we believe that the most efficient way to tackle the distribution of its broad range of patient and professional products is by partnering with entities that have either direct access to the end users or a desire and financial wherewithal to leverage the NovaVision therapy platform. As a result, the Company has now closed the NovaVision German office and is entering into a license agreement with HelferApp, a cognitive therapy specialist, for Germany, Austria and Switzerland, and is seeking similar partnerships in other territories with regional companies able to leverage NovaVision’s clinically supported vision therapies. Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.

²Operating Loss before Depreciation, Amortization and non-cash Stock Compensation

However, the Company believes it may not have sufficient cash to meet its various cash needs through November 30, 2021 unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Included within the working capital deficiency above is a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”), together with accrued interest of $316,798, which has a maturity date of December 31, 2020, having been extended on a number of occasions from its initial due date of June 11, 2011. At this time, it is not known whether any further extension of the note beyond December 31, 2020 will be available. Fountainhead, the Company’s largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case. The Company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all. If adequate funds are not available, the Company may have to delay or curtail development or commercialization of products, or cease some of its operations.

Critical Accounting Policies and Estimates

Uses of estimates in the preparation of financial statements

The preparation of unaudited consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the unaudited consolidated financial statements and accompanying notes. Actual results could differ from those estimated. To the extent management’s estimates prove to be incorrect, financial results for future periods may be adversely affected. Significant estimates and assumptions contained in the accompanying unaudited consolidated financial statements include management’s estimate of the allowance for uncollectible accounts receivable, amortization of intangible assets, and the fair values of options and warrant included in the determination of debt discounts and stock-based compensation.

A detailed description of our significant accounting policies can be found in our most recent Annual Report on Form 10-K for the year ended December 31, 2019.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable

ITEM 4. CONTROLS AND PROCEDURES

(a) Disclosure Controls and Procedures

We are required to maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer (also our principal executive officer) and our chief financial officer (also our principal financial and accounting officer) to allow for timely decisions regarding required disclosure.

The Company’s management, including our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), have evaluated the effectiveness of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, our CEO and our CFO have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective as of that date to provide reasonable assurance that the information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that information required to be disclosed by the Company in the reports its files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its CEO and its CFO, as appropriate, to allow timely decisions regarding required disclosure. There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

(b) Changes in Internal Controls

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during the fiscal period to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

The Company’s management, including the Company’s CEO and CFO, does not expect that the Company’s internal control over financial reporting will prevent all errors and all fraud. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.

PART II

ITEM 1. LEGAL PROCEEDINGS

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of November 13, 2020, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements.

ITEM 1A. RISK FACTORS.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuance Type		Security				Shares
FHC Management Fees			Common				1,607,142

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None

Index to Exhibits

31.1		Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 13, 2020

	Vycor Medical, Inc.
	(Registrant)

	By:	/s/ Peter C. Zachariou
		Peter C. Zachariou
		Chief Executive Officer and Director (Principal Executive Officer)

	Date	November 13, 2020

	By:	/s/ Adrian Liddell
		Adrian Liddell
		Chairman of the Board and Director
		(Principal Financial and Accounting Officer)

	Date	November 13, 2020

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

I, Peter Zachariou, certify that:

	1.	I have reviewed this Form 10-Q for the period ended September 30, 2020 of Vycor Medical, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2020

/s/ Peter Zachariou
Peter C. Zachariou
Principal Executive Officer

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

I, Adrian Liddell, certify that:

	1.	I have reviewed this Form 10-Q for the period ended September 30, 2020 of Vycor Medical, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2020

/s/ Adrian Liddell
Adrian Liddell
Principal Financial Officer

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Vycor Medical, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The report on Form 10-Q for the period ended September 30, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2020

	/s/ Peter Zachariou
	Peter Zachariou
	Principal Executive Officer

A signed original of this written statement required by Section 906 has been provided to VYCOR MEDICAL, INC. and will be retained by VYCOR MEDICAL, INC. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ex32-2.htm

EXHIBIT 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

Date: November 13, 2020

	/s/ Adrian Liddell
	Adrian Liddell
	Principal Accounting Officer

EX-101.INS 6 vyco-20200930.xml XBRL INSTANCE FILE 0001424768 2020-01-01 2020-09-30 0001424768 2018-12-31 0001424768 2019-12-31 0001424768 us-gaap:CommonStockMember 2018-12-31 0001424768 VYCO:PreferredCMember 2018-12-31 0001424768 VYCO:PreferredDMember 2018-12-31 0001424768 us-gaap:TreasuryStockMember 2018-12-31 0001424768 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001424768 us-gaap:RetainedEarningsMember 2018-12-31 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001424768 VYCO:StockOptionPlanMember 2020-01-01 2020-09-30 0001424768 VYCO:WarrantsToPurchaseCommonStockMember 2020-01-01 2020-09-30 0001424768 VYCO:DebenturesConvertibleIntoCommonStockMember 2020-01-01 2020-09-30 0001424768 VYCO:PreferredSharesConvertibleToCommonStockMember 2020-01-01 2020-09-30 0001424768 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-01-01 2020-09-30 0001424768 VYCO:StockOptionPlanMember 2019-01-01 2019-09-30 0001424768 VYCO:WarrantsToPurchaseCommonStockMember 2019-01-01 2019-09-30 0001424768 VYCO:DebenturesConvertibleIntoCommonStockMember 2019-01-01 2019-09-30 0001424768 VYCO:PreferredSharesConvertibleToCommonStockMember 2019-01-01 2019-09-30 0001424768 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2018-01-31 0001424768 VYCO:EuroAmericanInvestmentCorpMember us-gaap:WarrantMember 2018-01-31 0001424768 VYCO:InsurancePolicyFinanceAgreementsMember 2019-12-31 0001424768 VYCO:PeterZachariouMember 2019-12-31 0001424768 VYCO:EuroAmericanInvestmentCorpMember VYCO:TermNoteMember 2011-03-25 0001424768 VYCO:EuroAmericanInvestmentCorpMember VYCO:TermNoteMember 2011-03-24 2011-03-25 0001424768 VYCO:VycorMedicalMember 2020-01-01 2020-09-30 0001424768 VYCO:NovaVisionMember 2020-01-01 2020-09-30 0001424768 VYCO:VycorMedicalMember 2020-09-30 0001424768 VYCO:NovaVisionMember 2020-09-30 0001424768 VYCO:VycorMedicalMember 2019-01-01 2019-09-30 0001424768 VYCO:NovaVisionMember 2019-01-01 2019-09-30 0001424768 VYCO:VycorMedicalMember 2019-12-31 0001424768 VYCO:NovaVisionMember 2019-12-31 0001424768 country:US 2020-01-01 2020-09-30 0001424768 srt:EuropeMember 2020-01-01 2020-09-30 0001424768 country:US 2020-09-30 0001424768 srt:EuropeMember 2020-09-30 0001424768 country:US 2019-01-01 2019-09-30 0001424768 srt:EuropeMember 2019-01-01 2019-09-30 0001424768 country:US 2019-12-31 0001424768 srt:EuropeMember 2019-12-31 0001424768 VYCO:FountainheadConsultingAgreementMember VYCO:MarchTwoThousandSeventeenandEffectiveAprilOneTwoThousandSeventeenMember 2020-01-01 2020-09-30 0001424768 VYCO:FountainheadConsultingAgreementMember VYCO:MarchTwoThousandSeventeenandEffectiveAprilOneTwoThousandSeventeenMember 2020-09-30 0001424768 VYCO:FountainheadMember VYCO:DirectorsMember 2020-09-30 0001424768 VYCO:FountainheadMember VYCO:DirectorsMember us-gaap:SeriesDPreferredStockMember 2020-09-30 0001424768 VYCO:FountainheadMember VYCO:UnsecuredLoanMember 2020-01-01 2020-09-30 0001424768 VYCO:FountainheadMember VYCO:UnsecuredLoanMember 2020-09-30 0001424768 VYCO:PeterZachariouMember 2018-06-24 2018-06-25 0001424768 VYCO:PeterZachariouMember 2018-06-25 0001424768 us-gaap:CommonStockMember 2019-12-31 0001424768 VYCO:PreferredCMember 2019-12-31 0001424768 VYCO:PreferredDMember 2019-12-31 0001424768 us-gaap:TreasuryStockMember 2019-12-31 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001424768 us-gaap:RetainedEarningsMember 2019-12-31 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2019-12-31 0001424768 VYCO:CustomerOneMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001424768 VYCO:FountainheadMember VYCO:UnsecuredLoanMember 2019-01-01 2019-09-30 0001424768 VYCO:ConsultingAgreementMember VYCO:FountainheadMember 2020-01-01 2020-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember us-gaap:ExtendedMaturityMember 2011-03-24 2011-03-25 0001424768 VYCO:CustomerOneMember us-gaap:AccountsReceivableMember 2019-01-01 2019-12-31 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2019-12-31 0001424768 VYCO:FountainheadMember VYCO:UnsecuredLoanMember 2019-09-30 0001424768 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001424768 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001424768 us-gaap:CommonStockMember 2019-06-30 0001424768 us-gaap:CommonStockMember 2019-09-30 0001424768 VYCO:PreferredCMember 2019-01-01 2019-09-30 0001424768 VYCO:PreferredCMember 2019-07-01 2019-09-30 0001424768 VYCO:PreferredCMember 2019-06-30 0001424768 VYCO:PreferredCMember 2019-09-30 0001424768 VYCO:PreferredDMember 2019-01-01 2019-09-30 0001424768 VYCO:PreferredDMember 2019-07-01 2019-09-30 0001424768 VYCO:PreferredDMember 2019-06-30 0001424768 VYCO:PreferredDMember 2019-09-30 0001424768 us-gaap:TreasuryStockMember 2019-01-01 2019-09-30 0001424768 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0001424768 us-gaap:TreasuryStockMember 2019-06-30 0001424768 us-gaap:TreasuryStockMember 2019-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001424768 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001424768 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001424768 us-gaap:RetainedEarningsMember 2019-06-30 0001424768 us-gaap:RetainedEarningsMember 2019-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001424768 2019-01-01 2019-09-30 0001424768 2019-07-01 2019-09-30 0001424768 2019-06-30 0001424768 2019-09-30 0001424768 VYCO:NonemployeeDirectorsMember VYCO:DirectorsDeferredCompensationPlanMember 2019-01-01 2019-09-30 0001424768 VYCO:NonemployeeDirectorsMember VYCO:DirectorsDeferredCompensationPlanMember 2020-01-01 2020-09-30 0001424768 VYCO:DirectorsMember VYCO:DirectorsDeferredCompensationPlanMember 2020-09-30 0001424768 VYCO:CustomerOneMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-09-30 0001424768 VYCO:ManufacturerOneMember VYCO:PurchaseMember 2020-01-01 2020-09-30 0001424768 VYCO:ManufacturerTwoMember VYCO:PurchaseMember 2020-01-01 2020-09-30 0001424768 us-gaap:SalesRevenueNetMember 2020-01-01 2020-09-30 0001424768 us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001424768 us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0001424768 us-gaap:AccountsReceivableMember 2019-01-01 2019-12-31 0001424768 VYCO:FountainheadMember VYCO:ConsultancyAgreementMember 2020-01-01 2020-09-30 0001424768 VYCO:FountainheadMember VYCO:ConsultancyAgreementMember 2019-01-01 2019-09-30 0001424768 VYCO:PreferredDStockDividendMember 2020-09-30 0001424768 VYCO:FountainheadMember 2020-09-30 0001424768 VYCO:ManufacturerThreeMember VYCO:PurchaseMember 2020-01-01 2020-09-30 0001424768 VYCO:EuroCurrencyMember 2012-06-30 0001424768 VYCO:EuroCurrencyMember 2012-06-29 2012-06-30 0001424768 2012-06-30 0001424768 2020-09-30 0001424768 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001424768 us-gaap:CommonStockMember 2020-09-30 0001424768 VYCO:PreferredCMember 2020-01-01 2020-09-30 0001424768 VYCO:PreferredCMember 2020-09-30 0001424768 VYCO:PreferredDMember 2020-01-01 2020-09-30 0001424768 VYCO:PreferredDMember 2020-09-30 0001424768 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0001424768 us-gaap:TreasuryStockMember 2020-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001424768 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001424768 us-gaap:RetainedEarningsMember 2020-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2020-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2020-01-01 2020-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember us-gaap:ExtendedMaturityMember 2020-01-01 2020-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2020-09-28 2020-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2018-01-01 2018-01-31 0001424768 VYCO:PeterZachariouMember 2020-09-30 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2020-09-30 0001424768 VYCO:InsurancePolicyFinanceAgreementsMember 2020-09-30 0001424768 VYCO:EmployeeStockOptionsMember 2020-01-01 2020-09-30 0001424768 VYCO:EmployeeStockOptionsMember 2019-01-01 2019-09-30 0001424768 VYCO:NonemployeeMember 2020-01-01 2020-09-30 0001424768 VYCO:NonemployeeMember 2019-01-01 2019-09-30 0001424768 VYCO:DirectorsMember VYCO:DirectorsDeferredCompensationPlanMember 2019-09-30 0001424768 country:DE VYCO:EuroCurrencyMember 2020-01-01 2020-09-30 0001424768 country:DE 2020-01-01 2020-09-30 0001424768 VYCO:OfficeSpaceMember 2020-01-01 2020-09-30 0001424768 VYCO:AmendmentAgreementMember 2020-01-01 2020-09-30 0001424768 VYCO:FountainheadMember us-gaap:SeriesDPreferredStockMember VYCO:PeterZachariouMember 2020-09-30 0001424768 VYCO:PeterZachariouMember 2020-09-30 0001424768 2020-07-01 2020-09-30 0001424768 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001424768 us-gaap:CommonStockMember 2020-06-30 0001424768 VYCO:PreferredCMember 2020-07-01 2020-09-30 0001424768 VYCO:PreferredCMember 2020-06-30 0001424768 VYCO:PreferredDMember 2020-07-01 2020-09-30 0001424768 VYCO:PreferredDMember 2020-06-30 0001424768 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0001424768 us-gaap:TreasuryStockMember 2020-06-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001424768 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001424768 us-gaap:RetainedEarningsMember 2020-06-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001424768 2020-06-30 0001424768 VYCO:CitizensBankMember 2020-09-30 0001424768 VYCO:CitizensBankMember 2019-12-31 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2018-03-26 2020-04-24 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2020-04-24 0001424768 VYCO:CitizensBankMember VYCO:PayrollProtectionProgramMember 2020-05-14 2020-05-16 0001424768 VYCO:CitizensBankMember VYCO:PaycheckProtectionProgramMember 2020-05-16 0001424768 VYCO:VycorMedicalMember 2020-07-01 2020-09-30 0001424768 VYCO:VycorMedicalMember 2019-07-01 2019-09-30 0001424768 VYCO:NovaVisionMember 2020-07-01 2020-09-30 0001424768 VYCO:NovaVisionMember 2019-07-01 2019-09-30 0001424768 VYCO:DiscontinuedOperationsMember 2020-09-30 0001424768 VYCO:DiscontinuedOperationsMember 2019-12-31 0001424768 country:US 2020-07-01 2020-09-30 0001424768 country:US 2019-07-01 2019-09-30 0001424768 srt:EuropeMember 2020-07-01 2020-09-30 0001424768 srt:EuropeMember 2019-07-01 2019-09-30 0001424768 2012-06-29 2012-06-30 0001424768 us-gaap:SalesRevenueNetMember 2020-07-01 2020-09-30 0001424768 us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001424768 VYCO:CustomerOneMember us-gaap:SalesRevenueNetMember 2020-07-01 2020-09-30 0001424768 VYCO:CustomerOneMember us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001424768 VYCO:SmallBusinessAdministrationMember 2020-07-06 2020-07-07 0001424768 VYCO:SmallBusinessAdministrationMember 2020-07-07 0001424768 VYCO:OfficeSpaceMember 2020-09-30 0001424768 VYCO:ConsultingAgreementMember VYCO:FountainheadMember 2019-01-01 2019-09-30 0001424768 VYCO:AmendmentAgreementMember 2019-01-01 2019-09-30 0001424768 2020-11-13 0001424768 VYCO:CustomerOneMember us-gaap:AccountsReceivableMember srt:MinimumMember 2020-01-01 2020-09-30 0001424768 VYCO:CustomerOneMember us-gaap:AccountsReceivableMember srt:MaximumMember 2020-01-01 2020-09-30 0001424768 VYCO:SmallBusinessAdministrationMember 2020-09-30 0001424768 VYCO:SmallBusinessAdministrationMember 2019-12-31 0001424768 VYCO:EuroCurrencyMember 2016-10-31 0001424768 VYCO:EuroCurrencyMember 2016-10-29 2016-10-31 0001424768 2016-10-29 2016-10-31 0001424768 VYCO:PreferredDStockDividendMember 2019-09-30 0001424768 VYCO:FountainheadMember 2019-09-30 0001424768 VYCO:PeterZachariouMember 2019-09-30 0001424768 2016-10-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure VYCO:Number iso4217:EUR 2020 VYCOR MEDICAL INC 10-Q 2020-09-30 false --12-31 Non-accelerated Filer true false Q3

1091943

990852

36540

1036857

25395

1014817

12575

1055312

6940

1029396

2004

29691

230873

30000

200873

310873

30000

280873

328032

28032

300000

555666

300000

47066

58600

150000

-768827

-1354463

2324

-1033

27771868

-28669686

127673

2539

-1033

28306592

-29790258

127670

2432

2486

-1033

28039699

28173146

-29197473

-29569267

127668

127675

-1028680

-1266966

-1907450

2700

-1033

28699931

-30736750

127675

2646

-1033

28573484

-30376278

127672

-1673482

0.0001

10000000

270307

0.0001

55000000

25391884

26999026

25288550

26895692

103334

850430

776932

73498

988786

72607

839992

10438

1051237

10156

1061393

322884

275925

250648

301053

25277

21831

270851

320476

5074

2408

752092

683125

68967

895484

68463

741675

10417

953861

10086

963947

293922

235374

211089

273146

24285

20776

230321

291536

5053

2386

-946492

-899581

-371794

-899581

-371794

-946492

-360472

23244028

270306

-103334

25391884

270306

-103334

24320456

24856170

270306

-103334

26999026

270306

-103334

26463312

270306

-103334

56000 63000 21000 63000 21000 56000 14000 14000

393500

5000

401440

Yes No false

0001424768

300000

30000

300000

280873

58600

2020-12-31

2021-11-30

2022-05-16

6331756

680000

2937133

1272052

1442571

700000

3717826

2707933

1272052

1075908

9473719

300000

The Notes will be due between December 2020 and July 2021 or on demand by the Payee.

The Loan, which was in the form of a Note dated May 16, 2020 issued by the Borrower, matures on May 16, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 16, 2020.

The Loan, evidenced by a promissory note dated July 7, 2020, has a term of thirty (30) years, bears interest at a fixed rate of three and three-quarters percent (3.75%) per annum, with monthly payments in the amount of $731.00 per month commencing twelve (12) months from the date of the note and is secured by essentially all of the assets of the Company.

0.21

2308405

0.27

0.16

0.10

0.01

0.0375

2011-06-25

2021-06-25

2020-12-31

266664

56000

1607142

337500

P0Y

3717826

0.27 0.00 0.27

700000

680000

20000

0.28

266664

299997

56000 63000 75000 82000 75000 82000

12000

13200

12000

13200

450000

0.21

0.597

0.70

0.26

80000

17873

324370

226037

83386

324370

226037

83386

0.10

0.37

0.14

0.10

0.00

0.12

0.11

0.15

1 1 2 1 0 1

59008

57202

1650

1815

5700

3717826

2020-09-30

2023-08-31

0.27

Based on the original lease agreement, the Company has the one-time option to renew the lease for another three years with minimum annual rent at market price, not less than the original lease payment amount. In January 2020, the Company exercised the option to extend the original lease for another three years with the expiration date of August 31, 2023. In accordance with ASC 842-10-35, the Company considered this lease extension as the modification of the original lease and re-measured the lease liability and the right-of-use assets on the commencement date of the lease extension.

731

150000

337500

162

338278

112447

338440

112501

161

337339

112501

112447

1612142

535714

1607142

535714

P3Y

P30Y

26895692

364953

389146

656432

484904

20117

2004

92694

90854

208353

179714

274551

137397

60717

74935

70558 155346

9574

6000

23326 14343

88097

2446406

2848749

82216

9884

233067

116085

44921 66767 280765 316798

245412

131117

1091943

1029396

127670

127675

-29790258

-30736750

1033

28306592

28699931

2539

2700

98338

97446

28962

40551

-552430

-425761

-165667

-206371

1304522

1389708

459589

441745

43780

44855

15218

14495

25832084

23689516

24222946

26365801

-0.04

-0.02

-0.01

-0.00

0.00

-0.02

-0.01

324370

162185

-622122

-575211

-209609

-198287

-605138

-477373

-183094

-220790

605138

477373

183094

220790

-52708

-51612

-17427

-14419

6000 6000

829

207

484

36033

36074

12109

12099

21846

15331

5315

7836

78011

60717

90176

74935

14218

12165

-1093

307634

43117

19034

25244

208600

80000

17873

-50558

-19064

9574

2496

60132

21560

-242862

-10795

-54218

497

-116982

-25818

-114295

104518

36033 35901

21846

15332

-2661

33309

-19221

34455

-137154

-44521

9418

35939

37201

8983

9170

688725

1675120

316798

34727

36692

56283

20859

2235

4835

9188

2565

616

41527

65471

23424

2851

87986

152396

46942

15304

87986

152240

47045

15304

-51294

-96113

-26083

-13069

-2141

-1725

-432

-879

-16984

-97838

-26515

22503

-16984

-97838

-26515

22503

2937133

31658

135003

31658 135003

28010

132176

88097

28010

44079

P8M26D

1260742

1344853

444371

427250

-622117

-575209

-209602

-198284

36451 36451 12308 -10584 34310 -1725 -432 35572 973110 1297480 156 -103

1. BASIS OF PRESENTATION   The accompanying unaudited consolidated financial statements of Vycor Medical, Inc. (the “Company” or “Vycor”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in consolidated financial statements have been omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2019 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.   The unaudited consolidated financial statements as of and for the nine months ended September 30, 2020 and 2019, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition, results of operations and cash flows. The results of operations for the nine months ended September 30, 2020 and 2019 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts on the unaudited consolidated financial statements have been reclassified to conform to the current period presentation.   Ability to continue as a Going Concern   The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $946,492 for the nine months ended September 30, 2020 and has not generated sufficient positive cash flows from operations. As of September 30, 2020 the Company had a working capital deficiency of $688,725, excluding related party liabilities of $1,675,120. These conditions, among others, raise substantial doubt regarding our ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.   The Company is executing on a plan to achieve a reduction in cash operating losses. Included within the working capital deficiency above is a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”), together with accrued interest of $316,798, which has a maturity date of December 31, 2020, having been extended on a number of occasions from its initial due date of June 11, 2011. At this time, it is not known whether any further extension of the note beyond December 31, 2020 will be available. However, the Company believes it may not have sufficient cash to meet its various cash needs through November 30, 2021 unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Fountainhead, the Company’s largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case. The Company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all. If adequate funds are not available, the Company may have to delay or curtail development or commercialization of products, or cease some of its operations.

2. SIGNIFICANT ACCOUNTING POLICIES   Principles of Consolidation   The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision GmbH have been accounted for as discontinued operations.   Recent Accounting Pronouncements   From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that, other than as disclosed above, such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.   Discontinued Operations   In accordance with ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meets the criteria in paragraph 205-20-45-1E to be classified as held for sale. When all of the criteria to be classified as held for sale are met, including management, having the authority to approve the action, commits to a plan to sell the entity, the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations (which we presented as operations to be disposed and operations disposed), less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations in accordance with ASC 205-20-45.   Leases   The Company has one leased building in Boca Raton, Florida that is classified as operating lease right-of use (“ROU”) assets and operating lease liabilities in the Company’s unaudited consolidated balance sheet as per ASC 842. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement. Operating lease expense is recognized on a straight-line basis over the lease term and is included in cost of Selling, General and Administrative expenses.   The standard was effective for us beginning January 1, 2019. The Company elected the available practical expedients on adoption. The adoption had a material impact on our unaudited consolidated balance sheets, but did not have a material impact on our unaudited consolidated statements of comprehensive loss. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.   Net Loss Per Share   Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.   The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Stock options outstanding</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">680,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">700,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrants to purchase common stock</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,717,826</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Debentures convertible into common stock</td> <td> </td> <td> </td> <td style="text-align: right">2,937,133</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,707,933</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Preferred shares convertible into common stock</td> <td> </td> <td> </td> <td style="text-align: right">1,272,052</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,272,052</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Directors Deferred Compensation Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,442,571</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,075,908</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Total</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,331,756</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,473,719</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   Covid-19   In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China, and has since spread to a number of other countries, including the United States. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition, as of the time of the filing of this Form 10-Q, several states in the United States remain in states of emergency, and travel restrictions continue to be applied in several countries around the world, including the United States. Vycor Medical experienced a reduction in demand during the nine months ended September 30, 2020 in the US and Internationally. Although neurosurgery is not considered an elective procedure, general hospital dislocation and diversion of resources away from non-emergency surgeries, or surgeries that can be postponed for a short period without harm, has impacted our revenues during the nine months ended September 30, 2020 and could continue to do so. In addition, sales and marketing efforts by Vycor’s representatives have been disrupted or curtailed due to lockdown and social distancing, and this has and may continue to hinder the recovery of revenues. While our operations are principally located in the United States, and our sub-contract manufacturers are located in the United States, we participate in a global supply chain, and the existence of a worldwide pandemic, the fear associated with COVID-19, or any, pandemic, and the reactions of governments around the world in response to COVID-19, or any, pandemic, to regulate the flow of labor and products and impede the travel of personnel, may impact our ability to conduct normal business operations, which could adversely affect our results of operations and liquidity. Disruptions to our supply chain and business operations, or to our suppliers’ or customers’ supply chains and business operations, could include disruptions from the closure of supplier and manufacturer facilities, interruptions in the supply of raw materials and components, personnel absences, or restrictions on the shipment of our or our suppliers’ or customers’ products, any of which could have adverse ripple effects on our manufacturing output and delivery schedule. Although we have implemented business continuity plans for our offices and personnel to enable continuity of service remotely, if a critical number of our employees become too ill to work, or we are not able to access a sufficient quantity of our inventory for shipment due to enforced office closures, our production ability could be materially adversely affected in a rapid manner. Similarly, if our customers experience adverse business consequences due to COVID-19, or any other, pandemic, demand for our products could also be materially adversely affected in a rapid manner. Global health concerns, such as COVID-19, could also result in social, economic, and labor instability in the countries and localities in which we or our suppliers and customers operate. Any of these uncertainties could have a material adverse effect on our business, financial condition or results of operations.

3. DISCONTINUED OPERATIONS   In April 2020, the board of Vycor took the decision to close the German operations of NovaVision, including the German office and NovaVision GmbH, and instead migrate to a licensed business model; in June 2020 Vycor announced that it would be entering into a license agreement and transition agreement (the “Agreements”) with HelferApp GmbH, a cognitive therapy specialist. Under the Agreements, HelferApp is licensed to provide NovaVision’s products and therapies in Germany, Austria and Switzerland to patients and professionals; and has assumed responsibility for the current patients of NovaVision in the territory. The NovaVision German office was closed effective June 30, 2020. The Company will continue to fund the remaining expenses of the German operations, which are non-material, until such a time as NovaVision GmbH will be formally wound up.   Reconciliation of the Major Line Items constituting Loss from discontinued operations, net of tax, that are presented in the Consolidated Statements of Comprehensive Loss   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">For the three months ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">For the nine months ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Major line items constituting loss from discontinued operations</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%">Revenue</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2,851</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">23,424</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">41,527</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">65,471</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cost of Goods Sold</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">616</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,565</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,835</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,188</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right">2,235</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">20,859</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,692</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">56,283</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating expenses:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Depreciation and Amortization</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(103</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">156</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Selling, general and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">15,304</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">47,045</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">87,986</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">152,240</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 20pt">Total Operating expenses</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">15,304</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">46,942</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">87,986</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">152,396</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating loss</td> <td> </td> <td> </td> <td style="text-align: right">(13,069</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(26,083</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(51,294</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(96,113</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Other income (expense)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Loss on foreign currency exchange</td> <td> </td> <td> </td> <td style="text-align: right">(879</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(432</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(2,141</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(1,725</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Other income (loss)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">36,451</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">36,451</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 20pt">Total Other Income (expense)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">35,572</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(432</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">34,310</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,725</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Income (loss) Before Credit for Income Taxes</td> <td> </td> <td> </td> <td style="text-align: right">22,503</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(26,515</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(16,984</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(97,838</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Credit for income taxes</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Loss from discontinued operations, net of tax</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$ </td> <td style="border-bottom: black 2.25pt double; text-align: right">22,503</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$ </td> <td style="border-bottom: black 2.25pt double; text-align: right">(26,515</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$ </td> <td style="border-bottom: black 2.25pt double; text-align: right">(16,984</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$ </td> <td style="border-bottom: black 2.25pt double; text-align: right">(97,838</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>   Other income comprises the net of non-cash adjustments made in connection with the Agreements with HeflerApp and the closure of the German operation: adjustments for assets and liabilities transferred to HelferApp or NovaVision Inc. or otherwise written off - $12,308; elimination of historic balance for NovaVision GmbH legal expenses funded by NovaVision Inc. - $34,727; and certain accruals for employee costs – ($10,584).

4. NOTES PAYABLE   Related Parties Notes Payable   Related Party Notes Payable consists of:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify">On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $30,000. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2021 or on demand by the Payee.</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">30,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">30,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify">Between March 26, 2018 and April 24, 2020 the Company issued various promissory notes to Fountainhead Capital Management Limited for $280,873. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. Six notes were extended on their due dates for another twelve months. The Notes will be due between December 2020 and July 2021 or on demand by the Payee.</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">280,873</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">200,873</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">Total Related Party Notes Payable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">310,873</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">230,873</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   Other Notes Payable   Other Notes Payable consists of:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify">On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011, and has been extended on a number of occasions. On the note’s most recent due date, the note was extended to December 31, 2020. The note is personally guaranteed by certain officers and directors of the Company. See further note below</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">300,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">300,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">On May 16, 2020, the Company was granted a loan from Citizens Bank N.A. in the aggregate amount of $58,600, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The Loan, which was in the form of a Note dated May 16, 2020 issued by the Borrower, matures on May 16, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 16, 2020. The Note may be prepaid by the Borrower at any time prior to maturity with no prepayment penalties. Under the terms of the PPP, the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. The Company’s use of the Loan qualifies and intends to apply once the forgiveness program commences.</td> <td> </td> <td> </td> <td style="text-align: right">58,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">On July 7, 2020, the Company was advised that the Small Business Administration (SBA) had approved a $150,000 loan under the Economic Injury Disaster Loan Program pursuant to the Coronavirus Aid, Relief and Economic Security (CARES) Act (“Loan”). The Loan, evidenced by a promissory note dated July 7, 2020, has a term of thirty (30) years, bears interest at a fixed rate of three and three-quarters percent (3.75%) per annum, with monthly payments in the amount of $731.00 per month commencing twelve (12) months from the date of the note and is secured by essentially all of the assets of the Company. The proceeds of the Loan will be used for general working capital purposes to alleviate economic injury caused by disaster occurring in the month of January 2020 and continuing thereafter.</td> <td> </td> <td> </td> <td style="text-align: right">150,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify">Insurance policy finance agreements and other.</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">47,066</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">28,032</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify">Total Other Notes Payable:</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">555,666</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">328,032</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   In January 2018 the Company entered into an amendment agreement (the “Amendment”) with EuroAmerican Investments (“EuroAmerican”) regarding its $300,000 loan note (the “Note”). Under the Amendment, the Note was extended and the conversion terms of the Note were reduced to $0.21, the same as the offering price of the 2018 Offering. Conversion of the Note and accrued interest would result in the issuance of 2,937,133 shares of Common Stock as of September 30, 2020. Notwithstanding, EuroAmerican agreed that the Note could not be converted without first offering the Company the right to redeem the Note at principal and accrued interest, and secondly Fountainhead the right to purchase the Note, which cannot be converted prior to such offer and the failure of the Company and Fountainhead to exercise such option in accordance with the amendment terms. In addition, the Company agreed to issue warrants to purchase 2,308,405 shares of Common Stock at $0.27, the same terms as the 2018 Offering, exercisable for three years from January 1, 2018, if and when the conversion option is exercised. The amendment was recognized as a modification, based on the guidance in ASC 470-50.   The Company routinely finances all their insurance policies through a third party finance company which requires a down payment and subsequent monthly payments, the time periods vary from 10 months to 12 equal monthly payments.

5. LEASE   The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $5,700 plus sales tax per month that will expire on September 30, 2020. Based on the original lease agreement, the Company had the one-time option to renew the lease for another three years with minimum annual rent at market price, not less than the original lease payment amount. In January 2020, the Company exercised the option to extend the original lease for another three years with the expiration date of August 31, 2023. In accordance with ASC 842-10-35, the Company considered this lease extension as the modification of the original lease and re-measured the lease liability and the right-of-use assets on the commencement date of the lease extension.   The Company recognized the following in its unaudited consolidated balance sheet at September 30, 2020 and December 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; padding-bottom: 1.5pt">Operating Lease ROU Assets</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 22%; text-align: right">135,003</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 22%; text-align: right">31,658</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">135,003</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">31,658</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating Lease Liabilities</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> Current portion</td> <td> </td> <td> </td> <td style="text-align: right">44,079</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">28,010</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"> Long-term portion</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">88,097</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">132,176</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">28,010</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

6. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION   (a) Business segments   The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Revenue:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; padding-left: 10pt">Vycor Medical</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">250,648</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">301,053</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">776,932</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">988,786</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">NovaVision</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">25,277</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">21,831</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">73,498</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">72,607</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">275,925</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">322,884</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">850,430</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,061,393</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Vycor Medical</td> <td> </td> <td>$</td> <td style="text-align: right">211,089</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">273,146</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">683,125</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">895,484</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">NovaVision</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">24,285</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">20,776</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">68,967</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">68,463</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">235,374</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">293,922</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">752,092</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">963,947</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> September 30, 2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> December 31, 2019</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt">Vycor Medical</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">990,852</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,036,857</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">NovaVision</td> <td> </td> <td> </td> <td style="text-align: right">36,540</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,395</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Discontinued operations</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,004</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">29,691</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,029,396</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,091,943</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   (b) Geographic information   The Company operates in two geographic segments, the United States and Europe. Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Revenue:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; padding-left: 10pt">United States</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">270,851</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">320,476</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">839,992</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">1,051,237</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Europe</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,074</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,408</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">10,438</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">10,156</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">275,925</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">322,884</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">850,430</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,061,393</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">United States</td> <td> </td> <td>$</td> <td style="text-align: right">230,321</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">291,536</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">741,675</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">953,861</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Europe</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,053</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,386</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">10,417</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">10,086</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">235,374</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">293,922</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">752,092</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">963,947</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt">United States</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,014,817</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,055,312</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Europe</td> <td> </td> <td> </td> <td style="text-align: right">12,575</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,940</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Discontinued operations</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,004</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">29,691</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 20pt">Total Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,029,396</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,091,943</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

7. EQUITY   Common Stock and Stock Grants   During January to September 2020 and 2019, the Company granted 266,664 shares of Common Stock (valued at $56,000) to non-employee Directors. Under the terms of the Directors Deferred Compensation Plan, the receipt of these shares is deferred until the January 15th following the termination of their services as a director. As of September 30, 2020 these shares have yet to be issued.   During January to September 2020 and 2019, under the terms of the Consulting Agreement referred to in note 10, the Company issued 1,607,142 of Common Stock to Fountainhead for fees of $337,500 in each period respectively.   Warrants and Options   The details of the outstanding warrants and options are as follows:   STOCK WARRANTS:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">exercise price per share</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Outstanding at December 31, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">3,717,826</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">0.27</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Cancelled or expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,717,826</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.27</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.00</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   STOCK OPTIONS:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">exercise price per share</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Outstanding at December 31, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">700,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">0.28</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Cancelled or expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(20,000</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.27</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">680,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.28</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of September 30, 2020, the weighted-average remaining contractual life of outstanding warrants and options is 0 and 0.74 years, respectively.

8. SHARE-BASED COMPENSATION   Stock Option Plan   Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option-vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis.   For each of the nine months ended September 30, 2020 and 2019, the Company recognized share-based compensation of $0 for employee stock options.   Stock appreciation rights may be granted either on a stand-alone basis or in conjunction with all or part of any other stock options granted under the plan. As of September 30, 2020 there were no awards of any stock appreciation rights.   Non-Employee Stock Compensation   The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date”. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.   Aggregate stock-based compensation for stock granted to non-employees for each of the nine months ended September 30, 2020 and 2019 was $266,664 and $299,997. The expense related to stock not issued during each of the periods ended September 30, 2020 and 2019 comprises $56,000 and $63,000, related to stock granted but not issued to directors under the Directors Deferred Compensation Plan. As of September 30, 2020, there was $0 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.   Stock-based Compensation Valuation Methodology   Stock-based compensation resulting from the issuance of Common Stock is calculated by reference to the valuation of the Stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. Expected volatility is based on the historical volatility of a peer group of publicly traded companies. The expected term of options and warrants was based upon the expected life of the option or warrant, and the risk-free rate is based on the U.S. Treasury Constant Maturity rate.   There were no options or warrants issued during either of the periods ending September 30, 2020 and 2019.

9. COMMITMENTS AND CONTINGENCIES   Lease   The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $5,700 plus sales tax per month. The lease terminates September 30, 2020 and has been extended for a further three years to August 31, 2023. The Company’s subsidiary in Germany occupied premises on a rolling 12 month lease agreement with a 3 month notice period of EUR1,650 per month (approximately $1,815), which was terminated effective June 30, 2020. Rent expense for the nine months ended September 30, 2020 and 2019 for the continuing operations was $59,008 and $57,202 respectively. See Note 5.   Potential German tax liability   In June 2012 the Company’s NovaVision German subsidiary received a preliminary assessment for Magdeburg City trade tax of €75,000 (approximately $82,000), with an additional interest charge of €12,000 (approximately $13,200). This assessment is for the 2010 fiscal year and relates to the Company’s acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period was preliminarily reduced to zero. The Company did not accept this trade tax assessment and appealed against it to the relevant tax authorities with a view to its reduction. The relevant tax authorities agreed to suspend the assessment pending the outcome of certain court hearings and proposed tax legislation, and the Company agreed to make monthly payments on account totaling €75,000 (approximately $82,000) which were completed in October 2016 and fully expensed. At that time the Company appealed against the interest charge of €12,000 (approximately $13,200) which the tax authorities did not accept but also agreed to suspend pending the outcome of the hearings and proposed legislation outlined above. Accordingly, the Company has made no provision for this liability in the nine months ended September 30, 2020 and the year ended December 31, 2019 respectively.

10. CONSULTING AND OTHER AGREEMENTS   The following agreements were entered into or remained in force during the period ended September 30, 2020:   Consulting Agreement with Fountainhead   In March 2017 and effective April 1, 2017, the Company amended the Fountainhead Consulting Agreement (“the Amended Agreement”). Under the Amended Agreement, fees of $450,000 are payable to Fountainhead, with an option to receive $5,000 per month in cash and the remainder payable in Company Common Stock issued at the higher of $0.21 and the average price for the 30 days prior to issuance, and deliverable at the end of each fiscal quarter. The Consulting Agreement also contains provisions for Fountainhead to receive a higher proportion of its fees in cash subject to certain future liquidity events and Board approval. Under the terms of the Amended Agreement, Fountainhead provides the executive management team of the Company, including the positions of CEO, President and CFO, whose employment agreements with the Company stipulate they receive no remuneration from the Company.   During the nine months ended September 30, 2020 and September 30, 2019, under the terms of the Amended Agreement, Fountainhead received total fees of $337,500, which were paid through the issuance of 1,607,142 shares of Company Common Stock.

11. RELATED PARTY TRANSACTIONS   Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at September 30, 2020, 59.7% of the Company’s Common Stock and 70% of the Company’s Preferred D Stock. Peter Zachariou owns 26% of the Company’s Preferred D Stock. Adrian Liddell, Chairman, is a consultant for Fountainhead.   During each of the nine months ended September 30, 2020 and September 30, 2019, under the terms of the Consulting Agreement referred to in note 10, the Company issued 1,607,142 shares of Common Stock to Fountainhead for fees of $337,500.   During each of the nine months ended September 30, 2020 and 2019, the Company accrued an aggregate of $324,370 of Preferred D Stock dividends, of which $226,037 was in respect of Fountainhead and $83,386 was in respect of Peter Zachariou.   During the nine months ended September 30, 2020 and 2019 the Company issued unsecured loan notes to Fountainhead for a total of $80,000 and $17,873, respectively. The loan notes bear interest at a rate of 10% and are due on demand or by their one-year anniversary.   There were no other related party transactions during the nine months ended September 30, 2020 and 2019.

12. CONCENTRATION   Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals.   Sales Concentration:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%">Number of customers over 10%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">0</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">1</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">1</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">1</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Percentage of sales</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">12</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">14</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">10</td> <td>%</td></tr> </table>   Accounts Receivable Concentration   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">At September 30,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">At December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Number of customers over 10%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">2</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">1</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Percentage of accounts receivable</td> <td> </td> <td> </td> <td style="text-align: right"> 11% and 15</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">37</td> <td>%</td></tr> </table>   The Company has three sub-contract manufacturers from which it purchases, respectively, VBAS injection molded parts, completed and sterilized VBAS units, and VBAS extension arms. Purchases from these manufacturers vary from quarter to quarter, with no purchases in some quarters, however on an annual basis purchases from each manufacturer represent over 10% of total annual purchases.

13. SUBSEQUENT EVENTS   The Company has evaluated the existence of events and transactions subsequent to the balance sheet date through the date the unaudited consolidated financial statements were issued and has determined that there were no significant subsequent events or transactions which would require recognition or disclosure in the financial statements.

Principles of Consolidation   The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision GmbH have been accounted for as discontinued operations.

Recent Accounting Pronouncements   From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that, other than as disclosed above, such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

Discontinued Operations   In accordance with ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meets the criteria in paragraph 205-20-45-1E to be classified as held for sale. When all of the criteria to be classified as held for sale are met, including management, having the authority to approve the action, commits to a plan to sell the entity, the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations (which we presented as operations to be disposed and operations disposed), less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations in accordance with ASC 205-20-45.

Leases   The Company has one leased building in Boca Raton, Florida that is classified as operating lease right-of use (“ROU”) assets and operating lease liabilities in the Company’s unaudited consolidated balance sheet as per ASC 842. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement. Operating lease expense is recognized on a straight-line basis over the lease term and is included in cost of Selling, General and Administrative expenses.   The standard was effective for us beginning January 1, 2019. The Company elected the available practical expedients on adoption. The adoption had a material impact on our unaudited consolidated balance sheets, but did not have a material impact on our unaudited consolidated statements of comprehensive loss. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

Net Loss Per Share   Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.   The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Stock options outstanding</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">680,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">700,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrants to purchase common stock</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,717,826</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Debentures convertible into common stock</td> <td> </td> <td> </td> <td style="text-align: right">2,937,133</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,707,933</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Preferred shares convertible into common stock</td> <td> </td> <td> </td> <td style="text-align: right">1,272,052</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,272,052</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Directors Deferred Compensation Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,442,571</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,075,908</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Total</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,331,756</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,473,719</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>

Covid-19   In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China, and has since spread to a number of other countries, including the United States. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition, as of the time of the filing of this Form 10-Q, several states in the United States remain in states of emergency, and travel restrictions continue to be applied in several countries around the world, including the United States. Vycor Medical experienced a reduction in demand during the nine months ended September 30, 2020 in the US and Internationally. Although neurosurgery is not considered an elective procedure, general hospital dislocation and diversion of resources away from non-emergency surgeries, or surgeries that can be postponed for a short period without harm, has impacted our revenues during the nine months ended September 30, 2020 and could continue to do so. In addition, sales and marketing efforts by Vycor’s representatives have been disrupted or curtailed due to lockdown and social distancing, and this has and may continue to hinder the recovery of revenues. While our operations are principally located in the United States, and our sub-contract manufacturers are located in the United States, we participate in a global supply chain, and the existence of a worldwide pandemic, the fear associated with COVID-19, or any, pandemic, and the reactions of governments around the world in response to COVID-19, or any, pandemic, to regulate the flow of labor and products and impede the travel of personnel, may impact our ability to conduct normal business operations, which could adversely affect our results of operations and liquidity. Disruptions to our supply chain and business operations, or to our suppliers’ or customers’ supply chains and business operations, could include disruptions from the closure of supplier and manufacturer facilities, interruptions in the supply of raw materials and components, personnel absences, or restrictions on the shipment of our or our suppliers’ or customers’ products, any of which could have adverse ripple effects on our manufacturing output and delivery schedule. Although we have implemented business continuity plans for our offices and personnel to enable continuity of service remotely, if a critical number of our employees become too ill to work, or we are not able to access a sufficient quantity of our inventory for shipment due to enforced office closures, our production ability could be materially adversely affected in a rapid manner. Similarly, if our customers experience adverse business consequences due to COVID-19, or any other, pandemic, demand for our products could also be materially adversely affected in a rapid manner. Global health concerns, such as COVID-19, could also result in social, economic, and labor instability in the countries and localities in which we or our suppliers and customers operate. Any of these uncertainties could have a material adverse effect on our business, financial condition or results of operations.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Stock options outstanding</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">680,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">700,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrants to purchase common stock</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,717,826</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Debentures convertible into common stock</td> <td> </td> <td> </td> <td style="text-align: right">2,937,133</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,707,933</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Preferred shares convertible into common stock</td> <td> </td> <td> </td> <td style="text-align: right">1,272,052</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,272,052</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Directors Deferred Compensation Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,442,571</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,075,908</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Total</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,331,756</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,473,719</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>

Reconciliation of the Major Line Items constituting Loss from discontinued operations, net of tax, that are presented in the Consolidated Statements of Comprehensive Loss   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">For the three months ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">For the nine months ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Major line items constituting loss from discontinued operations</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%">Revenue</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2,851</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">23,424</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">41,527</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">65,471</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cost of Goods Sold</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">616</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,565</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,835</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,188</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right">2,235</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">20,859</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,692</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">56,283</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating expenses:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Depreciation and Amortization</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(103</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">156</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Selling, general and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">15,304</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">47,045</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">87,986</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">152,240</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 20pt">Total Operating expenses</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">15,304</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">46,942</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">87,986</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">152,396</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating loss</td> <td> </td> <td> </td> <td style="text-align: right">(13,069</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(26,083</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(51,294</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(96,113</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Other income (expense)</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Loss on foreign currency exchange</td> <td> </td> <td> </td> <td style="text-align: right">(879</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(432</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(2,141</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(1,725</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Other income (loss)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">36,451</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">36,451</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 20pt">Total Other Income (expense)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">35,572</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(432</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">34,310</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,725</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Income (loss) Before Credit for Income Taxes</td> <td> </td> <td> </td> <td style="text-align: right">22,503</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(26,515</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(16,984</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(97,838</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Credit for income taxes</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Loss from discontinued operations, net of tax</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$ </td> <td style="border-bottom: black 2.25pt double; text-align: right">22,503</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$ </td> <td style="border-bottom: black 2.25pt double; text-align: right">(26,515</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$ </td> <td style="border-bottom: black 2.25pt double; text-align: right">(16,984</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$ </td> <td style="border-bottom: black 2.25pt double; text-align: right">(97,838</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

Related Party Notes Payable consists of:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify">On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $30,000. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2021 or on demand by the Payee.</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">30,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">30,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify">Between March 26, 2018 and April 24, 2020 the Company issued various promissory notes to Fountainhead Capital Management Limited for $280,873. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. Six notes were extended on their due dates for another twelve months. The Notes will be due between December 2020 and July 2021 or on demand by the Payee.</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">280,873</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">200,873</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">Total Related Party Notes Payable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">310,873</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">230,873</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   Other Notes Payable   Other Notes Payable consists of:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify">On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011, and has been extended on a number of occasions. On the note’s most recent due date, the note was extended to December 31, 2020. The note is personally guaranteed by certain officers and directors of the Company. See further note below</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">300,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">300,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">On May 16, 2020, the Company was granted a loan from Citizens Bank N.A. in the aggregate amount of $58,600, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The Loan, which was in the form of a Note dated May 16, 2020 issued by the Borrower, matures on May 16, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 16, 2020. The Note may be prepaid by the Borrower at any time prior to maturity with no prepayment penalties. Under the terms of the PPP, the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. The Company’s use of the Loan qualifies and intends to apply once the forgiveness program commences.</td> <td> </td> <td> </td> <td style="text-align: right">58,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">On July 7, 2020, the Company was advised that the Small Business Administration (SBA) had approved a $150,000 loan under the Economic Injury Disaster Loan Program pursuant to the Coronavirus Aid, Relief and Economic Security (CARES) Act (“Loan”). The Loan, evidenced by a promissory note dated July 7, 2020, has a term of thirty (30) years, bears interest at a fixed rate of three and three-quarters percent (3.75%) per annum, with monthly payments in the amount of $731.00 per month commencing twelve (12) months from the date of the note and is secured by essentially all of the assets of the Company. The proceeds of the Loan will be used for general working capital purposes to alleviate economic injury caused by disaster occurring in the month of January 2020 and continuing thereafter.</td> <td> </td> <td> </td> <td style="text-align: right">150,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify">Insurance policy finance agreements and other.</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">47,066</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">28,032</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify">Total Other Notes Payable:</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">555,666</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">328,032</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The Company recognized the following in its unaudited consolidated balance sheet at September 30, 2020 and December 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; padding-bottom: 1.5pt">Operating Lease ROU Assets</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 22%; text-align: right">135,003</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 22%; text-align: right">31,658</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">135,003</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">31,658</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating Lease Liabilities</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> Current portion</td> <td> </td> <td> </td> <td style="text-align: right">44,079</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">28,010</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"> Long-term portion</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">88,097</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">132,176</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">28,010</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Revenue:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; padding-left: 10pt">Vycor Medical</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">250,648</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">301,053</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">776,932</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">988,786</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">NovaVision</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">25,277</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">21,831</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">73,498</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">72,607</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">275,925</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">322,884</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">850,430</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,061,393</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Vycor Medical</td> <td> </td> <td>$</td> <td style="text-align: right">211,089</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">273,146</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">683,125</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">895,484</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">NovaVision</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">24,285</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">20,776</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">68,967</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">68,463</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">235,374</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">293,922</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">752,092</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">963,947</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> September 30, 2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> December 31, 2019</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt">Vycor Medical</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">990,852</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,036,857</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">NovaVision</td> <td> </td> <td> </td> <td style="text-align: right">36,540</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,395</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Discontinued operations</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,004</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">29,691</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,029,396</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,091,943</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Revenue:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; padding-left: 10pt">United States</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">270,851</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">320,476</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">839,992</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">1,051,237</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Europe</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,074</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,408</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">10,438</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">10,156</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">275,925</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">322,884</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">850,430</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,061,393</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">United States</td> <td> </td> <td>$</td> <td style="text-align: right">230,321</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">291,536</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">741,675</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">953,861</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Europe</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,053</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,386</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">10,417</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">10,086</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">235,374</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">293,922</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">752,092</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">963,947</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt">United States</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,014,817</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,055,312</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Europe</td> <td> </td> <td> </td> <td style="text-align: right">12,575</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,940</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Discontinued operations</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,004</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">29,691</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 20pt">Total Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,029,396</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,091,943</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

STOCK WARRANTS:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">exercise price per share</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Outstanding at December 31, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">3,717,826</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">0.27</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Cancelled or expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,717,826</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.27</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.00</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

STOCK OPTIONS:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">exercise price per share</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Outstanding at December 31, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">700,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">0.28</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Cancelled or expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(20,000</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.27</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">680,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.28</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Sales Concentration:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%">Number of customers over 10%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">0</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">1</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">1</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">1</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Percentage of sales</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">12</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">14</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">10</td> <td>%</td></tr> </table>   Accounts Receivable Concentration   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">At September 30,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">At December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Number of customers over 10%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">2</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">1</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Percentage of accounts receivable</td> <td> </td> <td> </td> <td style="text-align: right"> 11% and 15</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">37</td> <td>%</td></tr> </table>

EX-101.SCH 7 vyco-20200930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Stockholders' Deficiency (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Lease link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Segment Reporting, Geographical Information link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Consulting and Other Agreements link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Concentration link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Segment Reporting, Geographical Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Concentration (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Significant Accounting Policies - Schedule of Common Stock Not Included in Calculation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Discontinued Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Discontinued Operations - Schedule of Loss from Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Notes Payable - Summary of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Notes Payable - Summary of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Lease (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Lease - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Segment Reporting, Geographical Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Segment Reporting, Geographical Information - Schedule of Business Segments Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Segment Reporting, Geographical Information - Summary of Geographic Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Equity - Schedule of Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Equity - Schedule of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Consulting and Other Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Concentration (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Concentration - Schedule of Concentration (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vyco-20200930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 vyco-20200930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 vyco-20200930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Preferred C [Member] Preferred D [Member] Treasury Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Income (Loss) [Member] Antidilutive Securities [Axis] Stock Options Outstanding [Member] Warrants to Purchase Common Stock [Member] Debentures Convertible into Common Stock [Member] Preferred Shares Convertible into Common Stock [Member] Directors Deferred Compensation Plan [Member] Related Party [Axis] EuroAmerican Investment Corp. [Member] Stock Warrants [Member] Short-Term Debt, Type [Axis] Insurance Policy Finance Agreements [Member] Peter Zachariou [Member] Legal Entity [Axis] Debt Instrument [Axis] Term Note [Member] Business Segments [Axis] Vycor Medical [Member] Nova Vision [Member] Geographical [Axis] United States [Member] Europe [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Fountainhead Consulting Agreement [Member] Scenario [Axis] March 2017 and Effective April 1, 2017 [Member] Related Party Transaction [Axis] Fountainhead [Member] Title of Individual [Axis] Directors [Member] Class of Stock [Axis] Series D Preferred Stock [Member] Unsecured Loan [Member] Customer [Axis] Customer One [Member] Concentration Risk Benchmark [Axis] Sales Revenue [Member] Consulting Agreement [Member] Loan Restructuring Modification [Axis] Extended Maturity [Member] Accounts Receivable [Member] Fountainhead Capital Management Limited [Member] Non Employee Directors [Member] Plan Name [Axis] Directors Deferred Compensation Plan [Member] Manufacturer One [Member] Purchase [Member] Manufacturer Two [Member] Consultancy Agreement [Member] Preferred D Stock dividends [Member] Manufacturer Three [Member] Award Type [Axis] Euro Currency [Member] Employee Stock Options [Member] Non-employee [Member] German [Member] Long-Lived Tangible Asset [Axis] Office Space [Member] Amendment Agreement [Member] Credit Facility [Axis] Citizens Bank [Member] Payroll Protection Program [Member] Paycheck Protection Program [Member] Discontinued Operations [Member] Small Business Administration [Member] Range [Axis] Minimum [Member] Maximum [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Trade accounts receivable Inventory Prepaid expenses and other current assets Current assets of discontinued operations Total Current Assets Fixed assets, net Intangible and Other assets: Patents, net of accumulated amortization Security deposits Operating lease - right of use assets Long term assets of discontinued operations Total Intangible and Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIENCY Current Liabilities Accounts payable Accrued interest: Other Accrued interest: Related party Accrued liabilities - Other Accrued liabilities - Related Party Notes payable: Other Notes payable: Related Party Current operating lease liabilities Current liabilities of discontinued operations Total Current Liabilities Operating lease liability - Long term STOCKHOLDERS' DEFICIENCY Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 270,307 and 270,307 issued and outstanding as at September 30, 2020 and December 31, 2019 respectively Common Stock, $0.0001 par value, 55,000,000 shares authorized at September 30, 2020 and December 31, 2019, 26,999,026 and 25,391,884 shares issued and 26,895,692 and 25,288,550 outstanding at September. 30, 2020 and December 31, 2019 respectively Additional Paid-in Capital Treasury Stock (103,334 shares of Common Stock as at September 30, 2020 and December 31, 2019 respectively, at cost) Accumulated Deficit Accumulated Other Comprehensive Income Total Stockholders' Deficiency TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] Revenue Cost of Goods Sold Gross Profit Operating expenses: Depreciation and Amortization General and administrative Total Operating expenses Operating loss Other income (expense) Interest expense: Related Party Interest expense: Other Loss on foreign currency exchange Gain on other income Total Other Income (expense) Loss Before Credit for Income Taxes Credit for income taxes Net Loss from continuing operations Income (Loss) from discontinued operations, net of tax Net loss Preferred stock dividends Net Loss available to common stockholders Other Comprehensive Loss Foreign Currency Translation Adjustment Comprehensive Loss Net Loss Per Share - basic and diluted Loss from continuing operations Income (Loss) from discontinued operations Net loss available to common stockholders Weighted Average Number of Shares Outstanding - Basic and Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Issuance of stock for board and consulting fees Issuance of stock for board and consulting fees, shares Directors deferred compensation granted Issuance of shares pursuant to exercise of warrants Issuance of shares pursuant to exercise of warrants, shares Accumulated Comprehensive Loss Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to cash used in operating activities: Amortization of intangible assets Depreciation of fixed assets Inventory provision Stock based compensation Changes in assets and liabilities: Accounts receivable Inventory EX-101.PRE 11 vyco-20200930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 13, 2020
Cover [Abstract]
Entity Registrant Name	VYCOR MEDICAL INC
Entity Central Index Key	0001424768
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,895,692
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current Assets
Cash	$ 74,935	$ 60,717
Trade accounts receivable	137,397	274,551
Inventory	179,714	208,353
Prepaid expenses and other current assets	90,854	92,694
Current assets of discontinued operations	2,004	20,117
Total Current Assets	484,904	656,432
Fixed assets, net	389,146	364,953
Intangible and Other assets:
Patents, net of accumulated amortization	14,343	23,326
Security deposits	6,000	6,000
Operating lease - right of use assets	135,003	31,658
Long term assets of discontinued operations		9,574
Total Intangible and Other assets	155,346	70,558
TOTAL ASSETS	1,029,396	1,091,943
Current Liabilities
Accounts payable	131,117	245,412
Accrued interest: Other	316,798	280,765
Accrued interest: Related party	66,767	44,921
Accrued liabilities - Other	116,085	233,067
Accrued liabilities - Related Party	1,297,480	973,110
Notes payable: Other	555,666	328,032
Notes payable: Related Party	310,873	230,873
Current operating lease liabilities	44,079	28,010
Current liabilities of discontinued operations	9,884	82,216
Total Current Liabilities	2,848,749	2,446,406
Operating lease liability - Long term	88,097
STOCKHOLDERS' DEFICIENCY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 270,307 and 270,307 issued and outstanding as at September 30, 2020 and December 31, 2019 respectively	27	27
Common Stock, $0.0001 par value, 55,000,000 shares authorized at September 30, 2020 and December 31, 2019, 26,999,026 and 25,391,884 shares issued and 26,895,692 and 25,288,550 outstanding at September. 30, 2020 and December 31, 2019 respectively	2,700	2,539
Additional Paid-in Capital	28,699,931	28,306,592
Treasury Stock (103,334 shares of Common Stock as at September 30, 2020 and December 31, 2019 respectively, at cost)	(1,033)	(1,033)
Accumulated Deficit	(30,736,750)	(29,790,258)
Accumulated Other Comprehensive Income	127,675	127,670
Total Stockholders' Deficiency	(1,907,450)	(1,354,463)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$ 1,029,396	$ 1,091,943

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	270,307	270,307
Preferred stock, shares outstanding	270,307	270,307
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	55,000,000	55,000,000
Common stock, shares issued	26,999,026	25,391,884
Common stock, shares outstanding	26,895,692	25,288,550
Treasury stock, shares	103,334	103,334

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue	$ 275,925	$ 322,884	$ 850,430	$ 1,061,393
Cost of Goods Sold	40,551	28,962	98,338	97,446
Gross Profit	235,374	293,922	752,092	963,947
Operating expenses:
Depreciation and Amortization	14,495	15,218	43,780	44,855
General and administrative	427,250	444,371	1,260,742	1,344,853
Total Operating expenses	441,745	459,589	1,304,522	1,389,708
Operating loss	(206,371)	(165,667)	(552,430)	(425,761)
Other income (expense)
Interest expense: Related Party	(7,836)	(5,315)	(21,846)	(15,331)
Interest expense: Other	(12,099)	(12,109)	(36,033)	(36,074)
Loss on foreign currency exchange	(484)	(3)	(829)	(207)
Gain on other income	6,000		6,000
Total Other Income (expense)	(14,419)	(17,427)	(52,708)	(51,612)
Loss Before Credit for Income Taxes	(220,790)	(183,094)	(605,138)	(477,373)
Credit for income taxes
Net Loss from continuing operations	(220,790)	(183,094)	(605,138)	(477,373)
Income (Loss) from discontinued operations, net of tax	22,503	(26,515)	(16,984)	(97,838)
Net loss	(198,287)	(209,609)	(622,122)	(575,211)
Preferred stock dividends	(162,185)	(162,185)	(324,370)	(324,370)
Net Loss available to common stockholders	(360,472)	(371,794)	(946,492)	(899,581)
Other Comprehensive Loss
Foreign Currency Translation Adjustment	3	7	5	2
Comprehensive Loss	$ (198,284)	$ (209,602)	$ (622,117)	$ (575,209)
Net Loss Per Share - basic and diluted
Loss from continuing operations	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Income (Loss) from discontinued operations	0.00	(0.00)	(0.00)	(0.00)
Net loss available to common stockholders	$ (0.01)	$ (0.02)	$ (0.04)	$ (0.04)
Weighted Average Number of Shares Outstanding - Basic and Diluted	26,365,801	24,222,946	25,832,084	23,689,516

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Common Stock [Member]
Balance	$ 2,646	$ 2,432	$ 2,539	$ 2,324
Balance, shares	26,463,312	24,320,456	25,391,884	23,244,028
Issuance of stock for board and consulting fees	$ 54	$ 54	$ 161	$ 162
Issuance of stock for board and consulting fees, shares	535,714	535,714	1,607,142	1,612,142
Directors deferred compensation granted
Accumulated Comprehensive Loss
Net loss
Balance	$ 2,700	$ 2,486	$ 2,700	$ 2,486
Balance, shares	26,999,026	24,856,170	26,999,026	24,856,170
Preferred C [Member]
Balance	$ 0	$ 0	$ 0	$ 0
Balance, shares	1	1	1	1
Issuance of stock for board and consulting fees
Directors deferred compensation granted
Accumulated Comprehensive Loss
Net loss
Balance	$ 0	$ 0	$ 0	$ 0
Balance, shares	1	1	1	1
Preferred D [Member]
Balance	$ 27	$ 27	$ 27	$ 27
Balance, shares	270,306	270,306	270,306	270,306
Issuance of stock for board and consulting fees
Directors deferred compensation granted
Accumulated Comprehensive Loss
Net loss
Balance	$ 27	$ 27	$ 27	$ 27
Balance, shares	270,306	270,306	270,306	270,306
Treasury Stock [Member]
Balance	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)
Balance, shares	(103,334)	(103,334)	(103,334)	(103,334)
Issuance of stock for board and consulting fees
Directors deferred compensation granted
Accumulated Comprehensive Loss
Net loss
Balance	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)
Balance, shares	(103,334)	(103,334)	(103,334)	(103,334)
Additional Paid-In Capital [Member]
Balance	$ 28,573,484	$ 28,039,699	$ 28,306,592	$ 27,771,868
Issuance of stock for board and consulting fees	112,447	112,447	337,339	338,278
Directors deferred compensation granted	14,000	21,000	56,000	63,000
Accumulated Comprehensive Loss
Net loss
Balance	28,699,931	28,173,146	28,699,931	28,173,146
Accumulated Deficit [Member]
Balance	(30,376,278)	(29,197,473)	(29,790,258)	(28,669,686)
Issuance of stock for board and consulting fees
Directors deferred compensation granted
Accumulated Comprehensive Loss
Net loss	(360,472)	(371,794)	(946,492)	(899,581)
Balance	(30,736,750)	(29,569,267)	(30,736,750)	(29,569,267)
Accumulated Other Comprehensive Income (Loss) [Member]
Balance	127,672	127,668	127,670	127,673
Issuance of stock for board and consulting fees
Directors deferred compensation granted
Accumulated Comprehensive Loss	3	7	5	2
Net loss
Balance	127,675	127,675	127,675	127,675
Balance	(1,673,482)	(1,028,680)	(1,354,463)	(768,827)
Issuance of stock for board and consulting fees	112,501	112,501	337,500	338,440
Directors deferred compensation granted	14,000	21,000	56,000	63,000
Issuance of shares pursuant to exercise of warrants
Accumulated Comprehensive Loss	3	7	5	2
Net loss	(360,472)	(371,794)	(946,492)	(899,581)
Balance	$ (1,907,450)	$ (1,266,966)	$ (1,907,450)	$ (1,266,966)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (622,122)	$ (575,211)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization of intangible assets	8,983	9,170
Depreciation of fixed assets	35,939	37,201
Inventory provision	9,418	9,418
Stock based compensation	393,500	401,440
Changes in assets and liabilities:
Accounts receivable	137,154	44,521
Inventory	19,221	(34,455)
Prepaid expenses	2,661	(33,309)
Accrued interest - Related Party	21,846	15,332
Accrued interest - Other	36,033	35,901
Accounts payable	(114,295)	104,518
Accrued liabilities - Other	(116,982)	(25,818)
Changes in discontinued operations, net	(54,218)	497
Cash used in operating activities	(242,862)	(10,795)
Cash flows from investing activities:
Purchase of fixed assets	(60,132)	(21,560)
Changes in investing activities of discontinued operations, net	9,574	2,496
Cash used in investing activities	(50,558)	(19,064)
Cash flows from financing activities:
Proceeds from Notes Payable - Related Party	80,000	17,873
Proceeds from Paycheck Protection Program and EIDL	208,600
Proceeds net of repayments Notes Payable - Other	19,034	25,244
Cash provided by financing activities	307,634	43,117
Effect of exchange rate changes on cash	4	(1,093)
Net increase (decrease) in cash	14,218	12,165
Cash at beginning of period	60,717	78,011
Cash at end of period	74,935	90,176
Non-Cash Transactions:
Common stock issued to related party for payment of accrued liabilities	$ 0	$ 0

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Sep. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

1. BASIS OF PRESENTATION

Ability to continue as a Going Concern

XML 19 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Significant Accounting Policies

2. SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

Recent Accounting Pronouncements

Discontinued Operations

Leases

Net Loss Per Share

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

	September 30, 2020		September 30, 2019
Stock options outstanding		680,000		700,000
Warrants to purchase common stock		-		3,717,826
Debentures convertible into common stock		2,937,133		2,707,933
Preferred shares convertible into common stock		1,272,052		1,272,052
Directors Deferred Compensation Plan		1,442,571		1,075,908
Total		6,331,756		9,473,719

Covid-19

XML 20 R9.htm IDEA: XBRL DOCUMENT

Discontinued Operations

9 Months Ended

Sep. 30, 2020

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

3. DISCONTINUED OPERATIONS

Reconciliation of the Major Line Items constituting Loss from discontinued operations, net of tax, that are presented in the Consolidated Statements of Comprehensive Loss

	For the three months ended September 30,						For the nine months ended September 30,
	2020			2019			2020			2019
Major line items constituting loss from discontinued operations
Revenue	$	2,851		$	23,424		$	41,527		$	65,471
Cost of Goods Sold		616			2,565			4,835			9,188
Gross Profit		2,235			20,859			36,692			56,283

Operating expenses:
Depreciation and Amortization		-			(103	)		-			156
Selling, general and administrative		15,304			47,045			87,986			152,240
Total Operating expenses		15,304			46,942			87,986			152,396
Operating loss		(13,069	)		(26,083	)		(51,294	)		(96,113	)

Other income (expense)
Loss on foreign currency exchange		(879	)		(432	)		(2,141	)		(1,725	)
Other income (loss)		36,451						36,451
Total Other Income (expense)		35,572			(432	)		34,310			(1,725	)

Income (loss) Before Credit for Income Taxes		22,503			(26,515	)		(16,984	)		(97,838	)
Credit for income taxes		-			-			-			-
Loss from discontinued operations, net of tax	$	22,503		$	(26,515	)	$	(16,984	)	$	(97,838	)

XML 21 R10.htm IDEA: XBRL DOCUMENT

Notes Payable

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Notes Payable

4. NOTES PAYABLE

Related Parties Notes Payable

Related Party Notes Payable consists of:

	September 30, 2020		December 31, 2019

On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $30,000. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2021 or on demand by the Payee.	$	30,000	$	30,000
Between March 26, 2018 and April 24, 2020 the Company issued various promissory notes to Fountainhead Capital Management Limited for $280,873. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. Six notes were extended on their due dates for another twelve months. The Notes will be due between December 2020 and July 2021 or on demand by the Payee.		280,873		200,873
Total Related Party Notes Payable	$	310,873	$	230,873

Other Notes Payable

Other Notes Payable consists of:

	September 30, 2020		December 31, 2019
On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011, and has been extended on a number of occasions. On the note’s most recent due date, the note was extended to December 31, 2020. The note is personally guaranteed by certain officers and directors of the Company. See further note below	$	300,000	$	300,000
On May 16, 2020, the Company was granted a loan from Citizens Bank N.A. in the aggregate amount of $58,600, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The Loan, which was in the form of a Note dated May 16, 2020 issued by the Borrower, matures on May 16, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 16, 2020. The Note may be prepaid by the Borrower at any time prior to maturity with no prepayment penalties. Under the terms of the PPP, the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. The Company’s use of the Loan qualifies and intends to apply once the forgiveness program commences.		58,600		-
On July 7, 2020, the Company was advised that the Small Business Administration (SBA) had approved a $150,000 loan under the Economic Injury Disaster Loan Program pursuant to the Coronavirus Aid, Relief and Economic Security (CARES) Act (“Loan”). The Loan, evidenced by a promissory note dated July 7, 2020, has a term of thirty (30) years, bears interest at a fixed rate of three and three-quarters percent (3.75%) per annum, with monthly payments in the amount of $731.00 per month commencing twelve (12) months from the date of the note and is secured by essentially all of the assets of the Company. The proceeds of the Loan will be used for general working capital purposes to alleviate economic injury caused by disaster occurring in the month of January 2020 and continuing thereafter.		150,000		-
Insurance policy finance agreements and other.		47,066		28,032
Total Other Notes Payable:	$	555,666	$	328,032

XML 22 R11.htm IDEA: XBRL DOCUMENT

Lease

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Lease

5. LEASE

The Company recognized the following in its unaudited consolidated balance sheet at September 30, 2020 and December 31, 2019:

	September 30, 2020		December 31, 2019

Operating Lease ROU Assets	$	135,003	$	31,658
	$	135,003	$	31,658

Operating Lease Liabilities
Current portion		44,079		28,010
Long-term portion	$	88,097	$	-
	$	132,176	$	28,010

XML 23 R12.htm IDEA: XBRL DOCUMENT

Segment Reporting, Geographical Information

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Segment Reporting, Geographical Information

6. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION

(a) Business segments

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Revenue:
Vycor Medical	$	250,648	$	301,053	$	776,932	$	988,786
NovaVision	$	25,277	$	21,831	$	73,498	$	72,607
	$	275,925	$	322,884	$	850,430	$	1,061,393
Gross Profit
Vycor Medical	$	211,089	$	273,146	$	683,125	$	895,484
NovaVision	$	24,285	$	20,776	$	68,967	$	68,463
	$	235,374	$	293,922	$	752,092	$	963,947

	September 30, 2020		December 31, 2019
Total Assets:
Vycor Medical	$	990,852	$	1,036,857
NovaVision		36,540		25,395
Discontinued operations		2,004		29,691
Total Assets	$	1,029,396	$	1,091,943

(b) Geographic information

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Revenue:
United States	$	270,851	$	320,476	$	839,992	$	1,051,237
Europe	$	5,074	$	2,408	$	10,438	$	10,156
	$	275,925	$	322,884	$	850,430	$	1,061,393
Gross Profit
United States	$	230,321	$	291,536	$	741,675	$	953,861
Europe	$	5,053	$	2,386	$	10,417	$	10,086
	$	235,374	$	293,922	$	752,092	$	963,947

	September 30, 2020		December 31, 2019
Total Assets:
United States	$	1,014,817	$	1,055,312
Europe		12,575		6,940
Discontinued operations		2,004		29,691
Total Assets	$	1,029,396	$	1,091,943

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Equity

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Equity

7. EQUITY

Common Stock and Stock Grants

Warrants and Options

The details of the outstanding warrants and options are as follows:

STOCK WARRANTS:

				Weighted average
	Number of shares			exercise price per share
Outstanding at December 31, 2019		3,717,826		$	0.27
Granted		-			-
Exercised		-			-
Cancelled or expired		(3,717,826	)	$	0.27
Outstanding at September 30, 2020		-		$	0.00

STOCK OPTIONS:

				Weighted average
	Number of shares			exercise price per share
Outstanding at December 31, 2019		700,000		$	0.28
Granted		-			-
Exercised		-			-
Cancelled or expired		(20,000	)		(0.27	)
Outstanding at September 30, 2020		680,000		$	0.28

As of September 30, 2020, the weighted-average remaining contractual life of outstanding warrants and options is 0 and 0.74 years, respectively.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

8. SHARE-BASED COMPENSATION

Stock Option Plan

For each of the nine months ended September 30, 2020 and 2019, the Company recognized share-based compensation of $0 for employee stock options.

Non-Employee Stock Compensation

Stock-based Compensation Valuation Methodology

There were no options or warrants issued during either of the periods ending September 30, 2020 and 2019.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES

Lease

The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $5,700 plus sales tax per month. The lease terminates September 30, 2020 and has been extended for a further three years to August 31, 2023. The Company’s subsidiary in Germany occupied premises on a rolling 12 month lease agreement with a 3 month notice period of EUR1,650 per month (approximately $1,815), which was terminated effective June 30, 2020. Rent expense for the nine months ended September 30, 2020 and 2019 for the continuing operations was $59,008 and $57,202 respectively. See Note 5.

Potential German tax liability

XML 27 R16.htm IDEA: XBRL DOCUMENT

Consulting and Other Agreements

9 Months Ended

Sep. 30, 2020

Consulting And Other Agreements

Consulting and Other Agreements

10. CONSULTING AND OTHER AGREEMENTS

The following agreements were entered into or remained in force during the period ended September 30, 2020:

Consulting Agreement with Fountainhead

XML 28 R17.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2020

Related Party Transactions

11. RELATED PARTY TRANSACTIONS

There were no other related party transactions during the nine months ended September 30, 2020 and 2019.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Concentration

9 Months Ended

Sep. 30, 2020

Risks and Uncertainties [Abstract]

Concentration

12. CONCENTRATION

Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals.

Sales Concentration:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Number of customers over 10%		0			1			1			1
Percentage of sales		0	%		12	%		14	%		10	%

Accounts Receivable Concentration

	At September 30,			At December 31,
	2020			2019

Number of customers over 10%		2			1
Percentage of accounts receivable		11% and 15	%		37	%

XML 30 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

13. SUBSEQUENT EVENTS

XML 31 R20.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Discontinued Operations

Discontinued Operations

Leases

Leases

Net Loss Per Share

Net Loss Per Share

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

	September 30, 2020		September 30, 2019
Stock options outstanding		680,000		700,000
Warrants to purchase common stock		-		3,717,826
Debentures convertible into common stock		2,937,133		2,707,933
Preferred shares convertible into common stock		1,272,052		1,272,052
Directors Deferred Compensation Plan		1,442,571		1,075,908
Total		6,331,756		9,473,719

Covid-19

Covid-19

XML 32 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Schedule of Common Stock Not Included in Calculation of Diluted Net Loss Per Share

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

	September 30, 2020		September 30, 2019
Stock options outstanding		680,000		700,000
Warrants to purchase common stock		-		3,717,826
Debentures convertible into common stock		2,937,133		2,707,933
Preferred shares convertible into common stock		1,272,052		1,272,052
Directors Deferred Compensation Plan		1,442,571		1,075,908
Total		6,331,756		9,473,719

XML 33 R22.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2020

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Loss from Discontinued Operations

Reconciliation of the Major Line Items constituting Loss from discontinued operations, net of tax, that are presented in the Consolidated Statements of Comprehensive Loss

	For the three months ended September 30,						For the nine months ended September 30,
	2020			2019			2020			2019
Major line items constituting loss from discontinued operations
Revenue	$	2,851		$	23,424		$	41,527		$	65,471
Cost of Goods Sold		616			2,565			4,835			9,188
Gross Profit		2,235			20,859			36,692			56,283

Operating expenses:
Depreciation and Amortization		-			(103	)		-			156
Selling, general and administrative		15,304			47,045			87,986			152,240
Total Operating expenses		15,304			46,942			87,986			152,396
Operating loss		(13,069	)		(26,083	)		(51,294	)		(96,113	)

Other income (expense)
Loss on foreign currency exchange		(879	)		(432	)		(2,141	)		(1,725	)
Other income (loss)		36,451						36,451
Total Other Income (expense)		35,572			(432	)		34,310			(1,725	)

Income (loss) Before Credit for Income Taxes		22,503			(26,515	)		(16,984	)		(97,838	)
Credit for income taxes		-			-			-			-
Loss from discontinued operations, net of tax	$	22,503		$	(26,515	)	$	(16,984	)	$	(97,838	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

XML 34 R23.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Summary of Notes Payable

Related Party Notes Payable consists of:

	September 30, 2020		December 31, 2019

On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $30,000. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2021 or on demand by the Payee.	$	30,000	$	30,000
Between March 26, 2018 and April 24, 2020 the Company issued various promissory notes to Fountainhead Capital Management Limited for $280,873. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. Six notes were extended on their due dates for another twelve months. The Notes will be due between December 2020 and July 2021 or on demand by the Payee.		280,873		200,873
Total Related Party Notes Payable	$	310,873	$	230,873

Other Notes Payable

Other Notes Payable consists of:

	September 30, 2020		December 31, 2019
On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011, and has been extended on a number of occasions. On the note’s most recent due date, the note was extended to December 31, 2020. The note is personally guaranteed by certain officers and directors of the Company. See further note below	$	300,000	$	300,000
On May 16, 2020, the Company was granted a loan from Citizens Bank N.A. in the aggregate amount of $58,600, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The Loan, which was in the form of a Note dated May 16, 2020 issued by the Borrower, matures on May 16, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 16, 2020. The Note may be prepaid by the Borrower at any time prior to maturity with no prepayment penalties. Under the terms of the PPP, the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. The Company’s use of the Loan qualifies and intends to apply once the forgiveness program commences.		58,600		-
On July 7, 2020, the Company was advised that the Small Business Administration (SBA) had approved a $150,000 loan under the Economic Injury Disaster Loan Program pursuant to the Coronavirus Aid, Relief and Economic Security (CARES) Act (“Loan”). The Loan, evidenced by a promissory note dated July 7, 2020, has a term of thirty (30) years, bears interest at a fixed rate of three and three-quarters percent (3.75%) per annum, with monthly payments in the amount of $731.00 per month commencing twelve (12) months from the date of the note and is secured by essentially all of the assets of the Company. The proceeds of the Loan will be used for general working capital purposes to alleviate economic injury caused by disaster occurring in the month of January 2020 and continuing thereafter.		150,000		-
Insurance policy finance agreements and other.		47,066		28,032
Total Other Notes Payable:	$	555,666	$	328,032

XML 35 R24.htm IDEA: XBRL DOCUMENT

Lease (Tables)

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Schedule of Supplemental Balance Sheet Information Related to Leases

The Company recognized the following in its unaudited consolidated balance sheet at September 30, 2020 and December 31, 2019:

	September 30, 2020		December 31, 2019

Operating Lease ROU Assets	$	135,003	$	31,658
	$	135,003	$	31,658

Operating Lease Liabilities
Current portion		44,079		28,010
Long-term portion	$	88,097	$	-
	$	132,176	$	28,010

XML 36 R25.htm IDEA: XBRL DOCUMENT

Segment Reporting, Geographical Information (Tables)

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Schedule of Business Segments Information

Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Revenue:
Vycor Medical	$	250,648	$	301,053	$	776,932	$	988,786
NovaVision	$	25,277	$	21,831	$	73,498	$	72,607
	$	275,925	$	322,884	$	850,430	$	1,061,393
Gross Profit
Vycor Medical	$	211,089	$	273,146	$	683,125	$	895,484
NovaVision	$	24,285	$	20,776	$	68,967	$	68,463
	$	235,374	$	293,922	$	752,092	$	963,947

	September 30, 2020		December 31, 2019
Total Assets:
Vycor Medical	$	990,852	$	1,036,857
NovaVision		36,540		25,395
Discontinued operations		2,004		29,691
Total Assets	$	1,029,396	$	1,091,943

Summary of Geographic Information

Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Revenue:
United States	$	270,851	$	320,476	$	839,992	$	1,051,237
Europe	$	5,074	$	2,408	$	10,438	$	10,156
	$	275,925	$	322,884	$	850,430	$	1,061,393
Gross Profit
United States	$	230,321	$	291,536	$	741,675	$	953,861
Europe	$	5,053	$	2,386	$	10,417	$	10,086
	$	235,374	$	293,922	$	752,092	$	963,947

	September 30, 2020		December 31, 2019
Total Assets:
United States	$	1,014,817	$	1,055,312
Europe		12,575		6,940
Discontinued operations		2,004		29,691
Total Assets	$	1,029,396	$	1,091,943

XML 37 R26.htm IDEA: XBRL DOCUMENT

Equity (Tables)

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Schedule of Stock Warrants

STOCK WARRANTS:

				Weighted average
	Number of shares			exercise price per share
Outstanding at December 31, 2019		3,717,826		$	0.27
Granted		-			-
Exercised		-			-
Cancelled or expired		(3,717,826	)	$	0.27
Outstanding at September 30, 2020		-		$	0.00

Schedule of Stock Options

STOCK OPTIONS:

				Weighted average
	Number of shares			exercise price per share
Outstanding at December 31, 2019		700,000		$	0.28
Granted		-			-
Exercised		-			-
Cancelled or expired		(20,000	)		(0.27	)
Outstanding at September 30, 2020		680,000		$	0.28

XML 38 R27.htm IDEA: XBRL DOCUMENT

Concentration (Tables)

9 Months Ended

Sep. 30, 2020

Risks and Uncertainties [Abstract]

Schedule of Concentration

Sales Concentration:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Number of customers over 10%		0			1			1			1
Percentage of sales		0	%		12	%		14	%		10	%

Accounts Receivable Concentration

	At September 30,			At December 31,
	2020			2019

Number of customers over 10%		2			1
Percentage of accounts receivable		11% and 15	%		37	%

XML 39 R28.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Basis of Presentation (Details Narrative) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net loss	$ (360,472)	$ (371,794)	$ (946,492)	$ (899,581)
Working capital deficiency	688,725		688,725
Related party liabilities	1,675,120		1,675,120
EuroAmerican Investment Corp. [Member]
Term note	300,000		300,000
Accrued interest	$ 316,798		$ 316,798
Maturity date			Dec. 31, 2020
EuroAmerican Investment Corp. [Member] \| Extended Maturity [Member]
Maturity date			Nov. 30, 2021

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

XML 40 R29.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Schedule of Common Stock Not Included in Calculation of Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Potential shares of common stock that are not included in the calculation of diluted net loss per share	6,331,756	9,473,719
Stock Options Outstanding [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	680,000	700,000
Warrants to Purchase Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share		3,717,826
Debentures Convertible into Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	2,937,133	2,707,933
Preferred Shares Convertible into Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,272,052	1,272,052
Directors Deferred Compensation Plan [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,442,571	1,075,908

XML 41 R30.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Details Narrative)	Sep. 30, 2020 USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Written off related to assets and liabilities transferred operations	$ 12,308
Legal expenses funded	34,727
Accruals employee costs	$ (10,584)

XML 42 R31.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Schedule of Loss from Discontinued Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]
Revenue	$ 2,851	$ 23,424	$ 41,527	$ 65,471
Cost of Goods Sold	616	2,565	4,835	9,188
Gross Profit	2,235	20,859	36,692	56,283
Depreciation and Amortization		(103)		156
Selling, general and administrative	15,304	47,045	87,986	152,240
Total Operating expenses	15,304	46,942	87,986	152,396
Operating loss	(13,069)	(26,083)	(51,294)	(96,113)
Loss on foreign currency exchange	(879)	(432)	(2,141)	(1,725)
Other income (loss)	36,451		36,451
Total Other Income (expense)	35,572	(432)	34,310	(1,725)
Income (loss) Before Credit for Income Taxes	22,503	(26,515)	(16,984)	(97,838)
Credit for income taxes
Loss from discontinued operations, net of tax	$ 22,503	$ (26,515)	$ (16,984)	$ (97,838)

XML 43 R32.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Narrative) - USD ($)		1 Months Ended
Notes Payable (Details Narrative) - USD ($)	Sep. 30, 2020	Jan. 31, 2018
EuroAmerican Investment Corp. [Member]
Debt conversion shares issued	2,937,133
Warrants exercisable term		3 years
EuroAmerican Investment Corp. [Member]
Note payable other		$ 300,000
Conversion price		$ 0.21
EuroAmerican Investment Corp. [Member] \| Stock Warrants [Member]
Warrant to purchase common stock		2,308,405
Warrant exercise price		$ 0.27

XML 44 R33.htm IDEA: XBRL DOCUMENT

Notes Payable - Summary of Notes Payable (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Total Related Party Notes Payable	$ 310,873	$ 230,873
Total Other Notes Payable	555,666	328,032
Citizens Bank [Member]
Total Other Notes Payable	58,600
EuroAmerican Investment Corp. [Member]
Total Other Notes Payable	300,000	300,000
Peter Zachariou [Member]
Total Related Party Notes Payable	30,000	30,000
Fountainhead Capital Management Limited [Member]
Total Related Party Notes Payable	280,873	200,873
Small Business Administration [Member]
Total Other Notes Payable	150,000
Insurance Policy Finance Agreements [Member]
Total Other Notes Payable	$ 47,066	$ 28,032

XML 45 R34.htm IDEA: XBRL DOCUMENT

Notes Payable - Summary of Notes Payable (Details) (Parenthetical) - USD ($)					9 Months Ended	25 Months Ended
	Jul. 07, 2020	May 16, 2020	Jun. 25, 2018	Mar. 25, 2011	Sep. 30, 2020	Apr. 24, 2020
Small Business Administration [Member]
Notes interest rate	3.75%
Debt due date description	The Loan, evidenced by a promissory note dated July 7, 2020, has a term of thirty (30) years, bears interest at a fixed rate of three and three-quarters percent (3.75%) per annum, with monthly payments in the amount of $731.00 per month commencing twelve (12) months from the date of the note and is secured by essentially all of the assets of the Company.
Loans payable	$ 150,000
Monthly payments	$ 731
Debt term	30 years
Citizens Bank [Member] \| Paycheck Protection Program [Member]
Value of notes issued		$ 58,600
Notes interest rate		1.00%
Citizens Bank [Member] \| Payroll Protection Program [Member]
Debt due date description		The Loan, which was in the form of a Note dated May 16, 2020 issued by the Borrower, matures on May 16, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 16, 2020.
Debt maturity date		May 16, 2022
EuroAmerican Investment Corp. [Member]
Value of notes issued					$ 300,000
Debt maturity date					Dec. 31, 2020
EuroAmerican Investment Corp. [Member] \| Extended Maturity [Member]
Debt due date				Dec. 31, 2020
Debt maturity date					Nov. 30, 2021
EuroAmerican Investment Corp. [Member] \| Term Note [Member]
Value of notes issued				$ 300,000
Notes interest rate				16.00%
Debt due date				Jun. 25, 2011
Peter Zachariou [Member]
Value of notes issued			$ 30,000
Notes interest rate			10.00%
Debt due date			Jun. 25, 2021
Fountainhead Capital Management Limited [Member]
Value of notes issued						$ 280,873
Notes interest rate						10.00%
Debt due date description						The Notes will be due between December 2020 and July 2021 or on demand by the Payee.

XML 46 R35.htm IDEA: XBRL DOCUMENT

Lease (Details Narrative) - USD ($)	9 Months Ended
Lease (Details Narrative) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Rent expense	$ 59,008	$ 57,202
Lease expiration date	Sep. 30, 2020
Office Space [Member]
Rent expense	$ 5,700
Lease expiration date	Aug. 31, 2023
Lease renewal term	3 years
Lease term description	Based on the original lease agreement, the Company has the one-time option to renew the lease for another three years with minimum annual rent at market price, not less than the original lease payment amount. In January 2020, the Company exercised the option to extend the original lease for another three years with the expiration date of August 31, 2023. In accordance with ASC 842-10-35, the Company considered this lease extension as the modification of the original lease and re-measured the lease liability and the right-of-use assets on the commencement date of the lease extension.

XML 47 R36.htm IDEA: XBRL DOCUMENT

Lease - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Operating Lease ROU Assets	$ 135,003	$ 31,658
Operating Lease ROU Assets	135,003	31,658
Operating Lease Liabilities Current portion	44,079	28,010
Operating Lease Liabilities Long-term portion	88,097
Operating Lease Liabilities	$ 132,176	$ 28,010

XML 48 R37.htm IDEA: XBRL DOCUMENT

Segment Reporting, Geographical Information (Details Narrative)	9 Months Ended
	Sep. 30, 2020 Number
Segment Reporting [Abstract]
Number of reportable segments	2

XML 49 R38.htm IDEA: XBRL DOCUMENT

Segment Reporting, Geographical Information - Schedule of Business Segments Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue	$ 275,925	$ 322,884	$ 850,430	$ 1,061,393
Gross Profit	235,374	293,922	752,092	963,947
Total Assets	1,029,396		1,029,396		$ 1,091,943
Vycor Medical [Member]
Revenue	250,648	301,053	776,932	988,786
Gross Profit	211,089	273,146	683,125	895,484
Total Assets	990,852		990,852		1,036,857
Nova Vision [Member]
Revenue	25,277	21,831	73,498	72,607
Gross Profit	24,285	$ 20,776	68,967	$ 68,463
Total Assets	36,540		36,540		25,395
Discontinued Operations [Member]
Total Assets	$ 2,004		$ 2,004		$ 29,691

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 50 R39.htm IDEA: XBRL DOCUMENT

Segment Reporting, Geographical Information - Summary of Geographic Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue	$ 275,925	$ 322,884	$ 850,430	$ 1,061,393
Gross Profit	235,374	293,922	752,092	963,947
Total Assets	1,029,396		1,029,396		$ 1,091,943
Discontinued Operations [Member]
Total Assets	2,004		2,004		29,691
United States [Member]
Revenue	270,851	320,476	839,992	1,051,237
Gross Profit	230,321	291,536	741,675	953,861
Total Assets	1,014,817		1,014,817		1,055,312
Europe [Member]
Revenue	5,074	2,408	10,438	10,156
Gross Profit	5,053	$ 2,386	10,417	$ 10,086
Total Assets	$ 12,575		$ 12,575		$ 6,940

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

XML 51 R40.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative) - USD ($)	9 Months Ended
Equity (Details Narrative) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Weighted-average remaining contractual life of outstanding warrants	0 years
Weighted-average remaining contractual life of outstanding options	8 months 26 days
Fountainhead [Member] \| Consulting Agreement [Member]
Number of common stock issued for fees	1,607,142	1,607,142
Number of common stock issued for fees, value	$ 337,500	$ 337,500
Non Employee Directors [Member] \| Directors Deferred Compensation Plan [Member]
Shares issued for services	266,664	266,664
Value of shares issued for services	$ 56,000	$ 56,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

Equity - Schedule of Stock Warrants (Details)	9 Months Ended
Equity - Schedule of Stock Warrants (Details)	Sep. 30, 2020 $ / shares shares
Equity [Abstract]
Number of shares Warrants Outstanding, Beginning Balance \| shares	3,717,826
Number of shares Warrants, Granted \| shares
Number of shares Warrants, Exercised \| shares
Number of shares Warrants, Cancelled or expired \| shares	(3,717,826)
Number of shares Warrants Outstanding, Ending Balance \| shares
Weighted average exercise price per share Warrants, Outstanding, Beginning Balance \| $ / shares	$ 0.27
Weighted average exercise price per share Warrants, Granted \| $ / shares
Weighted average exercise price per share Warrants, Exercised \| $ / shares
Weighted average exercise price per share Warrants, Cancelled or expired \| $ / shares	0.27
Weighted average exercise price per share Warrants, Outstanding, Ending balance \| $ / shares	$ 0.00

XML 53 R42.htm IDEA: XBRL DOCUMENT

Equity - Schedule of Stock Options (Details)	9 Months Ended
Equity - Schedule of Stock Options (Details)	Sep. 30, 2020 $ / shares shares
Equity [Abstract]
Number of shares Options Outstanding, Beginning Balance \| shares	700,000
Number of shares Options, Granted \| shares
Number of shares Options, Exercised \| shares
Number of shares Options, Cancelled or expired \| shares	(20,000)
Number of shares Options Outstanding, Ending Balance \| shares	680,000
Weighted average exercise price per share Options, Outstanding, Beginning Balance \| $ / shares	$ 0.28
Weighted average exercise price per share Options, Granted \| $ / shares
Weighted average exercise price per share Options, Exercised \| $ / shares
Weighted average exercise price per share Options, Cancelled or Expired \| $ / shares	(0.27)
Weighted average exercise price per share Options, Outstanding, Ending balance \| $ / shares	$ 0.28

XML 54 R43.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details Narrative) - USD ($)	9 Months Ended
Share-Based Compensation (Details Narrative) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Non-employee [Member]
Share-based compensation	$ 266,664	$ 299,997
Directors [Member] \| Directors Deferred Compensation Plan [Member]
Stock granted but not issued	56,000	63,000
Total unrecognized compensation costs	0	0
Employee Stock Options [Member]
Share-based compensation	$ 0	$ 0

XML 55 R44.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative)				9 Months Ended
Commitments and Contingencies (Details Narrative)	Oct. 31, 2016 USD ($)	Jun. 30, 2012 USD ($)	Jun. 30, 2012 EUR (€)	Sep. 30, 2020 USD ($)	Sep. 30, 2020 EUR (€)	Sep. 30, 2019 USD ($)	Jun. 30, 2012 EUR (€)
Rent expense				$ 59,008		$ 57,202
Lease termination date				Sep. 30, 2020	Sep. 30, 2020
Trade tax reduced	$ 82,000	$ 82,000
Interest expenses	13,200	$ 13,200
Euro Currency [Member]
Trade tax reduced	75,000						€ 75,000
Interest expenses	$ 12,000		€ 12,000
German [Member]
Rent expense				$ 1,815
German [Member] \| Euro Currency [Member]
Rent expense \| €					€ 1,650
Office Space [Member]
Rent expense				$ 5,700
Lease termination date				Aug. 31, 2023	Aug. 31, 2023

XML 56 R45.htm IDEA: XBRL DOCUMENT

Consulting and Other Agreements (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Stock option cash	$ 393,500	$ 401,440
Fountainhead Consulting Agreement [Member] \| March 2017 and Effective April 1, 2017 [Member]
Payment of fees	450,000
Stock option cash	$ 5,000
Common stock exercise price	$ 0.21
Amendment Agreement [Member]
Number of common stock issued for fees, value	$ 337,500	$ 337,500
Number of common stock issued for fees	1,607,142	1,607,142

XML 57 R46.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Fountainhead [Member] \| Consultancy Agreement [Member]
Number of common stock issued for fees	1,607,142	1,607,142
Number of common stock issued for fees, value	$ 337,500	$ 337,500
Preferred D Stock dividends [Member]
Accrued dividends	324,370	324,370
Fountainhead [Member]
Accrued dividends	226,037	226,037
Fountainhead [Member] \| Unsecured Loan [Member]
Unsecured loan notes issued	$ 80,000	$ 17,873
Unsecured loan notes interest rate	10.00%	10.00%
Fountainhead [Member] \| Directors [Member]
Equity ownership percentage	59.70%
Fountainhead [Member] \| Directors [Member] \| Series D Preferred Stock [Member]
Equity ownership percentage	70.00%
Fountainhead [Member] \| Peter Zachariou [Member] \| Series D Preferred Stock [Member]
Equity ownership percentage	26.00%
Peter Zachariou [Member]
Accrued dividends	$ 83,386	$ 83,386

XML 58 R47.htm IDEA: XBRL DOCUMENT

Concentration (Details Narrative) - Purchase [Member]	9 Months Ended
Concentration (Details Narrative) - Purchase [Member]	Sep. 30, 2020
Manufacturer One [Member]
Concentration risk, percentage	10.00%
Manufacturer Two [Member]
Concentration risk, percentage	10.00%
Manufacturer Three [Member]
Concentration risk, percentage	10.00%

XML 59 R48.htm IDEA: XBRL DOCUMENT

Concentration - Schedule of Concentration (Details) - Number	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Sales Revenue [Member]
Number of customers over 10%	0	1	1	1
Sales Revenue [Member] \| Customer One [Member]
Concentration risk, percentage	0.00%	12.00%	14.00%	10.00%
Accounts Receivable [Member]
Number of customers over 10%			2		1
Accounts Receivable [Member] \| Customer One [Member]
Concentration risk, percentage					37.00%
Accounts Receivable [Member] \| Customer One [Member] \| Minimum [Member]
Concentration risk, percentage			11.00%
Accounts Receivable [Member] \| Customer One [Member] \| Maximum [Member]
Concentration risk, percentage			15.00%

EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

20Z$BE+*K)L& Z)/-[W'.KQ!#V9:= M0)"- ([9M_G?T5XAWW,GRN7X2^@]YM08DFNZ-!'=A<>O9TB @DW0:M'CW?J ;%KQ_9-[,8:05-?8O2(0 MIV7G.0_P$,-K$=#LEUV0GY? 2K_B8 P FA'4ARM+/P+#LTD=1+HC\2)G=#E2 MK8S5Y#AJQZ1O:_)X>AMIA&HZ1NL)0]!!J!UF+P)9K!A^T&U+O3312KVE&G/% M$;$-FH(ZW='X&(Q>-]9Z[QLP/SID#2E#$>T<4NA=VDC "Y(:>)8?Q#_I4Z/2+N:("6^"4"VPEEY<\K<^H\8B?8J$A= M^[%NG:6"A[J#GGPJ-4-86.+%:SRR[$K3(9Y^&7I;A%?*8(P?' 'S0N#TC IRW+ M9?D"B1X0,JIG;4)IDC"3SGNY<7MTX3C%KJ.<B?U5Y=K?IN?)YL*IY)(V=TDZI[L^+A# M^]T6IOJ-36%J35=DY:3SO[02%J5IHCE-H>#>BYY/V7-<_NP^; GRZG;8MOK8 MK[756WFGFV?81??T2=R#O(N5%9<84C1_9R_(LF6=M/M6L]W>>_)L6?U&'W:[ M^D[KPBS3;MFIHV$/2;1IM?HMJ]$MU3]C)TET?3NM3N5]11DOPE^3V1.?-"UG M9XJS:Y=[6S&SWC**UK[@2F6(5J?3LKK]LN6(M;!(=Q/AC7[7.FD,-HSP34N: M5^'Z@^E?N^)!>CZ^\A;8[S.0QU_E-@]AJMYM6OUM4D3;7>46$GUB=/EHO M)]5?YZT6O*:AWC?BMU/C9I^=(;:8CH38B1(M OB#.MV##.]>>&D?(#F9A]/D MY/M \)\R)=CSGX4KTV"\-/LW\#W^[ 1QR([.KGY1X6:J5'YGXW7-T&#[YEQ^X0_9/P=WHB5T%C]QS_D_JC3C0A]N8CX%9/AITS)SB(-6\ MH1@Y]C&[2,?&6Y3\);.(J" D,ZGLP:$!WO0;)V2?_6 $!_/A?RP68JVR+F5+ MIT[0!I@$7HW]I%)G^0LL*1V) (<[3RQ=5HK(Q]DU@:-J,G7^HIXS@0%&S V5 M2-&3'T1ZX#+FQL+=@FL0C"RZ##)A!]/-8JQ:>19PKLN- MQ+$QV"S3L%/Z8$,?9. 4.5/;4'H'^,-/$:DL"("3TC'H_'.IATDR/F6J9:L" M :E!/";X TSPCKB#<^2'L40& ("L?^B_2)R'/J78X_04S+;'C#@94L=21JYA MFF0IG#TYR=@W3&=Z1DJ@$Y.XPIQY^";A+YO3']#D6ZR_19)2>5.VYDPS9"\! MP446-UR@15]?!).].>K>\-F(:J$Y>W3]>V0$,=Q1"0BP(,>SDFR"7$DYEW?T M!2@\84>2I3W0#*J0<(C?I$1KS;^(*FDR8_I2.EU85W/#^H^(02];NY9G#GH, MFH\9D8#^USY >1Z/R;19*H+";[C\GAZF.E)D&/)D@=:%JN)5;,U_D'<&D.M[ MGG M.GV=) >'(5/3)C)YR,.EX%H&(VS\$(,+^%.V%< ME8+0#9M3Q27Q@ EQ>FPP9N\08>LT?4D8>(",#H_V,Q<$.54Y>=[!1AWI79+7 M1#6.ROX^NW@*T-POR.WI[-=A!M D>5_7XF.FD()"W:U,/PSX(2G#H,K@9!U) MVS(I0\*%%XZ_)'F,.LM(%Q58+#E".+(0:5FB(B>W5$IQ^.2,1RHSEVYM4!I= MFMD3;2&A3](1@!(],O%2D@"H_+"T3E,*=?9EB@P2X7$TCJ/L$&S@^?832!.L MRTD$$EQP6CI3Y"=EL#XI72(!1(M5,RJG$K=)9+2%)I M=%(>MVVJ+H$#0 @Q2Q:;KJBR+[D^3GK%B; 36:JD#W H.;3PX+>H'\@M2A:G M"M$L>E\=%8E>=:-MG1NE:0HOZM25E6P6Y_6-'2)>#P>.WSHCQ^6!P@DNG[9B M2[45>8<4 61/1S:;L$G*SN5P4@G-\CDU%%"?9,+4%*/!.><+-B*A>&4S7Z1P M>)**JHT=9@*\Y%2J"A(Q!2[S,$?L".^%O'FRX0^6L=(8=EHN>P\3W.1.)2W1 MPV_I,[(RM7C(\Y,>(W-Y][S!UHMMT)GN/.J"7SV< M Z0>\6)U,23LY5JB.: MJV>4-TI?O7J8-HKK9.6:Q#N3>'=0^6(F\F<0[DWBW*$6@P Y- MXMVZ(:]NAR;Q;@?)TB3>F<2[FA^<2;RK(PX+P6B3>9;J4KSU2L#@6H1LW?L%VB^&%SM69W[GL@GJTW>J6,1]E,YI;[$5S MZ@U/5=('=S/-(>L4K,"5R=]X@R$L#$@G,04,,WRC7HY?,0?F C8H WB1$\5) M0TQJTT*![P6]^"P*2N!Z_)>5!C72SA".[J:;:<%SFVO!O_LRY0F.>0EF]]%CP3L'PFXJ\VCK)4@VCJZ9[+I:H+M M)93*.MT>,S-SAU!7891OWU!GJ&X7J&Y-%OH:0A7)_J4>2PU$G1D]5F;,O*;# MED9=48HH2W\+[+DM>'8-Y(<)^9HN]YON-V7P=$JDC61L6:I-6)KAK2T;H@#0 M[Y:$K;':!&%KT-W$A-R#Q6?;ZK0Z!J%K0VBG:75;1>?=&H06<*!WK4[I8%B% M:5(;#ZLFTN%,-87_XF.'VEO?'6[9J-BIN$"O:4(P%:&Z975[1:>?&V2OB.R. M-6@;9%<67&P.=CU/H+3<^1+01 .:[%I:XE1L(A;B3JW"%V;=T%>XRP982D5C MX+N[S7;/ZIWL?S)AMV>U!K5)=GW+P5D_%!^HS\M OG]^QM+B.YU:IB>%_5YW M*7Z@I&,@W]GK6L(+E";@%A;_G["/DNVD/:A.1SC:638FJ^<5+K"K_:^B.VHV M2BEM!99\;XZ[MCML%L[RWI[Z\*I78EZ50.'=)[-*'S.S2GEN5FE![!RP@ZG9 MM=J-LO$XX\Y;UG?:MQH=XSRM"-N#OG4R,$&8RCA)RVIURO:7J%_*7"F!U2HC ML/ 9,H*IE(W-VLFT.Q->-8*K=MCN]*R33E&WM\&V$5P[A&T47.V33:-[TW96 M:2&4BA]WMDYP%^W]HV;;:O1*A2 +K+J[_H^C5L]JE OB[3<^NDVK=5)493@ M?)STK&:S.OK8O.J^;AROZ2P.--)A(-_9Z-(:M0R:D^-0[P=VI S=]W77-@Z4 M>@SD.WMC-QL/IMXEOH>-V04 @@-T AHV)'[93]Q[+!IHJ:$2-.@;BR%!1J== M*K5QOY'1LIJ=HG5 !X".IM5OE4IC7@D=FU9D-A>6SFL\Z%LI>N@'[(-K]ZQ. MZ3I;X_%<4ALQ"#3D6A=L;W#KU:O6FXL5DU"Y6-6,WEJ7^I%@$;G2 MZEG=9G6.N-KCH]FS3@8FJR/-ZNA;@W;1GB'U5RTVYZC-L$+EK8T25F@,B5<0 M5[2PSM@0!M$&T0;1%2)Z\VKX(LA:R_58+#45IK267@#850FC==Q"RACZ\;TK M"N__W=1WBV_E;2!6ZB18QHA8+W;-&6W$ EK/?5W5O6P.A]F*=MS MTX9>/L%D_4NWWR@^A.!*-/XCZJT_B[&^'2O+EK'D03=NE'L-XU MG\@9;H .)Z0)=++3EYDRMZXI<_/\0:\@8)/FQM9&\N0&G3$SVVAI1'X2ML)C M$_%8[T%'F[H-RQS3NM?>#@S5V<:*._9:O[W"N@M0[I7'_HP]P5I=HM>!&G\Z M I1,F!.&:"F/01S"CWXP81Y)I*H/K#[ M"3T-(E6(%$;VPD,&"*0)D/0\AU]C*ECT(MSG9$(D@.: _!W&" *\!CC((*[5 M1 #]Y+NY;Y6\^;LP_Z.WTOP/22?;0HM!:'&TK(FA+1MZ6H6S?11P@8$3?..! M_<1:/<7?J-7F.'!RWLFKA;.97V?86<1=[PGP8?LC(\=S![]QCW^ M2&8*^^J,G$CQDG>M0<,:]-N[P1-OG5\*QA< +N6*$@0G2+A?N)A1RIU*Z^7% M<5W8+KUVKXXCT9 (]0C/G[$[63,+/4"WOR*T7=36=Q+=C2K079T^N0$&+-/J M7_%JU/A2;T#2;S3ON'D8EW_'CJ75WA*32)VP6_<.;NB[;J[YQ2Q;25TN-?*4 M;N:[>FK;,XSW#E\(AA)SY[R29)O! WW M\SCP3T? +6SNL0OO&*TO?MGF(H=!C=B7= /A9 M#5&S_T<(5C=\.!!(@(EY;B6/YKV;@(,I@FMEO+6 0@0]Q) J6.2/,0\X[$R0 M*6X#17#' Z >'/@Y)/B'#GPX\H.0DJ?2PS@&G@SHCP.23 I3KO]B'*$S?COC M"=T5C%;E"EV914X A_)N6SD.B:S@D:XTLDG7!R9(69%G3@2K>"'[R+V?[/+X M]!@X&KW)'Q\#\8C1#CY"IR=>\W?=@=4#)+-Q'(0QK(9<13GJ["IV$2B)%PEC.;TYOV6G M=F0A D$&$%_SN(V;45*AGV5H7WW4$--GU8Y )(QP34[Z,C'+80YE6HXH[^-' M/PC\%Q%8H/I&F&""'#KS?(OXX*P8X"Q M,&7FAEY8"5.7?*5 I.U_1&((%2" M<>%+_UDR9PU-ZDR%[T_0E3H.Q)@[,_#1-^&,(U")X1D')!\<"\'L1'#T3O0$ M?%B^+3V_8\">&SD"1,MWPGZD)%O"S.&0) $A+O7W 8&/SC.(+(<>FI"K.@Z5 MN_OO& CW89)MN,]0_(G0#IQ[>$@=0W*<T- MR1W/QV- I._90I\P 2A"\MX3^2DLPUX+\H6BW+$L%UUA6BC=NBV!7]TV5Q\H M59U>NW+8'/H> M],DA7H< V BR^'?-KM1]B=?'R2T_MWW/'SDVZ,#_CH,)\-V0AQC.IXNF>?8T M?P(X>O.T$+/KB,>Z#HF*]X*6W*<([KB[_&.YS1K_,2L1BVYM7AV MAGA-B;OQZ=B;8M9YM*$&K51^8A8..IF/VHWW%" +K;FL^<'Y!0MI!AT]!:"L MXB[HIP_ :(((-5Q@VZ15'[6/^]W?WF?9./%3S<,51TUD3$96]MO-8\ _ODE/ M9_F]BIH=-5OO=8X!B6.*WB6P*=6<>%[(0D2OQ \0 7S4(54=*4,]S>'7T:P^ MCD@&?-J@S8;:Z?H9I M5\6TMY%F<.&%<8!YR6SLNXX] >[BT3\YZ,Y",@:D;0J5FSAVH?EM/3.8I;*L M :NQSC92-8MBM]85Q9X38_E]1:S5H,2EW 8V6]C2[7:MWLH7?V_J NMT-.VU M<(FWD#J'2ZPYC+TP/CFO4FE^F9 N*_KQK[.K[,/Q>.R2L.=NMDSIPD.'$YEH M*@_FSO\J.*C1=[BS.E4?9?PP&$[P'ST@@J%RJ>C,0H>2H.DP8H_'0\ISQ%@S MRB$RS^[E[EF(VT=S:S942.K03.!K(V'JPXA(5ZSGF*CSKB-RIZ+.JU#\*D=1 MG^9[54%7G9ZN.&,7&>-J#3D3FDYG+9* 93=7W]DI.<.6)NXD*O@JD&NUY#8? M9BT,0VLZ7Z.D\ZO=M1JE^WRL'>7F#%=**[9ZW;*]!E; ^)H84&DWH+$:-V U M+L< S-%48= OM)+@1UU.E:CW!S&^A%7@6VBJ[KP!([Z::(EC=\$ M]J\^+$)I,.7H=!NASZT81,M3U HZJ2_%7R:4UDYYV1'8];&XEFW,=JRFGT3 M7:[AT922V!L)+O_G/]8)^F.=HL*?YG?,EOUA MQCR@--=+_YG_H,H-0BZ&=P/Q+. =F?JFC,KPQD$PH5&E#&^O%8*4X MDF5B5%. @6>]BL6 J\I\_@='Y=-%E)>CEL;$5<'M)UB34&AJGC=3\UP+M2:) MAO4J#IO>4:;X-YFK?4X5E;F0=&FO@D$K_G#I>+7 ZA(JWR%G8YC\BQ505V'* MQ;ZASE#=+E#=YNWGHON_D4IDT73MHN=8EFJ,I]] OA?1E3=]VLHHZ623NY:8 M'?AC8H-5]TT,$:R2W&H7^ERLEIK3ZC:L7F?IW)Q5\;*'&&TWFE:CNW3"FL'H MS%?[_9YU4KINQ&!T\5=/!@.K/RCKQJZPN\WRG697D!09_^,V[(&]C*^UNE:K M;Z*>=3N5IC5H-\VIU.M4^FVK<[)J.J4YE76?2LOJ-3;-P:JRJ184MN>%9O>X M8\+3:P]/][O626N-HU#-T:RO+KUE#=8YV-0;+5JHU[X %.[V2GJ_]Q_?/0&@(_"QLG^XV-PTK4ZA2V".NDN MQAM>9U]2JV.U!JOZ (R';^TS&*W^RC4=YE36?"J]@772,Y&C^IU*I[C.6E;)ZU-=VDU1[-,*++;LAHGYFAJ>#0G/;@UG575 ME>WW-EY<(G#0M8E%T5)>#5IMY26*0/)[UVMMAF;<>1UW:3OW"3V/MP#/G.J? M\0JJK*&.E4XCVT:X%L0Q4]]4(7&LR?991^\JC1 YNN*42N1_G\*,"7/6 _*J M3&;=<7E@BG)>^\)@M?3\DX8UZ)J"A_5AM&DUVCW :5D%O9XE#U5$S_%+Q6UVJ?K!Z*K4H@K#_PN*!7T(JF]2$,8;,:C55=JO4/F-0%V2=6 M[V33)335BY970R&EKG'6:E@13<;7.*W, /6U3TP;PGH>SDG3.NEL(2TZVXEP MQ9:!BSL/JC8H(?81//\5B<#C[ED< LPB"$^](780_NH\BZ&\^1\G7P3. 1\_ M(:LZ#02OW\BZ'6U.*(< FTEWI@^AZ4-8)[2:/H0[VM;,=(3;A8YP^X8Z0W6[ M0'6;M\2+[G]#?0BSYUCTG74_9V#8! QK(MVJ^O5]]V@:^&W$(U'6<;0+@:P5 M^_7U,318UN^XWZ'!%?OUM1I6IW3YA\'HXJ\.VB?62>DT58/15YV*W:;5:N]' M^'I]H4+I9=N*UKR7U3U=J[%R44;](X@[=B@MJ],P7>%J=BA-[$MD3J5^I]+L M;KJ2MRI[RH1K*PC7FK9\M3T:TY:OMD=CVO+5]FCVIRU?T1V;UGL&<@/YEI33 MBAS\I1"S 9Z]2J>+AM5N%778;X0DZX6/DZ;5;9O6>TE/AT[3ZO5-Z[VD]JW; MM@:]U>_+YO43X];>%;=0=XF!7,97MW&W=KOT!"IS*!6XM9NFZ5[]3J6Q\;M2 MM>5@O$"FO]Y!'HWIKU?7HS']]6I[-*:_GJFY6^,J.](9;<_[YIE3/\!^>#L1 M4TPV;WK?U1_RJBS7-?6^V_<"EY4[M34[UJ"T$VJ_RP=6QFFW:[6;FRC)V#S/ M7D/(N51 I6+65^3\6E9WNR'"2K;9 PMO]?Y^54D#T_BN/KW83..["I%]@(WO M6J;Q7;$-F,9WAWPXVV]\5[V/=EZKO77WR%O\V@C\_^2Z<:WC^=^Q$$VPV M]QN9,L\46;;+T%\"KQ HY!SPRQ_%%%%6;*FL3$YQ_X&%3SQ0KK,R)U$KU7]K:!2_1& [H6#CP+$%@7,?L'\D,(+=*1%< M&7ZK4_93#VYAO%W%41AQ#S?$>,2RL1F61$9VPTVYFA.Q;?6;?6O0,IURUH?3 MQG&KQBU=%KK BF[O"VJA8KBRH-R60_+#EB#?I1UNGGD7W6H/HQP^8^#5V@L)D><"NY:-E=8S5#NM]C4]F ZK+)D]P"86F MOM;"*Y[)\H9#+I6/)8ET=8T-K'7)52BJJ,0POOX*#Z5QW-@T^%K^:DP1^5,[#7I=C6:]K?*5#JX-U M< 3C2-^(([VT[;)Y1_J2_N]%'O7PZN',]]#/(@O:KAYNG/#GQPG^_S.W(S^H MWH6>]^7<I[@58S2'TG/>-FI/5NC+3>-]09JML% MJJO.]DSG41=&21H;M76Y)O,!*'CBMY)XV6;$9K5ALSL8FZH<1SLX@-O@Z$!P MM"8.NW+@\EH$*)'XHZ!D$[2Q"^ZVZ%F4/;/-\\2BZQ65)O7#1.$F8@> BJ(] MAPX %=5=D#GL;:/]/\IUAMAP7N^I;0./CD)V(VSA/)-[,.>WG-+CC=NR9GF] M\Z[:LG;;:;2B0VR'-OI*3^2*$R&,:\\X6?;0R5(U(USWVMN!84VVUF9RKO?$ MF[5:=O F>A[7[\T5^T-O $=KNAEK]D)PK3\'B?Z\LS97^I5F\S?&O2%KENH1 MO9(55G?DM(OFVJV.BCF4_EJ"38ETF/_Z?__QG__X=1^XSN_X?_CG_P=02P,$ M% @ CS%M46/12Z(]$ /*L !$ !V>6-O+3(P,C P.3,P+GAS9.T= M:V_;./+S'7#_01?@<#W@'.>Q[3;99A>)G10&DM@;N^W>?EG0$FT3D4B7DIRX MO_YF*,F61(F6G?3D6[L?4IOST#S(X7!$TA]^>?9<:T:ESP2_.#@^/#JP*+>% MP_CXXN!3OW'9;W4Z!]8O/__MKQ;\^_#W1L.Z8=1USJVVL!L=/A(_6??$H^?6 M1\JI)(&0/UF?B1MBB[AA+I562WA3EP84 -&3SJVWAV^'5J-1@>UGRATA/SUT M%FPG03 ];S:?GIX.N9B1)R$?_4-;5&/7%Z&TZ8+7Y_^TNM;)T#H_?G;W\\/SK]O>(# Q*$_N*! M1\]'\;]JY'?,MQ?$9^_NIOZ/SP_LMS'E[\,VX4_^%S)OA\/>V;>WO[_WZ.-D M]N7J9/B;]^YV_N@[/[*3FY8S^_;^JW M"CEN@C6.F[_=W?85WD&$>/[L,OY8A'Y\=G;65- $5<-\'DHW87W:1/"0^'3! M&:#,@,^X'Q!N9_"=8$&01G[;C( 95%:(^BY"90FJ0W-X/K4/QV+6!$ 3^T#C MZ+AQ>IR@AWYC3,AT03(B_E"QC@'%)%*XU"^D49 "(E\&.CXT%J,V@OFTZ $+ M4 $9%YR'7K']G4 VD:X)2 W HI+9"[K51%D"T+)$O 12(!V.T 7!;&X+Z5&' MV<2%(>\UDZ$+8$)HSR$*6]Y,XU M#U@PQR$O/?64 XLY%P=&#'PN2*&>[- 1XTR)%P>68ZMA)>3ICX0[5L3+2C'[ MT,RS23$/?>IT^<_J\U12']@HHEMHB ECE!(BT-H.W?5HEJ(4DL0-B<4W]L$5 M<3&H]">4!GYD]&R3VD2";A,:($Z![;-PLR-.-W.$]2;SD-UUS,)V?G>$F9JD$\I]-J.WPH_' MA1G%[)X?3.Y9,K;$R,JPMI#W?N2D'=0=]0-A/TZ$ZT >#;,"FFU\ M!L&JEU(KF69T@-D'/V(.!:LP5_BAI/!%L4";IYGLK*7[;,PAQ[8)Y*JV+4)( M,/FX!YT48D+2\8TH9NN_SUL_QY6$LV.VOQ>Q%0R%3G9.C2R,Z9%J-UCX_RUE6T5DR\LS:]I:HNA,:, M/IJM>)RWHB+:6>OUZ1CS@0#[ M;RO->5]Z #]=?PU9$*?M\6>SE4_S5HZH=M: _0FLW1M80W9PT0@KQG3'+@&: M3?R#UI$5FRMD8Z7Y[*S1P0@>"]1J_9*#:57B!>N^19YG0C ;_VW>^"E6JFZ9 M8;;#'N!^Z*(AP+[=8$+EY5C2J("2N," 8?;!.]T'"2_E L7-6K+;62\\4!?7 MWSTB@_E $@@+=BK7+H6:K:^M,F,^EF)DI3GMK.&A0]J@CTS%^FR3V<3:4C)# MO+-6[8=#GWX-0:7KV3*0:*UFVVJ+Q26]%3'87?N:JA]K%$JJ%4Q.M(7EBH*) M]2;YM+O50J/=![@@K^*@&-'L'FW%NM(]$=O==4YQ\2KM%2.&V1W:\K6DR+5W M0[JVE39^0;O9Y-I:-E/YVAM:E;#2%DXWF$VKK6$5Z=ZD%4M=F4B_%HG9+=KJ M=HT:V=YY4:DK[9M,B]GTVJ(VHMU;-;/V21NW"&"VL;9TS;#8F[K@E7.;!H2Y M_CV1:*09+7TWK2&:7:$M<0O?55MO8K;6@N_N>L>8TC=P"[03NE3M>_($5UM? M(&'I<-L-'>IT>&NI6G?49FX84.>>!KA[J4>E*B+'UJZPA'C=YYG[BKYD7[$2 M 8Q8NGBS%L@7[07"%,Y*1+08MU)"(FXLI@5R1MNZ0-*HOK[HBKO; 8M7+\41 MHB*NT?&G6H6@=,VS#Q,KO)0:K]BO;Z3PC"XR>7%M7F8O:X6&,B]GA[4:GB-X M]LI>L;M](;WD+1ZG1@RSW[2*1&YYO!^3A7YH]$//(W+>'1787G>*&=WLH14% M#*Q]*]XXG(J=MW?92A\4G!#8D-;L3*UDLKXS]R<)TI6KXH!8##*[1BN;Q-6L M?03,6CR5./3#Z30Z!T?<](&:5$$I?J\\$(HVFYB\'CNS9[6J3.39;":2?GCV M'$^F/I:\)P]$Q&6?H%2N=Q8/U4V)S2[7BD1KU4#W0WY=WZ9&\57H,TY]/Z;T M=2>NY?CU.)M[A;Z[?XU>D0T7B2P)"[^P!^W[S4KO)HG5$N'%':822W-/T:M5 MZ_6491:WQ-KWD((7+<630@G,Z+,?M$)3\O)E'\YS1D_G7%A0_8*&@1B6&6[5 M4,TNT:I"L4MRJ9Z]5/'I0YK8U*,Q^*S@>8CR: ML/=,*Q5ZKC&WVF%;A*3_.L'=6V;:AF[_ M,:LHS'XR'U71=F(4^?!/Y#G\@[G: QU9ZI[!<[PL[N+ 9WBOY$'<-I%T='& MSFPD=[C] :H=/GMN@H*L#?<,*K_GK1$_.&%!I*UQT>Y!!"9B2F4 240S$3YA M$+ R3/[L? YT(F:KZ&R2X;KJ@PDU/V.NMXB_U=5$D?JFDKF.NQW4C6]\>DU M%8:ALZ["V='VG?1M+QZ25C>^);&YO"8Q_IZ_2O$#*"YD8''M7D;3+:#1_:6W MPE:L#"3XK9'0-;"I<7S2.#T^?/:=I:3K"+$TPWI")'0;"&&\B[1("K^,"#\T MEM15!3#>;%IB!O7\0L(F=0,_:7FA-/J=H9N+HWAM($^%ZU*K=)4TY7U$B'WE M#/O*\;L7"K.9(!M+D>E\:A^IG*_?:].$R9<-_)/E&4J)-]5M($V:^GE\=I>E!XW3%;"9:Z+.W,N#@(9XD2%UTJ?PP3&A#-0\ZP3)F?'(]@PVE5P M<6 #3Q8<6-%T' $]P2&3EO-.0#TD!\N$0Q_FO3!ZJ@BG"2H#%).NJBYXE:\V M7F)Y?:Q0K^9+E!Z9JXM_GXAT[@6/*[Q1#;@#;3'HQ>FIBP7A%6>B::I!<>@-B#8"71_\+^_@;:JW[G=WA/ MJ?$J/OCN8JPQ0OY_')$H6;\OUI5DZ]VQ@0UNA!Q1$ ;6MWAW^?.4Q1O'7]4[ M-0A6N[/PA5\\V5V% 1X*\OUP.4D:X-7#;VY>=.CP>TZ+Q(U]@78>D.=X:^T# M=4)5&VZI- OOP >_1CE7L%!W0^*-;?&=4 MO)%/;+ FS=;F1[#@&5+9';5"/Q"PZE@H6 18>QS&,L"X&%/Y"M(F%HUMK"X^ MH-)+9"X';RAYTOH:G8Q#UQXS$&+Q3L[W*?27 #?9QYW*C+.EL>32MD,O5.^8 M+CW<$/9-V>R>!CUH6X:-"GC;JR'(XX![8 7D!^D7=2GE#"C;&OER4JLN5Z)1 M MM653X2QKM<2=GA-D2L1(\BP-:&XYX4-J6..H((LZH]H?8CM 54S:OP:2R) MAU-OIWV;*+@FS>:Z?]]!!LZ1T5&5Z']3WZR(NZVJ?A'R$5;N+3)E$-FQD&^S M19@L V[KP+NE8^)"3@]+!>K?A-Q9YL7%H"T-\O$Y6SY69UD><$'2'7V"OH53 M<"N; 5?$W5)-V\R?"I^XBBBZ.P!4*3SQG J;T6_2)%7!%W#8VE$I60!Y2'?WJGOK5S/,@X?$JBLV8<\_ M4)1R=>W.O$ ?(\XVJ/&2\\.#J%R24_I5.6Z#B7J21A-OZXYBA6NYBM+:-Q77 M$1ZL.5]3UG:)K.WMD?4ZE.)2;5L@O,-GL I#>$O(:5;V"GBUZW(O9N0SPY_+ MSLI>T%Z[K)!*.M0C\A&GD2]TZ -!5FHC1NWRIPYI]2"H9$4O ]8N=5)I'HA> M*.T)1+O4I7%9':JAUJY1FP[A.[ZB@WE[AEL/09P.#T2I8FM1U*[?(F9&[VM2 M(@_*55R7J'8M.Y!R29R:H_SDAG'\LLR[LNI5QJY=KQXD7?)W L,'GAGFG%0, MJUWF&]PX!ZPFE#AQ->^.&]3+G9)M]:NYR? M\9#)773()"MK(:1V>0>P4B+3>9O.F$US([8$5KO,R=3F],4H>()8F1NBI>#: M)5?O##AQ730J=<6T3(5"4FF=NS8IL0:I=^N>KJ<+ML098&U2[Q'7-A70M=.->K"]IKEW5 [8F' MKT[M_#RNM=5\US:BU*Y!:CXIG6BV1]J227$+9\)V4C1-[176RS@KL6K7 ZN2K?ADD5ZO MU""URYM9*:Z:W:LBUZ[5'8%EPN!)#"8B] EW^A1_OY!2#I^O1R/.JW Y&LI9L"O7;=+^.JH^;!X4!K@ MMS&H=HGC,@C2$;?- M_$"R81A@&:V@6%*.5;L>VN3 GC&>F!.9=8EJU[(L8G;4O34P_54/LL4DM6N8 M;#M+7_:8R^!,&+7+?R^2$S;YA8G67KNLB420+N7J1P6 VJ5]$" (+D>I]/-O M\DM@MJ7-G8[A(SB_I &U"YM^BJ#*HO6RNBU:]:?"!G@BS>U M[ZHDX5R%5+L6BTXSD?DJ33&H=HGO" ]'Q,8]$'I,+ /6+G7R,J[X%=WVR)DV MH!9ARH"U2YT*U.:7+<48M.1N>Z]"FL;]"@^ MYZDIL@*M=DV*?V@SGXH9<6K7H>\1UTU^!>?2\1C'BH=Z9"X'JX!8NS8EMQ#X MET.4U5Z<_EF-1^)/B2Z;7L. Y2,^?@W5UKBU(\)8*+L)Y:;J*OK7W?>AG<#) M>[,:;HT>_=",KL>#C_\%4$L#!!0 ( (\Q;5&2CGD DA$ ,'9 5 M=GEC;RTR,#(P,#DS,%]C86PN>&ULU1UK<]NX\7MG^A]8W[23FZGB5W)W\5UZ MX]A.QC.NY;.=2]LO-S0)26@H0@%(V^JO+P"2$BB">$@D 6?N$EO"+O>%W<5B M"?SRZ_,\"1X!)A"E[_<.7Q_L!2"-4 S3Z?N]SW>CT[NSR\N]@&1A&H<)2L'[ MO13M_?J//_\IH']^^/!^4 M?PKP7Q*8?CUA?SV$! 14.RDY>2;P_9[ YM/Q:X2G^Y3*P_U__?/J+IJ!>3B" M*=-2!/8J*(9%!G?X[MV[??YM-;0Q\OD!)]4SCO'1Z/CP]3.)]RKA0XF M,(+4+R^-Z=4AZ(7FLY#,/B;HR5RL$I@N[9- JK<;# A]E-%D5H!T*#$X32%5 M2$B=1A2AG'J-='J#$J8BO>A,@+NC]1R2"+%GY" >+UA IR+1$JF&ZHZZ:Y0! MZC^6X0/#I*9)-K8[2JY $1^5)-0&=6A/8,KFTBU8(,RLX1- 4QPN9FR412"S M1-,=_1??351W4HO1F-/R.64,3,PU/W;B8M-5AW]%'L$GIGE'MKS' M(=5<9.35='"=RC*BO&,C2Y0.[G!^Y \$?,OI$RX>3739-GZ@^-E)'.TOGBH? M>\]BTVZ4UU'TG0>8$6P"VT].8$9?.T3'^8$9.9*A@^<*AI:X#;*N\P8S4F5C M>_+79@0I0'I= 9V#+(0)N0XQ>_2C-F>U0#&0EQRQ>E><)X OR>$#F3X4>,YDH"M^-NVZ?T$\5L-68"VP^EH[M\/@_Q*PIA.]\P<-GI/9 M:G!'M(/S)RCG0TY@"@@I(4F3W(Z8W^J9#B13.8_U@!Y%8O.PKK-Y6R-70W5- MG>@_6*KWA3V0VHJA!JR0]$W[>&&3)]G@Z+TV:^T)[= ,4KNUY6$+5,/4=NT9 MLQDP'+23T8X:G;/@Y#$9!!27^&*9Q4* (:CAZ)5_>*E*C]X@2N=JXIS^S MB8P2&+-Y$)3P08$@>/4Y#?,8TF^^K_IR*L(3%-6(35AC$,)U]9>T\NZ?24@> M> M03D;3,%SL,[/8!TE&JD^XH8P.#LM.H._*C_\X)802(H M0#@&^/W>8?6<$$9>R1=NP(NJ%4K$7 M/ $XG66<>H=Z+$N%Y!9$@-).5_K7(-/;H1+*3&M'3K5FPK=WRKI,V3XEPDM* M:[MRZJ/,E''L5!DROKP3_@T&BQ#&%\\L*P>KC-#,<1L!FZGJC5-564C!.PT6 M5++-#;) )$P^890OB@T0ZJ>E97/#B+P=3C-]OW7K)W>668=FT$RU61<\=8M9 MF$XA]>$U>[Q'V;I&+6B.P:A!NB2.!II\GO,EV.FPVI=+[1"N'91>[EH6/)W48H>80#!C- D)@1,( M8NUTL4+BVBL;SZ$M1#/XQ.*QPVQ&E4-=ERBWFDHU-KV;0T4 +RBV"9(Z.-?5 M1>.98B8 /_4FSG(SC4DAS'3U@R>Z4C#MGY9JE:N*SZ5>5QHX,XW]Z('&C 3@ MG=X$_KK=L-D9L9GF?W*O^8Y$.%A6(M K)K_M&A5"O0[63&GO_,A;S 3AW905 MCW&I'X$@J;A+QKK=VY\ *MV8TZ7I79(.=KVV;Q=^'=Q!)(Y>NKVO%M-%=#+9#Y+I&8*S=+47DGZKC&#*QA,E-"/E+]PLH[U*J&&\#<%TR,%>=FF7O5"1D MWZ=I;)/4ZB%=9XFFO+6O)+=:A#C<<+%A4S'0-R/]"%/V$DN]IF/2+*,%=)VE M;:D[0X&H%?G+_B;+5_3WP5YFDA^N4'NSZ7B[-YN"5S7A>*Z.()U?G2>@<%B-.W MIHLVL)(633=I":4$E;/5H*9DN5=O28_,IA.DXY095 M,-#23R,9YWH+T%CX+?1[FLFM:99*Y0W3 M$"\OJ2EGU >0 N7> M0RN _VZI?8U.^M;7^W9&.9Z^DNIMIZU.^G=SPFKOJ=!W^5EA\7U MU+8W S.Y>*?<&J.GCR%,"AL5^GO+1@9V44UD.(]-$'DUT\TYWTP4I8;BFY;K M[?/G\!'&((U)0?FJ3^%ROJ#+_785VV'Q:@IOK=]M).=?+)8TGNH]MA+(]>PU MX$@U4RWLP;>YK.HDEE7P2J7$_\T)/]Y>J?-.D+N>^?:VT:%,-9-_^&8]\RO+ M:ZUM;XU:VUAGFXCU;^$"D9^#-?):D]M _7NR2\]KO/U@S!M#%'!,GG3KL?.> M*4TW&+%(%']8?B;LR(A52>\TRFB,RJ"J!\<&AR^IZ4M:0%HJZ$5FE&+#T'@B MG.VE.Q5/ ^*=/L1_,K/7-@_W-774E8]H[S?#+E3YLWJW4KJ.V M\R!Z5*Q/(2M%F_-L)&H9N0K@]>ZD&G@;H^ M5ZE'#[PAGB%NQ*B38G'NHQFHZ_.4ME>6.8\O)AMJ.4#19C:VHC L AQXJ&E[ M9E^,QL]S<(_JI\K::%L*;JAIC^L]5G+R4,OE)6A?,!73.7I2K$QE8PWUYW'! MIUT"WBG+D%%Y*X-BHW WM(8FX'$=J1.Y>F>B,#O=GSZJGGJ5O>H@R\ MXXEXGX'IM&R#]G0G=]OIJ1:2=QIFK+/_6<[T&": [WZ1#,.(>AGV!371^@?" MR!N (8J;183R!82+YV@6IE-P2SW6Q60"5/V]0]/A.BBXD7NSW<9SN)%WQXHSU=1H4PG9IXP-MKD.5%W;N@R)V=T;]]1IY MH:0MRHK>G?-*($VB;C @5##U=JM:0_6/P2A@=I(@DF- ?^&0K(&Z#MMO_S>< MIG!"/TNS<@N;OX"9L$[TED;PGS;I%G $:R3!&DNO'&BF6HWT=YNDB\"!S&/V M0K(TP18)/3S8))2#!(VU1R_D\9.5Y70=;M)5CNW71L&4K4SH$H5U":?33X"M M01-2PU@);L$+W]T!$&-0P]LK7QBG7-;*/-\G>/%>^'TFS M;M'10VN[:(W$-PW);!K(VVA[(9J]BP;Y&T7L\-?BS?(I2%L=V.';3<(% M#$&8,N)K.'JF/B5YPD-;=/[<;0B&AKL*"" M'&(H\PXQ*Q4 CB%KD54.Q6>1,*BX: ML;0 &8K 6CQ1T=D(FS7(H;5.<=4']2E#4 O^%J10Z[>#?):2IS#3+V%NH-P#PA+GF2 M"Z89OC7Q@HXHB2KO1Z%D%2^3,T<75)0%, T$VMC8DKJ DE?L.@_MJJXT9B8\_MP%=8 M7145:Q/3;"0]9=8VN$GRYPH>YBY?+!*^W \3\:(Q(>DJ%]KWB,.JO4XC+2KX MK/L8\9GU"\EJN5ZUP,]0@45T/1Y]"6O0A)S % MA)20I"DAN6":6]P6@JEG214)%0HB%:(WHJN2__4 4YDU2QEV,ELO"]:CG,BJ M* $:S: WC:I$53\=.H(RC8*O$--Q_E&^UF1M"8?M M&_9F+$KZ#Y0;^ Z8;-O4-V.P43YHW^1WH\#UUHD90[KM%[<\U/8IFKS)65+W M-C3V&63LEDR623#[BSDT^LG_ 5!+ P04 " "/,6U11O>HK48@ !P0@( M%0 '9Y8V\M,C R,# Y,S!?9&5F+GAM;.U=:V_;.IK^OL#^!VT&NS@+C)ND M]W:F.\CU($ ;9Y+TG#WSQ5 D.M96%CV4E,;SZY?4Q98LWF1+XNN6@\79)B&I MY^7#ZWOC7__V/ ^=)T3B $>?#HY?'!TX*/*P'T2/GPZ^WHU.[LZNK@Z<.'$C MWPUQA#X=1/C@;__S[__FT/_]]3]&(^QO*/(Q^7I[ MM6IVEB2+CX>'W[]_?Q'A)_<[)M_B%Q[6:^X.I\1#J[9^^^-L[+P\>GET].'5 MD7-\]'?G[Z^<\\OK%\]3*L>YF] R[,__^?+\^)C]Y]7]T?N/;]Y]/'KU#\T/ M)FZ2QJL/'CT?%?_+J_\U#*)O']E_'MP8.92=*/[X' >?#BIB?G_U I/'0XKR M^/!_OWR^\V9H[HZ"B+'DH8.R%FN%5^_XPXJPA+-J MF?[53U85JH7?'.9_K!8-)$U70,?!QSB3Y#/VW"0;CTI$CK $^VE4%ANQ7XV. M7XY>';]XCOV#DJ>LLPD.T2V:.NS_TW&U^NK3TL-DCOS S=#*$D5D'C%NX)RXU+:"?,4,+*M +&K=D=2C8W$2,H'D_9(D70 M#$5Q\(0^XUC9@UJ5>\ ZGMXEV/LVPZ%/5]-S- V\@"[A2VV\J@9ZP7SFQK/+ M$'_7[U9.G2['9QQ0WFX(BNFGM":SI$J'/18\1@$EQ*6+AN?AE*X:T>,-#AE% MZJ[3J=P=UO,@]C#[1HK\\8+M_;1+E"#EM;I#=XT31->/I?O 6I)CXI7M#LEG ME&^E4@BU0AV.)_3(YM(M6F#"1L.O"#\2=S%CI5IL9"V;Z0[_Q3]3NFVJX-5+ M==A[,[K_C-B!PF]7I+7JT[?+3U>9!D>Q ]8IQET^J1+N4::X5&U2YQ M1G$:LB_0;XWI?DY.'@G*-T\U4'7=[I#>HI!N/SX]=R3+>^)2YCRM54U5K].^ M]*CL1&LD<@MW.#_2AQC],Z5?N'C2X5)4?J#]LY-]M+_]5/K9>[8W[8:\WD3? MYP ]P#IU^SD3Z.$3U^CX?* 'AU-T\+."YDCUJO]0!)JO1Z M SI'B1N$\;5+V*>?E&?6%DT,M$J.F&K,3T.47F/K(OXK. MW-!+PPSL>'H>A"G=MJ]1PB[M-XAD1[="B)T6VUZ0]+UFMQT [5KI&WVERUD? M7A(\EP+<3KIMO]+/+M:6,9VZ_2 =W:7SN4N6XRD'0QO86@T9D*&5EG.W5CL^ M>[0=1-)*'6.K3+>[=$';9*<*-ZQJB2O'B>(:=H^SNKH3O?,/#7XF:\O@CLT. M+E^%G-,T#B(4QT7-N FW(^&W^J:!GBD7CW6!'KNDS<>Z/LVW'>3R6EVCJZX? M[*CW._L@'2N:#+1JI&_LXT6;"=LU,XCNMJT,6S0UC&ZWO2#M MV^I?]]M6BK;M]*1KV*+SU95[PEJ[+3=AM(*NV99,$I=XI3"\PE4P G^4TBV& M.:*\R3#.:!/$2Q_0R _FS%& *>2+#U5[:]5*$"6'M.AA4>:0VT#_N%A%-KHT_T?$>Q&MR7%./*;8?^FVWC. Q\M@LZ17TG;\#YY6ODIGY M__+? ^+F:U%J0KS:3@CGEUK;/0NEYW-6D^NU3*YU>PZ>.K46'=;D<'3I>Z?5 MI'NC)1T3KMKJ?[D+'/_%63=>D[.0LI0SQ%Y-N)!YJV+"7;JR)6?JQ@_9NI/& MHT?771RRL\HA"I.X_$UV>AD='1?NJ7\J?CU9 :8]BJ[H/U>*_NSZ#LLE:#:P13(@8,)'6.?#HZ/UEA"3.^7GPX2DG)$-L%2?F=G$QY' MV;WQ.= 9:_QJG7+(/>:J.*M3(>!+)C.'/J-$;6 ]+P[/(H($Q3LEIGF45[$B M[7"L(X"(G)='>\_.Y)@C0U<$EJ[7J46Q"6^M!-FI5<#"A=_LMGQ/D!NG9*FU:G *3WAK'A0R%+"%R[A9 M2DY\/^L[-[QQ@\RK:A$D;J@B1UIM\AH^36H!1(2]-DO8+=/#1\B_<$D41(^Q MBBE^^6-X,GE>.D\S\U5F?JMIA*XB#\^1*<6[Z6^6G7PP0U,+?0P7,LQ[?>9N$(_3)$NP0!<%"16;1>$S MP44L/,J9GQ17<9S2ULQ M5ZF[K]1MBB \^W5[)ST/"/)H86:GH9>XN@_5K\QU;6T$VKBGZE2%RT8K"82' MO6[)8*."62G'TWPTW*2$_2*YQQ?/B'A!3/]2.A0*2&G3!&QR6DLB/+R9(RDO MT0%5>8D?A["*/"+:WAG=I$27!693OT;)>'KO/HNW*9W:<,EL*X2(P?=&&;QF MX1XEWI,G-PBS$&!<4:L7=PX6!>F)R6S9$'A>MY%'1/&'BD_)X8:D%,>W8?Q- MFFF&:BXF;[5=3%A#3M;2D&Y.XJQ$-3'>,4>R(&:N""E!](>L)H-=K]NKDX]6 M@J(:[/>;L"MM..M&G'4KO;KRR9,7U9!_V$1>K>Q4:_>)F)O:J(KS^&@39U;% M6=7I$UT]ZU$-UO$FK*)LK^.S99JC&N"7C9&:M^:LFONS4VUP.!?.C?1(-=2O M-E&7A7OM9T6"I!K"UXU^S6J?LMI.O7J?F'42)M5PO]G$76DA\^3=:*-?\!I) ME&KHWS;1ETUDX+-&G&HK?>)7IE>J86]L=45U)ZOOU!OHN=LYZ9=J6!O[VT:= M7J>A*!U3#6%C'UM7<\IZQ@X-TL/#R\;6IC@\.+^4_^K;V[E%GJ::1(U=42E1 MWEK/\FBE<:H)TM@M!:>C@020Y'FJP6YLE[7#TD!@>5F@:B@;6V968R!TVV5^ MJN%O;)TMCE(#2,1/ASX*79\P7YVL\MZ4QJ?IU$5Z&JO+X"0-;BDJ>+"M"J;B>'3)Z0% MD<"C^OKF$N36U3_?D&, +XJKZA>7H4^6*N=V?GE3X2)M)AO6E4/$U&NS"ZTQ M?PQ#40J]^6/( A4Z/GC^CLDW.BJ+R*0\VT8B.&URR\+M?#GD/NZKNT^A\Y0. MBXHE+4#Q64I(GIGH&D=>_H-XZF@V )>U+>2 >>P\1P]TUK.5G\E[Z7KH9,Y, M/Q+N!#7@DR4#+CQ6&&7GBIZ]"-V7"ZO0F6I>\^15 M=]Y4ZX#G1P%=Q%$E*F%PI\SA7]2H69.:K@X*ZSHM48 J\J=16'FF,688=DID M3A Y%6RL;('.H?#R3&L48.[9M#)661.5-5$!-5%U$&E.9Y+/YD#PA.Z0QY8F M.J$NGO,)PUY58:Y]:5),YC*$OIS&ITM^ W(]::\?A:UA':"_H=UW^(C9J^PJ M99ZZIAFM[! DZ@R;9A^"4^;V1SYD-2Z\ 3*HI;/R\,1-Z$92\R:WK*&\;MJS M#&O@[WHQ%BGWBEC,>WR3$F_FQD@GH5ZF-U/7-)4);ALB=,41\M(Q,?3:1Y<( M>G^)SW#TA$@2T%,!O:MC77[T&S"56VX;FEI*U;F3@"JK7Q[37,%VKTU8JS9, MI:#;AK/V@@EW&L.J]S)O9"5<*=]Q6133C;O,8FA4UL5O1A!I& MB'<.[0.82HO?2?.38T-+@+9BHT,Q-4Y#0VLY6[Z:6]50OFI$- G#9C@>[P9" M@+9^+;+.YR-Q.MG%["1>#]+)-[0UI(N(O%Z,8G8 M2#R#D7AFG6YM))Z-Q&L5D@9MZ^J?;\B1>/9E4NV721RAV@5@ST,X]"P,)99#:\+DMNRLN<+,C57RUJZF&Z=HGY&XA%3)B= M"?40IHK_3_Y/MJ3<[<,$3^Z;+T MG2T*2@[Z.S8,?@1T(1],Q0Q7LO)-GVS!6C_L4XHCF?E;-;>?]&M)U?4M4>'N M7V#*=$[3F!Y4XOC$G],>BXN7+>3!X:IZIL+K6E"B)X/P^M@Q$U<1O6:P M]WVSW$G+RR!B/ZS?#Y/2H5?9V.U2GY,6@@AOG-:AU3JT6H=6Z]#Z(SNTVJ8G<^ M0.X977 VZ#9R1COK7U3J4S>29[II%C25SD8ZSK$2L;!GS6X45>O11H)T9J , MI@'RE>FL6S0R.09K$=Q6&!&S9E>ZAM.7DD51#?B4R9%KJ ?!6G+IR*-RS%#" MZO/-NHVG?]N;=9U?:M^Q9EYKYK5F7FOF-42(-?."N2Y9,Z\U\UHS;W]F7D,A M//V8>7M3AUH;EK5A61N6M6%UM<+W9<,:VD.D"QL6X,S*]>@W^36-5Q;H>BY! M#-.&54>J\Z"*N(:9*YJDKV6D[,&C-]UQ W(?Z8J_0;<7=K!FBE;I9E(O9,JY M4#G>L12Q<.,P&Y)JLWEME;"N@:8W+>L:N/^N@>_VSC7PG:1G MWYG5OS'#T'AZPE)DY.8>^5XA* Y[NY#*R-FZC1)2@1F?1/XUCMSU;ZHO6Z@. M7ZT;,K//R,G!NXD$=!;B*$/D,RZ]-"L? -75&-R;,I_:KL$KIO(101!,BE>T:V:H#BYI1)G8OLW M] 1._^ ^2ES<]=O8-P[5LHA8-3_KUOEFQR1X#"(W9+\]3]$YE6,\S7YPEU_H MZ6Q&%Z8_D"LY7F[7WGZPO:U;7X[?44S-1SE'LD6"15&[1JJDLJ+X? MO&J*(;P. *5Q&^[VF3 Y2V:MV/2<["'D9\^>L]S=+-E/OF*(61+7@<^2"CM, MTTM];-$-/,!^X-%+3_8C"2(O6*S#+57S2E0?/GMMY("I$JU+(,A/S94V2_2\ M9PRM,0O5(N9BFC\C-R[#EJ_9E38)GM9J]UK(\IO-D.6L[BH>V5E5MY'(-A+Y MAXU$IGOG I%D>1.Z44(O$NQAI063Y72ICDO6J@S;]M9"?FBW:2%TG1A9K3>]XWRAF*B&XS8[ "/M!5 M,K](Q)>8W"*9@G^CH*D,7_JW7@Y>F,K\[&!]\;P(\*3&#U.#SD.NI3M75-Q+RC;Q M:VC+C6@B1G?>#/EIB,;3NW2QR,]#;GCJADQ'>3=#*+F*IK1VMFH4B?[N<58W MEKZC]9:OO1@YY1=9IK7J-YWBHT[V5:?R6:?XKI/@O)6X\M;6NO]ZZ*.[_%QX MBQ:8,&Y_1F!M5&_<:.'E_RHX=4'=4L:"I# M'W=48Q72KI<@07]>XR?WMR!6>?UN%C/VD)JJ,[E A7W9<6>R,RF=?4&4(K^X MW\GN0S,[2.,%S M1"Z>O3#UZ07BA-[0Z?_Y]^ZS>(W?HK')2U,S1_":3N/C ZA2M#L8ZP(=1IPS*!DBU2E>,]9>5K)$YVV.QDV29$U?\ ML,E;\>O)USL.2<4?O]X-K6/1&O*8 Q+.TL1222_$KE6T2+7$X(J7-CW,P]JY M[L4:/08V>IAU$K%&#VOT^-F-'E:O;/7*5J]L]#W*[W3@2LWM^AWDIK$M-P.K,8ME\!Q-$2'(/\/S!94\6U09 M+H5&4ZNVJ:P#_"&/M\(/_ MO\3D#I&GP$-2!XDV[9AZ?[R%VT%K<40$@^3W-S=,T>[T\IO95W8ETL TSTE' MZ37ZGOUIVTF[JK^O=/+$@*E)EXW'[6FL5]]7%CE2P%2?9\/MU(WKAIS*_>-T MN2Y29#8^^>X2/W>.7+\^$H^3&2+W,S<:9^D_XW&:Q(D;,6?HWU'P.$N0?_*$ MB/N(;A&C@/Z^]*!.\R2OLL$""2;\00FNMV#J^;).>%#WT\-F/VW=&R\50WQ8 M,/LQD WTB<8EWHPG>S5O,=MY?L_T0HDT)?'K8X%C^T9.8M:>4S8X5*9AOE@% M?5*I7K:0JFAOL/3);$R.&N-6+PSA52-/3=9:ME8[U>9L8((-3-CCP(3M6Y@5_ ZO*YT-0W'#PN[3#L8X 0 V?7; #4K7=-8.# MFBPO"B?[ZO%':K,45S#D.RJ?!5@7.6*$>V' V#J8S9-YO\AU\ MHQCL39HKT]Z9GV*1J6(M7N3KAL#U\S4S9P$^O2WM0#OT+K@#P_X/)IWR&O:3;.W-@-HKM <^FMPJR2Z23,&D<^?V.\>&;_ ME)@;]>I/W@%WXF@AAHC(CJ=6IGG^E?DY(/\T3:YQDGOP">:2J#CBAJEE M7UD&!TD94W>696A^1)$7K%YT5WCFO-[TS*FTZ+@1\\ZI MM&G=)'[:*HUJUJ5@=^=]>6'MN\*H3/@ MRON>3F5#E^\6E&B2V>P1>!?UGMD$?:7OD_%!K__CZ92=RA:N)[>R-LJ92AW7 M8L9@!?Q!5DG[]*$:M,8I?B@B[-.'PVPW]NG#'_SIP_,+#DG%'\\O!O?1V>+M MPP*E<#Y87Q+K2[*7#@#6EP3(%6K_AQ+(G?6']"41!72D!)^EA*#(6\H#.1H% M3?G)]CK%L5)BX5I@^%V#7,[X$I/;RJCFJ$[J!8"[MH$VPT)GQ$= M^MG@#7>A.Z%?];*AIL2,J MOL>O($A%&L: U,[/X,Y#5,H :_@8U(L"/:&( 0]R)=;K_ +7URA>("^8!LB7 M6K/%Q0WZ%G [%^N 'N8,,2@3(,\!7; UZ$[_A38^N_^.[VG"Q($(XCQ"LGW6TZ:MW L]KJN81[$1.F$K%B1;A$LH3O&P4G M;X#K$'EX85I'^(:[M@9G\(1(8,-4=62 ;TC@R;2#JS+[T?]KJ#"7HT%>I0#/ ME+84&C81."1V_43,GM+($T/$XVMSMBU1GCL]N];;3;M6T9R3M>=4&[0F+6O2 M^IE,6H*)M57V6=#*(QWH,$]^ LAM$IERJH'*.JN9H%0H/3BC51^<@51$]<.K M,2.4ML7)J'E);TX(C$F#6XYN4(+(/UQOQO145-)3]IW\ M;>B>G8O'TZO(#YX"/Y7%GPJ* MW>Q8#AV(8: '\/DEDVS-C-8Q8L[O%%1&\N MXASE/"E5C0QO1Y(3(2%,KS] 6)=,< GR - ?WV8R)+;*F3Z\O6C;.2/)I=Z# M^K6GDX"!>.(.^ELHBK#732M,BXWV+'3CN'A%4?-=M&85H.<%-7"8VNPJ3M5M MDE?6\$MHPF[&2N1 ;_J[$0)R2^^,-,@)U^\08?J3-UE-CW9^IV,1'PL(!Y5TV 5]BO9K!L72-8EX"X@'G1Q]XAIF=C5)7\M(V8/:6)"CK]' MB# 3YPU=VNG/[J/$BUN[B#+;R"&XX_ KPJ9("%YXR3#]SY"'DQY=4Z-7N M?8T35,H@IDE9%3YAFB+ -&O5#V9EKLY;*GHFOZ]S>-%O SZ9;6714"P;2&3* M(!:IB[4B/-]Q,I>NV[!!G3:HL_V! TQ0IY9#^A?W_S Y2^,$S^D]11S6P2L' M5!4H0#O(,5VKSYD:8#RM892Y^TN*#Q^D(>E9K(-X&(W?H#2 U/'M3-7 :;ZB M=.IZ"=V$R3B2OS;)+6L@I$(]R+$&Z*Y7)8T.OO^.M3MX579P/]5=>KB.6JP^ M[;&/:4G]85PI;2)89?M^WL M7-S-JL)JA_K;(/YVNCQ%D3>;NT01H**N"?0, MI(T?IM:KB;M$K8R54-8T8RS59D)%(+\CP)E0^V,0Y'&K7Y8'/8O=I,2;N;%\ M]ZH7,I3/0GMR8!GP/5D!UPHXR:MCLEH3Z \F*<%KF$R-ZAQ'=]X,^2D+_.7I M(ODJR/=R%>3(*1MU\%2@GK1*2:N4W!>EI#V\#W!XAW;=LH=W>WBWAW>(T>SL M.=%;EN:?N<.(??C+98M7?$\._RH18*ZE)Y['0NTH8@\%3VRS4(;+"&I,WN\5 M3U(Q1%R]']Z69^VGPR?$L_93:S^U]M-:0%[Q:97MM%$.O+F)CW@80Y/6++AE M08/B=;_R9[C+?4.&GAUM]3M6.)I+U(8"N[F=AOG0 "W9;?H4ZK*LV>\#7KOT M#HJTW^;I7-;YM2(4__!+,V_<8AD^L29Q^ 7CB_NL[.%JD>&# M4]W,0G[.&N M$ZQ=I^RCX^GJQ",X0S3*38[!6I8D>#6,21 T;[N;_>"RHXU>0S7!C1'_S_U!+ P04 " "/,6U1#5!I,35/ "6? 0 %0 '9Y8V\M,C R M,# Y,S!?;&%B+GAM;.U]^W,D-W+F[Q=Q_P-./H>E"%(SH[%V=V2O'4TV.<

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�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�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end